

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTASXS1626

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	DEC 01	ChemPort single article sales feature unavailable
NEWS	3	FEB 02	Simultaneous left and right truncation (SLART) added for CERAB, COMPUAB, ELCOM, and SOLIDSTATE
NEWS	4	FEB 02	GENBANK enhanced with SET PLURALS and SET SPELLING
NEWS	5	FEB 06	Patent sequence location (PSL) data added to USGENE
NEWS	6	FEB 10	COMPENDEX reloaded and enhanced
NEWS	7	FEB 11	WTEXTILES reloaded and enhanced
NEWS	8	FEB 19	New patent-examiner citations in 300,000 CA/CAPLUS patent records provide insights into related prior art
NEWS	9	FEB 19	Increase the precision of your patent queries -- use terms from the IPC Thesaurus, Version 2009.01
NEWS	10	FEB 23	Several formats for image display and print options discontinued in USPATFULL and USPAT2
NEWS	11	FEB 23	MEDLINE now offers more precise author group fields and 2009 MeSH terms
NEWS	12	FEB 23	TOXCENTER updates mirror those of MEDLINE - more precise author group fields and 2009 MeSH terms
NEWS	13	FEB 23	Three million new patent records blast AEROSPACE into STN patent clusters
NEWS	14	FEB 25	USGENE enhanced with patent family and legal status display data from INPADOCDB
NEWS	15	MAR 06	INPADOCDB and INPAFAMDB enhanced with new display formats
NEWS	16	MAR 11	EPFULL backfile enhanced with additional full-text applications and grants
NEWS	17	MAR 11	ESBIOBASE reloaded and enhanced
NEWS	18	MAR 20	CAS databases on STN enhanced with new super role for nanomaterial substances
NEWS	19	MAR 23	CA/CAPLUS enhanced with more than 250,000 patent equivalents from China
NEWS	20	MAR 30	IMSPATENTS reloaded and enhanced
NEWS	21	APR 03	CAS coverage of exemplified prophetic substances enhanced
NEWS	22	APR 07	STN is raising the limits on saved answers
NEWS	23	APR 24	CA/CAPLUS now has more comprehensive patent assignee information
NEWS	24	APR 26	USPATFULL and USPAT2 enhanced with patent assignment/reassignment information
NEWS	25	APR 28	CAS patent authority coverage expanded
NEWS	26	APR 28	ENCOMPLIT/ENCOMPLIT2 search fields enhanced
NEWS	27	APR 28	Limits doubled for structure searching in CAS REGISTRY

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,

AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS      STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN      Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 14:17:54 ON 05 MAY 2009

=> file reg		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.22	0.22

FILE 'REGISTRY' ENTERED AT 14:18:06 ON 05 MAY 2009  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES:    3 MAY 2009    HIGHEST RN 1141929-94-3  
DICTIONARY FILE UPDATES:   3 MAY 2009    HIGHEST RN 1141929-94-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\STNEXP\Queries\10543109aa.str



```

chain nodes :
1  2  3  4  5  6  7  8  9  12  18  20
ring nodes :
21 22 23 24 25 26
chain bonds :
1-3  1-2  1-20  2-4  4-5  4-12  5-6  5-8  6-7  7-9  9-18
ring bonds :
21-22  21-26  22-23  23-24  24-25  25-26
exact/norm bonds :
1-3  1-2  1-20  2-4  4-5  4-12  5-6  5-8  6-7  7-9  9-18  21-22  21-26  22-23
23-24  24-25  25-26

```

G1:O,S

G2:O,N

G3:C,N

G4:Cb,Cy,Hy,Ak

G5:Cb,Cy,Hy

Match level :

```

1:CLASS  2:CLASS  3:CLASS  4:CLASS  5:CLASS  6:CLASS  7:CLASS  8:CLASS  9:Atom
12:CLASS 18:CLASS 20:CLASS 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom
27:CLASS

```

L1 STRUCTURE UPLOADED

=> s ll sss full

FULL SEARCH INITIATED 14:18:22 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 2546093 TO ITERATE

59.1% PROCESSED 1504956 ITERATIONS 1752 ANSWERS

74.2% PROCESSED 1889954 ITERATIONS 2056 ANSWERS

77.8% PROCESSED 1981325 ITERATIONS 2420 ANSWERS

78.6% PROCESSED 2000000 ITERATIONS 2423 ANSWERS  
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
SEARCH TIME: 00.01.02

FULL FILE PROJECTIONS: ONLINE \*\*INCOMPLETE\*\*  
BATCH \*\*COMPLETE\*\*



PROJECTED ITERATIONS: 2546093 TO 2546093

PROJECTED ANSWERS: 2918 TO 3250

L2 2423 SEA SSS FUL L1

=>

Uploading C:\Program Files\STNEXP\Queries\10543109bb.str



chain nodes :

1 2 3 4 5 6 7 8 9 12 16 18

ring nodes :

19 20 21 22 23 24

chain bonds :

1-3 1-2 1-18 2-4 4-5 4-12 5-6 5-8 6-7 7-9 9-16

ring bonds :

19-20 19-24 20-21 21-22 22-23 23-24

exact/norm bonds :

1-3 1-2 1-18 2-4 4-5 4-12 5-6 5-8 6-7 7-9 9-16 19-20 19-24 20-21

21-22 22-23 23-24



G1:O,S

G2:O,N

G3:C,N

G4:Cb,Cy,Hy,Ak

G5:Cb,Cy,Hy

Match level :

1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS  
12:CLASS 16:CLASS 18:CLASS 19:Atom 20:Atom 21:Atom 22:Atom 23:Atom 24:Atom  
25:CLASS

L3           STRUCTURE UPLOADED

=> s l3 sss full

FULL SEARCH INITIATED 14:20:06 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED -   160060 TO ITERATE

100.0% PROCESSED   160060 ITERATIONS

2526 ANSWERS

SEARCH TIME: 00.00.12

L4           2526 SEA SSS FUL L3

=> file capl

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

372.72

372.94

FILE 'CAPLUS' ENTERED AT 14:20:21 ON 05 MAY 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 5 May 2009   VOL 150 ISS 19

FILE LAST UPDATED: 4 May 2009   (20090504/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l4

L5 188 L4

=> d l5 50 ibib

L5 ANSWER 50 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 2004:580821 CAPLUS  
DOCUMENT NUMBER: 141:277856  
TITLE: Novel glycine transporter type-2 reuptake inhibitors.  
Part 1:  $\alpha$ -amino acid derivatives  
AUTHOR(S): Wolin, Ronald L.; Venkatesan, Hariharan; Tang, Liu;  
Santillan, Alejandro; Barclay, Tristin; Wilson, Sandy;  
Lee, Doo Hyun; Lovenberg, Timothy W.  
CORPORATE SOURCE: LLC, Johnson & Johnson Pharmaceutical Research and  
Development, San Diego, CA, 92121, USA  
SOURCE: Bioorganic & Medicinal Chemistry (2004), 12(16),  
4477-4492  
CODEN: BMECEP; ISSN: 0968-0896  
PUBLISHER: Elsevier Ltd.  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
OTHER SOURCE(S): CASREACT 141:277856  
REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d l5 60 ibib

L5 ANSWER 60 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 2003:598507 CAPLUS  
DOCUMENT NUMBER: 140:70458  
TITLE: Nonpeptide gastrin releasing peptide receptor  
antagonists inhibit the proliferation of lung cancer  
cells  
AUTHOR(S): Moody, Terry W.; Leyton, Julius; Garcia-Marin, Luis;  
Jensen, Robert T.  
CORPORATE SOURCE: Center for Cancer Research, Office of the Director,  
National Cancer Institute, Department of Health and  
Human Services, National Institutes of Health,  
Bethesda, MD, 20892, USA  
SOURCE: European Journal of Pharmacology (2003), 474(1), 21-29  
CODEN: EJPHAZ; ISSN: 0014-2999  
PUBLISHER: Elsevier Science B.V.  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
REFERENCE COUNT: 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d l5 55 ibib

L5 ANSWER 55 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 2004:308415 CAPLUS  
DOCUMENT NUMBER: 140:321240  
TITLE: Preparation of lactam-containing diaminoalkanes,  
 $\beta$ -amino acids,  $\alpha$ -amino acids and  
derivatives thereof as factor Xa inhibitors  
INVENTOR(S): Qiao, Jennifer X.; Han, Wei  
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: PCT Int. Appl., 172 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004031145	A2	20040415	WO 2003-US31079	20031001
WO 2004031145	A3	20040701		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 20040077635	A1	20040422	US 2003-677063	20031001
AU 2003279735	A1	20040423	AU 2003-279735	20031001
EP 1558606	A2	20050803	EP 2003-773077	20031001
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
US 20070129361	A1	20070607	US 2007-622484	20070112
PRIORITY APPLN. INFO.:			US 2002-415366P	P 20021002
			US 2002-417208P	P 20021009
			US 2003-677063	A1 20031001
			WO 2003-US31079	W 20031001

OTHER SOURCE(S): MARPAT 140:321240  
 REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d 15 51-59 ibib

L5 ANSWER 51 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2004:570499 CAPLUS  
 DOCUMENT NUMBER: 141:89373  
 TITLE: Preparation of novel heteroaryl peptidomimetics as thrombin receptor antagonists  
 INVENTOR(S): Zhang, Han-Cheng; Maryanoff, Bruce E.; Hoekstra, William J.; White, Kimberly  
 PATENT ASSIGNEE(S): USA  
 SOURCE: U.S. Pat. Appl. Publ., 33 pp.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20040138141	A1	20040715	US 2003-732701	20031210
CA 2508891	A1	20040722	CA 2003-2508891	20031210
WO 2004060913	A2	20040722	WO 2003-US39091	20031210
WO 2004060913	A3	20040910		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,			

LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ,  
OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,  
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,  
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,  
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  
AU 2003297773 A1 20040729 AU 2003-297773 20031210  
EP 1578786 A2 20050928 EP 2003-796841 20031210  
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK  
JP 2006525942 T 20061116 JP 2004-565279 20031210  
US 20060009396 A1 20060112 US 2005-227504 20050915  
PRIORITY APPLN. INFO.: US 2002-436130P P 20021223  
US 2003-732701 A3 20031210  
WO 2003-US39091 W 20031210

OTHER SOURCE(S): MARPAT 141:89373

L5 ANSWER 52 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 2004:566894 CAPLUS  
DOCUMENT NUMBER: 141:273359  
TITLE: Identification of Synthetic Phosphatidylserine  
Translocases from a Combinatorial Library Prepared by  
Directed Split-and-Pool Synthesis  
AUTHOR(S): Shukla, Rameshwer; Sasaki, Yoshihiro; Krchnak, Viktor;  
Smith, Bradley D.  
CORPORATE SOURCE: Department of Chemistry and Biochemistry and the  
Walther Center for Cancer Research, University of  
Notre Dame, Notre Dame, IN, 46556, USA  
SOURCE: Journal of Combinatorial Chemistry (2004), 6(5),  
703-709  
CODEN: JCCHFF; ISSN: 1520-4766  
PUBLISHER: American Chemical Society  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
OTHER SOURCE(S): CASREACT 141:273359  
REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 53 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 2004:523308 CAPLUS  
DOCUMENT NUMBER: 141:225134  
TITLE: Parallel synthesis and structure-activity  
relationships of a series of highly potent, selective,  
and neutral factor Xa inhibitors  
AUTHOR(S): Bauer, Shawn M.; Goldman, Erick A.; Huang, Wenrong;  
Su, Ting; Wang, Lingyan; Woolfrey, John; Wu, Yanhong;  
Zuckett, Jingmei F.; Arfsten, Ann; Huang, Brian;  
Kothule, Jaya; Lin, Joyce; May, Bridget; Sinha, Uma;  
Wong, Paul W.; Hutchaleelaha, Athiawat; Scarborough,  
Robert M.; Zhu, Bing-Yan  
CORPORATE SOURCE: Department of Medicinal Chemistry, Millennium  
Pharmaceuticals, Inc., San Francisco, CA, 94080, USA  
SOURCE: Bioorganic & Medicinal Chemistry Letters (2004),  
14(15), 4045-4050  
CODEN: BMCLE8; ISSN: 0960-894X  
PUBLISHER: Elsevier Science B.V.  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
OTHER SOURCE(S): CASREACT 141:225134

L5 ANSWER 54 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:403758 CAPLUS  
 DOCUMENT NUMBER: 141:150454  
 TITLE: Identification and optimization of novel partial agonists of Neuromedin B receptor using parallel synthesis  
 AUTHOR(S): Shuttleworth, Stephen J.; Lizarzaburu, Mike E.; Chai, Anne; Coward, Peter  
 CORPORATE SOURCE: Tularik Inc., Department of Chemistry, South San Francisco, CA, 94080, USA  
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2004), 14(12), 3037-3042  
 CODEN: BMCLE8; ISSN: 0960-894X  
 PUBLISHER: Elsevier Science B.V.  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 141:150454  
 REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 55 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:308415 CAPLUS  
 DOCUMENT NUMBER: 140:321240  
 TITLE: Preparation of lactam-containing diaminoalkanes,  $\beta$ -amino acids,  $\alpha$ -amino acids and derivatives thereof as factor Xa inhibitors  
 INVENTOR(S): Qiao, Jennifer X.; Han, Wei  
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA  
 SOURCE: PCT Int. Appl., 172 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004031145	A2	20040415	WO 2003-US31079	20031001
WO 2004031145	A3	20040701		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 20040077635	A1	20040422	US 2003-677063	20031001
AU 2003279735	A1	20040423	AU 2003-279735	20031001
EP 1558606	A2	20050803	EP 2003-773077	20031001
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
US 20070129361	A1	20070607	US 2007-622484	20070112
PRIORITY APPLN. INFO.:			US 2002-415366P	P 20021002
			US 2002-417208P	P 20021009
			US 2003-677063	A1 20031001
			WO 2003-US31079	W 20031001

OTHER SOURCE(S): MARPAT 140:321240  
 REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 56 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:252476 CAPLUS

DOCUMENT NUMBER: 140:287179

TITLE: Preparation of  
[phenylureido(hetero)cyclyl]carboxamides as inhibitors  
of factor Xa and other serine proteases involved in  
the coagulation cascade

INVENTOR(S): Bolton, Gary Louis; Filipinski, Kevin James; Kohrt,  
Jeffrey Thomas; La, Frances Thu; Leonard, Daniele  
Marie

PATENT ASSIGNEE(S): Warner-Lambert Company Llc, USA

SOURCE: PCT Int. Appl., 111 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	----	-----	-----
WO 2004024679	A1	20040325	WO 2003-IB3900	20030902
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2497003	A1	20040325	CA 2003-2497003	20030902
AU 2003260821	A1	20040430	AU 2003-260821	20030902
EP 1539686	A1	20050615	EP 2003-795154	20030902
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
BR 2003014219	A	20050719	BR 2003-14219	20030902
JP 2005538175	T	20051215	JP 2004-535772	20030902
US 20040167131	A1	20040826	US 2003-662046	20030911
MX 2005002703	A	20050505	MX 2005-2703	20050310
PRIORITY APPLN. INFO.:			US 2002-409891P	P 20020911
			WO 2003-IB3900	W 20030902

OTHER SOURCE(S): MARPAT 140:287179

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 57 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:143100 CAPLUS

DOCUMENT NUMBER: 140:199315

TITLE: Preparation of iminothiazolidinone amino acid  
derivatives as inhibitors of HCV replication

INVENTOR(S): Romine, Jeffrey Lee; Martin, Scott W.; Snyder,  
Lawrence B.; Serrano-Wu, Michael; Deshpande, Milind;  
Whitehouse, Darren; Lemm, Julie; O'Boyle, Donald; Gao,  
Min; Colonna, Richard

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: PCT Int. Appl., 127 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004014852	A2	20040219	WO 2003-US24717	20030808
WO 2004014852	A3	20040422		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003261434	A1	20040225	AU 2003-261434	20030808
US 20050069522	A1	20050331	US 2003-637156	20030808
US 20050096364	A1	20050505	US 2003-637099	20030808
US 7183302	B2	20070227		
PRIORITY APPLN. INFO.:			US 2002-402661P	P 20020812
			US 2002-403694P	P 20020815
			WO 2003-US24717	W 20030808
OTHER SOURCE(S):			MARPAT 140:199315	
REFERENCE COUNT:			1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT	

L5 ANSWER 58 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2004:142910 CAPLUS  
 DOCUMENT NUMBER: 140:199742  
 TITLE: Preparation of iminothiazolidinone amino acid derivatives as combination pharmaceutical agents for use as inhibitors of HCV replication  
 INVENTOR(S): Colonno, Richard; Lemm, Julie; O'Boyle, Donald; Gao, Min; Romine, Jeffrey Lee; Martin, Scott W.; Snyder, Lawrence B.; Serrano-Wu, Michael; Deshpande, Milind; Whitehouse, Darren  
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA  
 SOURCE: PCT Int. Appl., 129 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 3  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004014313	A2	20040219	WO 2003-US25036	20030808
WO 2004014313	A3	20051215		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003264038	A1	20040225	AU 2003-264038	20030808
US 20050069522	A1	20050331	US 2003-637156	20030808
US 20050096364	A1	20050505	US 2003-637099	20030808
US 7183302	B2	20070227		

PRIORITY APPLN. INFO.: US 2002-402661P P 20020812  
US 2002-403694P P 20020815  
WO 2003-US25036 W 20030808

OTHER SOURCE(S): MARPAT 140:199742

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 59 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:892749 CAPLUS

DOCUMENT NUMBER: 139:381378

TITLE: Preparation of carboxylic acid amides as inhibitors of  
blood-coagulation factor Xa and VIIa

INVENTOR(S): Dorsch, Dieter; Mederski, Werner; Gleitz, Johannes;  
Cezanne, Bertram; Tsaklakidis, Christos; Barnes,  
Christopher

PATENT ASSIGNEE(S): Merck Patent G.m.b.H., Germany

SOURCE: PCT Int. Appl., 79 pp.  
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003093235	A1	20031113	WO 2003-EP3331	20030331
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10218974	A1	20031127	DE 2002-10218974	20020427
DE 10236868	A1	20040226	DE 2002-10236868	20020812
CA 2483228	A1	20031113	CA 2003-2483228	20030331
AU 2003226755	A1	20031117	AU 2003-226755	20030331
EP 1499591	A1	20050126	EP 2003-747402	20030331
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005531547	T	20051020	JP 2004-501374	20030331
US 20050171154	A1	20050804	US 2004-512478	20041026
US 7183277	B2	20070227		

PRIORITY APPLN. INFO.: DE 2002-10218974 A 20020427  
DE 2002-10236868 A 20020812  
WO 2003-EP3331 W 20030331

OTHER SOURCE(S): MARPAT 139:381378

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d 15 61 ibib

L5 ANSWER 61 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:442763 CAPLUS

DOCUMENT NUMBER: 139:207078

TITLE: High-affinity thrombin receptor (PAR-1) ligands: a new  
generation of indole-based peptide mimetic antagonists  
with a basic amine at the C-terminus



AUTHOR(S): Zhang, Han-Cheng; White, Kimberly B.; McComsey, David F.; Addo, Michael F.; Andrade-Gordon, Patricia; Derian, Claudia K.; Oksenberg, Donna; Maryanoff, Bruce E.

CORPORATE SOURCE: Drug Discovery, Johnson & Johnson Pharmaceutical Research & Development, Spring House, PA, 19477-0776, USA

SOURCE: Bioorganic & Medicinal Chemistry Letters (2003), 13(13), 2199-2203  
CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 139:207078

REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d 15 62 ibib

L5 ANSWER 62 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:376636 CAPLUS

DOCUMENT NUMBER: 138:385436

TITLE: Preparation of  
4-(1,1-dioxido-2-isothiazolidinyl)benzenamines as  
inhibitors of blood-coagulation factor Xa for the  
treatment of thromboembolic diseases

INVENTOR(S): Dorsch, Dieter; Cezanne, Bertram; Tsaklakidis, Christos; Mederski, Werner; Gleitz, Johannes; Barnes, Christopher

PATENT ASSIGNEE(S): Merck Patent Gmbh, Germany

SOURCE: PCT Int. Appl., 81 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003039543	A1	20030515	WO 2002-EP11349	20021010
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
DE 10155075	A1	20030522	DE 2001-10155075	20011109
CA 2465713	A1	20030515	CA 2002-2465713	20021010
AU 2002363366	A1	20030519	AU 2002-363366	20021010
AU 2002363366	B2	20071122		
EP 1441726	A1	20040804	EP 2002-802623	20021010
EP 1441726	B1	20061220		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK			
BR 2002013680	A	20041026	BR 2002-13680	20021010
HU 2004001983	A2	20050128	HU 2004-1983	20021010
CN 1582148	A	20050216	CN 2002-821919	20021010

JP 2005522412	T	20050728	JP 2003-541834	20021010
AT 348611	T	20070115	AT 2002-802623	20021010
RU 2301228	C2	20070620	RU 2004-117594	20021010
ES 2277623	T3	20070716	ES 2002-802623	20021010
MX 2004004307	A	20040811	MX 2004-4307	20040506
US 20040254175	A1	20041216	US 2004-495254	20040510
US 7199133	B2	20070403		
ZA 2004004549	A	20050204	ZA 2004-4549	20040608
PRIORITY APPLN. INFO.:			DE 2001-10155075	A 20011109
			WO 2002-EP11349	W 20021010

OTHER SOURCE(S): MARPAT 138:385436  
REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d 15 59-180 ibib hitstr

L5 ANSWER 59 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 2003:892749 CAPLUS  
DOCUMENT NUMBER: 139:381378  
TITLE: Preparation of carboxylic acid amides as inhibitors of  
blood-coagulation factor Xa and VIIa  
INVENTOR(S): Dorsch, Dieter; Mederski, Werner; Gleitz, Johannes;  
Cezanne, Bertram; Tsaklakidis, Christos; Barnes,  
Christopher  
PATENT ASSIGNEE(S): Merck Patent G.m.b.H., Germany  
SOURCE: PCT Int. Appl., '79 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: German  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
WO 2003093235	A1	20031113	WO 2003-EP3331	20030331
W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW	
RW:			GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG	
DE 10218974	A1	20031127	DE 2002-10218974	20020427
DE 10236868	A1	20040226	DE 2002-10236868	20020812
CA 2483228	A1	20031113	CA 2003-2483228	20030331
AU 2003226755	A1	20031117	AU 2003-226755	20030331
EP 1499591	A1	20050126	EP 2003-747402	20030331
R:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK	
JP 2005531547	T	20051020	JP 2004-501374	20030331
US 20050171154	A1	20050804	US 2004-512478	20041026
US 7183277	B2	20070227		
PRIORITY APPLN. INFO.:			DE 2002-10218974	A 20020427
			DE 2002-10236868	A 20020812
			WO 2003-EP3331	W 20030331

OTHER SOURCE(S): MARPAT 139:381378  
IT 625102-49-0P 625102-86-5P 625102-88-7P  
625102-90-1P 625102-91-2P 625102-93-4P

625102-94-5P 625103-02-8P 625103-03-9P  
 625103-05-1P 625103-06-2P 625103-08-4P  
 625103-09-5P 625103-11-9P 625103-12-0P  
 625103-14-2P 625103-15-3P 625103-16-4P  
 625103-17-5P 625103-19-7P 625103-20-0P  
 625103-22-2P 625103-23-3P 625103-25-5P  
 625103-26-6P 625103-28-8P 625103-29-9P  
 625103-31-3P 625103-34-6P 625103-36-8P  
 625103-37-9P 625103-39-1P 625103-40-4P  
 625103-42-6P 625103-43-7P 625103-51-7P  
 625103-68-6P 625103-72-2P 625103-87-9P  
 625104-13-4P 625104-18-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(preparation of carboxylic acid amides as inhibitors of blood-coagulation  
 factor Xa and VIIa)

RN 625102-49-0 CAPLUS


CN Pentanamide, N-[4-(2-amino-4,5-dihydro-1H-imidazol-1-yl)-3-methylphenyl]-2-  
 [[[4-(4-chlorophenyl)amino]carbonyl]amino]-, (2R)-, 2,2,2-trifluoroacetate  
 (1:1) (CA INDEX NAME)

CM 1

CRN 625102-48-9

CMF C22 H27 Cl N6 O2


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 625102-86-5 CAPLUS

CN Pentanamide, 2-[[[4-(4-chlorophenyl)amino]carbonyl]amino]-N-[4-[2-(  
 (cyanoamino)-4,5-dihydro-1H-imidazol-1-yl]phenyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 625102-88-7 CAPLUS

CN Pentanamide, 2-[[[4-(2-cyanoimino)-3-methyl-1-imidazolidinyl]phenyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 625102-90-1 CAPLUS

CN Pentanamide, N-[4-(2-amino-4,5-dihydro-1H-imidazol-1-yl)phenyl]-2-[[[4-(4-chlorophenyl)amino]carbonyl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 625102-91-2 CAPLUS  
 CN Pentanamide, N-[4-(2-amino-4,5-dihydro-1H-imidazol-1-yl)phenyl]-2-[[[(4-chlorophenyl)amino]carbonyl]amino]-, (2R)-, 2,2,2-trifluoroacetate (1:1)  
 (CA INDEX NAME)

CM 1


CRN 625102-90-1  
 CMF C21 H25 Cl N6 O2

Absolute stereochemistry.




CM 2

CRN 76-05-1  
 CMF C2 H F3 O2



RN 625102-93-4 CAPLUS  
 CN Pentanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-imino-1-pyrrolidinyl)phenyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 625102-94-5 CAPLUS  
CN Pentanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-imino-1-pyrrolidinyl)phenyl]-, (2R)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1


CRN 625102-93-4  
CMF C22 H26 Cl N5 O2

Absolute stereochemistry.




CM 2

CRN 76-05-1  
CMF C2 H F3 O2



RN 625103-02-8 CAPLUS  
CN Propanamide, N-[4-(2-amino-4,5-dihydro-1H-imidazol-1-yl)phenyl]-2-[[[(4-chlorophenyl)amino]carbonyl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 625103-03-9 CAPLUS  
CN Propanamide, N-[4-(2-amino-4,5-dihydro-1H-imidazol-1-yl)phenyl]-2-[[[(4-chlorophenyl)amino]carbonyl]amino]-, (2R)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1


CRN 625103-02-8  
CMF C19 H21 Cl N6 O2

Absolute stereochemistry.



CM 2


CRN 76-05-1  
CMF C2 H F3 O2



RN 625103-05-1 CAPLUS

CN Propanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-[2-(cyanoimino)-3-methyl-1-imidazolidinyl]phenyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.



RN 625103-06-2 CAPLUS

CN Propanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-[2-(cyanoimino)-3-methyl-1-imidazolidinyl]phenyl]-, (2R)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 625103-05-1

CMF C21 H22 Cl N7 O2

Absolute stereochemistry.  
Double bond geometry unknown.






CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 625103-08-4 CAPLUS

CN Propanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-imino-1-pyrrolidinyl)phenyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 625103-09-5 CAPLUS


CN Propanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-imino-1-pyrrolidinyl)phenyl]-, (2R)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 625103-08-4

CMF C20 H22 Cl N5 O2


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 625103-11-9 CAPLUS

CN Butanamide, N-[4-(2-amino-4,5-dihydro-1H-imidazol-1-yl)phenyl]-2-[[[(4-chlorophenyl)amino]carbonyl]amino]-3-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 625103-12-0 CAPLUS

CN Butanamide, N-[4-(2-amino-4,5-dihydro-1H-imidazol-1-yl)phenyl]-2-[[[(4-


chlorophenyl)amino]carbonyl]amino]-3-methyl-, (2R)-,  
2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 625103-11-9

CMF C21 H25 Cl N6 O2


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 625103-14-2 CAPLUS

CN Butanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-[2-(cyanoimino)-3-methyl-1-imidazolidinyl]phenyl]-3-methyl-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 625103-15-3 CAPLUS  
 CN Butanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-[2-(cyanoimino)-3-methyl-1-imidazolidinyl]phenyl]-3-methyl-, (2R)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 625103-14-2  
 CMF C23 H26 Cl N7 O2

Absolute stereochemistry.  
 Double bond geometry unknown.



CM 2


CRN 76-05-1  
 CMF C2 H F3 O2



RN 625103-16-4 CAPLUS

CN Butanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-imino-1-pyrrolidinyl)phenyl]-3-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 625103-17-5 CAPLUS


CN Butanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-imino-1-pyrrolidinyl)phenyl]-3-methyl-, (2R)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 625103-16-4


CMF C22 H26 Cl N5 O2

Absolute stereochemistry.




CM 2

CRN 76-05-1  
CMF C2 H F3 O2



RN 625103-19-7 CAPLUS  
CN Pentanamide, N-[4-(2-amino-4,5-dihydro-1H-imidazol-1-yl)phenyl]-2-[[[4-chlorophenyl)amino]carbonyl]amino]-4-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 625103-20-0 CAPLUS  
CN Pentanamide, N-[4-(2-amino-4,5-dihydro-1H-imidazol-1-yl)phenyl]-2-[[[4-chlorophenyl)amino]carbonyl]amino]-4-methyl-, (2R)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 625103-19-7  
CMF C22 H27 Cl N6 O2


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 625103-22-2 CAPLUS

CN Pentanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-[2-(cyanoimino)-3-methyl-1-imidazolidinyl]phenyl]-4-methyl-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.



RN 625103-23-3 CAPLUS


CN Pentanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-[2-(cyanoimino)-3-methyl-1-imidazolidinyl]phenyl]-4-methyl-, (2R)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 625103-22-2

CMF C24 H28 Cl N7 O2


Absolute stereochemistry.  
Double bond geometry unknown.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 625103-25-5 CAPLUS

CN Pentanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-imino-1-pyrrolidinyl)phenyl]-4-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 625103-26-6 CAPLUS

CN Pentanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-imino-1-pyrrolidinyl)phenyl]-4-methyl-, (2R)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)




CM 1

CRN 625103-25-5

CMF C23 H28 Cl N5 O2


Absolute stereochemistry.



CM 2



CRN 76-05-1

CMF C2 H F3 O2



RN 625103-28-8 CAPLUS

CN Propanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-imino-1-pyrrolidinyl)phenyl]-3-methoxy- (CA INDEX NAME)




RN 625103-29-9 CAPLUS  
 CN Propanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-imino-1-pyrrolidinyl)phenyl]-3-methoxy-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 625103-28-8  
 CMF C21 H24 Cl N5 O3

PAGE 1-A




PAGE 2-A





CM 2

CRN 76-05-1  
CMF C2 H F3 O2



RN 625103-31-3 CAPLUS  
CN Propanamide, 2-[[[4-(4-chlorophenyl)amino]carbonyl]amino]-N-[4-[2-(cyanoamino)-4,5-dihydro-1H-imidazol-1-yl]phenyl]-3-methoxy- (CA INDEX NAME)




RN 625103-34-6 CAPLUS  
 CN 1H-Imidazole-4-propanamide,  $\alpha$ -[[[4-chlorophenyl]amino]carbonyl]amino]-N-[4-[2-(cyanoamino)-4,5-dihydro-1H-imidazol-1-yl]phenyl]-1-methyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 625103-33-5  
 CMF C24 H24 Cl N9 O2

PAGE 1-A




PAGE 2-A




CM 2

CRN 76-05-1  
CMF C2 H F3 O2



RN 625103-36-8 CAPLUS  
CN Propanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(5-ethyl-2-imino-1,3,4-thiadiazol-3(2H)-yl)phenyl]-3-methoxy- (CA INDEX NAME)




RN 625103-37-9 CAPLUS

CN Propanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(5-ethyl-2-imino-1,3,4-thiadiazol-3(2H)-yl)phenyl]-3-methoxy-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 625103-36-8


CMF C21 H23 Cl N6 O3 S



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 625103-39-1 CAPLUS


CN 1,3,4-Thiadiazole-2-carboxamide, 4-[4-[[2-[[[(4-chlorophenyl)amino]carbonyl]amino]-3-methoxy-1-oxopropyl]amino]phenyl]-4,5-dihydro-5-imino- (CA INDEX NAME)



RN 625103-40-4 CAPLUS  
 CN 1,3,4-Thiadiazole-2-carboxamide, 4-[4-[[2-[[[(4-chlorophenyl)amino]carbonyl]amino]-3-methoxy-1-oxopropyl]amino]phenyl]-4,5-dihydro-5-imino-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 625103-39-1  
 CMF C20 H20 Cl N7 O4 S




CM 2

CRN 76-05-1  
 CMF C2 H F3 O2




RN 625103-42-6 CAPLUS  
 CN 1,3,4-Thiadiazole-2-carboxylic acid, 4-[4-[[2-[[[(4-chlorophenyl)amino]carbonyl]amino]-3-methoxy-1-oxopropyl]amino]phenyl]-4,5-dihydro-5-imino-, ethyl ester (CA INDEX NAME)



RN 625103-43-7 CAPLUS  
 CN 1,3,4-Thiadiazole-2-carboxylic acid, 4-[4-[[2-[[[(4-chlorophenyl)amino]carbonyl]amino]-3-methoxy-1-oxopropyl]amino]phenyl]-4,5-dihydro-5-imino-, ethyl ester, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1


CRN 625103-42-6  
 CMF C22 H23 Cl N6 O5 S



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 625103-51-7 CAPLUS


CN Carbamic acid, (4-chlorophenyl)-, 2-[[4-(2-imino-1-piperidiny)phenyl]amino]-1-methyl-2-oxoethyl ester (9CI) (CA INDEX NAME)



RN 625103-68-6 CAPLUS

CN Propanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-imino-1-piperidiny)phenyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 625103-72-2 CAPLUS



CN Pentanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-imino-1-piperidinyl)phenyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 625103-87-9 CAPLUS

CN Pentanamide, N-[4-(2-amino-4,5-dihydro-1H-imidazol-1-yl)-3-methylphenyl]-2-[[[(4-chlorophenyl)amino]carbonyl]amino]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.




RN 625104-13-4 CAPLUS

CN 1H-Imidazole-4-propanamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-[2-(cyanoamino)-4,5-dihydro-1H-imidazol-1-yl]phenyl]-1-methyl-, ( $\alpha$ R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 625104-18-9 CAPLUS  
 CN Butanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-imino-1-piperidinyl)phenyl]-4-(methylsulfonyl)- (CA INDEX NAME)




REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 60 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2003:598507 CAPLUS  
 DOCUMENT NUMBER: 140:70458  
 TITLE: Nonpeptide gastrin releasing peptide receptor antagonists inhibit the proliferation of lung cancer cells  
 AUTHOR(S): Moody, Terry W.; Leyton, Julius; Garcia-Marin, Luis; Jensen, Robert T.  
 CORPORATE SOURCE: Center for Cancer Research, Office of the Director, National Cancer Institute, Department of Health and Human Services, National Institutes of Health, Bethesda, MD, 20892, USA  
 SOURCE: European Journal of Pharmacology (2003), 474(1), 21-29  
 CODEN: EJPHAZ; ISSN: 0014-2999  
 PUBLISHER: Elsevier Science B.V.  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 IT 204066-82-0, PD168368 204067-01-6, PD176252  
 RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (nonpeptide gastrin releasing peptide receptor antagonists inhibit the proliferation of lung cancer cells)  
 RN 204066-82-0 CAPLUS  
 CN 1H-Indole-3-propanamide,  $\alpha$ -methyl- $\alpha$ -[[[(4-


nitrophenyl)amino]carbonyl]amino]-N-[[1-(2-pyridinyl)cyclohexyl]methyl]-,  
( $\alpha$ S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 204067-01-6 CAPLUS  
CN 1H-Indole-3-propanamide, N-[[1-(5-methoxy-2-pyridinyl)cyclohexyl]methyl]-  
 $\alpha$ -methyl- $\alpha$ -[[[4-nitrophenyl)amino]carbonyl]amino]-,  
( $\alpha$ S)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 61 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 2003:442763 CAPLUS  
DOCUMENT NUMBER: 139:207078  
TITLE: High-affinity thrombin receptor (PAR-1) ligands: a new  
generation of indole-based peptide mimetic antagonists  
with a basic amine at the C-terminus  
AUTHOR(S): Zhang, Han-Cheng; White, Kimberly B.; McComsey, David  
F.; Addo, Michael F.; Andrade-Gordon, Patricia;  
Derian, Claudia K.; Oksenberg, Donna; Maryanoff, Bruce  
E.

CORPORATE SOURCE: Drug Discovery, Johnson & Johnson Pharmaceutical  
Research & Development, Spring House, PA, 19477-0776,  
USA

SOURCE: Bioorganic & Medicinal Chemistry Letters (2003),  
13(13), 2199-2203  
CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English


OTHER SOURCE(S): CASREACT 139:207078

IT 587887-12-5P 587887-14-7P 587887-15-8P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
(Uses)  
(high-affinity thrombin receptor (PAR-1) ligands as platelet  
aggregation inhibitors)

RN 587887-12-5 CAPLUS

CN L-Histidinamide, 4-chloro-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-  
pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(3-  
aminopropyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 587887-14-7 CAPLUS


CN L-Alaninamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-  
pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-2-fluoro-L-phenylalanyl-  
N-(2-aminoethyl)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 587887-15-8 CAPLUS  
 CN L-Alaninamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(2-aminoethyl)-3-(2-thienyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 62 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:376636 CAPLUS

DOCUMENT NUMBER: 138:385436

TITLE: Preparation of  
 4-(1,1-dioxido-2-isothiazolidinyl)benzenamines as  
 inhibitors of blood-coagulation factor Xa for the  
 treatment of thromboembolic diseases

INVENTOR(S): Dorsch, Dieter; Cezanne, Bertram; Tsaklakidis,  
 Christos; Mederski, Werner; Gleitz, Johannes; Barnes,  
 Christopher

PATENT ASSIGNEE(S): Merck Patent Gmbh, Germany

SOURCE: PCT Int. Appl., 81 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1


## PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003039543	A1	20030515	WO 2002-EP11349	20021010
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10155075	A1	20030522	DE 2001-10155075	20011109
CA 2465713	A1	20030515	CA 2002-2465713	20021010
AU 2002363366	A1	20030519	AU 2002-363366	20021010
AU 2002363366	B2	20071122		
EP 1441726	A1	20040804	EP 2002-802623	20021010
EP 1441726	B1	20061220		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002013680	A	20041026	BR 2002-13680	20021010
HU 2004001983	A2	20050128	HU 2004-1983	20021010
CN 1582148	A	20050216	CN 2002-821919	20021010
JP 2005522412	T	20050728	JP 2003-541834	20021010
AT 348611	T	20070115	AT 2002-802623	20021010
RU 2301228	C2	20070620	RU 2004-117594	20021010
ES 2277623	T3	20070716	ES 2002-802623	20021010
MX 2004004307	A	20040811	MX 2004-4307	20040506
US 20040254175	A1	20041216	US 2004-495254	20040510
US 7199133	B2	20070403		
ZA 2004004549	A	20050204	ZA 2004-4549	20040608
PRIORITY APPLN. INFO.:			DE 2001-10155075	A 20011109
			WO 2002-EP11349	W 20021010
OTHER SOURCE(S): MARPAT 138:385436				
IT	524957-18-4P 524957-19-5P 524957-21-9P			
	524957-22-0P			
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (drug candidate; preparation of isothiazolidinylbenzenamines as inhibitors of blood coagulation factor Xa for the treatment of thromboembolic diseases)			
RN	524957-18-4 CAPLUS			
CN	Benzenepropanamide, $\alpha$ -[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(1,1-dioxido-2-isothiazolidinyl)-3-methylphenyl]- (CA INDEX NAME)			

PAGE 1-A




PAGE 2-A




RN 524957-19-5 CAPLUS  
CN Pentanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(1,1-dioxido-2-isothiazolidinyl)-3-methylphenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 524957-21-9 CAPLUS  
CN Carbamic acid, (4-chlorophenyl)-, 1-[[[4-(1,1-dioxido-2-isothiazolidinyl)-3-methylphenyl]amino]carbonyl]butyl ester (9CI) (CA INDEX NAME)





PAGE 1-A



PAGE 2-A




RN 524957-22-0 CAPLUS  
CN Carbamic acid, (4-chlorophenyl)-, 2-[[4-(1,1-dioxido-2-isothiazolidinyl)-3-methylphenyl]amino]-2-oxo-1-(phenylmethyl)ethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 63 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2003:262954 CAPLUS  
 DOCUMENT NUMBER: 139:173167  
 TITLE: Design, synthesis, and structure-activity relationship of a new class of amidinophenylurea-based factor VIIa inhibitors  
 AUTHOR(S): Klingler, Otmar; Matter, Hans; Schudok, Manfred; Bajaj, S. Paul; Czech, Joerg; Lorenz, Martin; Nestler, Hans Peter; Schreuder, Herman; Wildgoose, Peter  
 CORPORATE SOURCE: Aventis Pharma Deutschland GmbH, Frankfurt, D-65926, Germany  
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2003), 13(8), 1463-1467  
 CODEN: BMCLE8; ISSN: 0960-894X  
 PUBLISHER: Elsevier Science B.V.  
 DOCUMENT TYPE: Journal

LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 139:173167  
 IT 379259-63-9P 581079-04-1P 581079-05-2P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (design, synthesis, and structure-activity relationship of a new class of amidinophenylurea-based factor VIIa inhibitors)  
 RN 379259-63-9 CAPLUS  
 CN Benzenepropanamide,  $\alpha$ -[[[4-(aminoiminomethyl)phenyl]amino]carbonyl]amino]-N-[[4-(dimethylamino)phenyl]methyl]- (CA INDEX NAME)




RN 581079-04-1 CAPLUS  
 CN Propanamide, 2-[[[4-(aminoiminomethyl)phenyl]amino]carbonyl]amino]-N-[[3,4-dichlorophenyl]methyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 581079-05-2 CAPLUS  
 CN Pentanoic acid, 4-[[[4-(aminoiminomethyl)phenyl]amino]carbonyl]amino]-5-[[[(1S)-1-(3-bromophenyl)ethyl]amino]-5-oxo-, (4S)- (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


ACCESSION NUMBER: 2003:76556 CAPLUS  
 DOCUMENT NUMBER: 138:131125  
 TITLE: Fat accumulation-modulating compounds  
 INVENTOR(S): Stevenson, Michael John; Leighton, Harry Jefferson  
 PATENT ASSIGNEE(S): Adipogenix, Inc., USA  
 SOURCE: PCT Int. Appl., 96 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003007888	A2	20030130	WO 2002-US23295	20020722
WO 2003007888	A3	20031127		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002322585	A1	20030303	AU 2002-322585	20020722
US 20030144350	A1	20030731	US 2002-201588	20020722
PRIORITY APPLN. INFO.:			US 2001-306837P	P 20010720
			WO 2002-US23295	W 20020722


OTHER SOURCE(S): MARPAT 138:131125  
 IT 491868-39-4 491868-45-2 491868-51-0  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (fat accumulation-modulating compds.)  
 RN 491868-39-4 CAPLUS  
 CN Pentanamide, N-[2-(3,4-dimethoxyphenyl)ethyl]-2-[[[(2,6-dimethylphenyl)amino]carbonyl]amino]- (CA INDEX NAME)



RN 491868-45-2 CAPLUS  
 CN Benzenepropanamide,  $\alpha$ -[[[(3,4-dichlorophenyl)amino]carbonyl]amino]-N-(3,3-diphenylpropyl)- (CA INDEX NAME)



RN 491868-51-0 CAPLUS  
 CN Benzenepropanamide, N-[1,1'-biphenyl]-2-yl-α-[[[(4-methoxyphenyl)amino]carbonyl]amino]- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 65 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:964345 CAPLUS

DOCUMENT NUMBER: 138:24952

TITLE: Preparation of novel amino nitriles useful as reversible inhibitors of cysteine proteases

INVENTOR(S): Hickey, Eugene R.; Bekkali, Younes; Patel, Usha R.; Spero, Denice M.; Thomson, David S.; Young, Erick R.

PATENT ASSIGNEE(S): Boehringer Ingelheim Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 223 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002100849	A2	20021219	WO 2002-US17590	20020605
WO 2002100849	A3	20031016		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 20030119827	A1	20030626	US 2002-163015	20020604
US 6982263	B2	20060103		
CA 2449192	A1	20021219	CA 2002-2449192	20020605
AU 2002314898	A1	20021223	AU 2002-314898	20020605
EP 1399431	A2	20040324	EP 2002-741825	20020605

EP 1399431 B1 20090218  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR  
 JP 2005501017 T 20050113 JP 2003-503617 20020605  
 AT 423108 T 20090315 AT 2002-741825 20020605  
 MX 2003011113 A 20040319 MX 2003-11113 20031203  
 PRIORITY APPLN. INFO.: US 2001-296863P P 20010608  
 WO 2002-US17590 W 20020605  
 OTHER SOURCE(S): MARPAT 138:24952  
 IT 478279-85-5P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)  
 (preparation of novel amino nitriles as reversible inhibitors of cysteine  
 proteases)  
 RN 478279-85-5 CAPLUS  
 CN Carbamic acid, 2-naphthalenyl-, 1-[[[3-cyano-1-cyclohexyl-3-  
 pyrrolidiny]amino]carbonyl]-3-methylbutyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 66 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2002:928230 CAPLUS  
 DOCUMENT NUMBER: 138:19472  
 TITLE: Method of identifying inhibitors of Cdc25 using three  
 dimensional crystal structure of the catalytic domain  
 of Cdc25  
 INVENTOR(S): Taylor, Neil R.; Borhani, David; Epstein, David;  
 Rudolph, Johannes; Ritter, Kurt; Fujimori, Taro;  
 Robinson, Simon; Eckstein, Jens; Haupt, Andreas;  
 Walker, Nigel; Dixon, Richard W.; Choquette, Deborah;  
 Blanchard, Jill; Kluge, Arthur; Pal, Kollol;  
 Bockovich, Nicholas; Come, Jon; Hediger, Mark  
 PATENT ASSIGNEE(S): Australia  
 SOURCE: U.S. Pat. Appl. Publ., 246 pp., Cont.-in-part of U.S.  
 Ser. No. 645,750.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20020183249	A1	20021205	US 2001-797500	20010301
PRIORITY APPLN. INFO.:			US 1999-172215P	P 19990831
			US 2000-645750	A2 20000824


OTHER SOURCE(S): MARPAT 138:19472  
 IT 329274-00-2P 329274-01-3P 329274-03-5P  
 RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)  
 (method of identifying inhibitors of Cdc25 using three dimensional

crystal structure of catalytic domain of Cdc25)

RN 329274-00-2 CAPLUS

CN L-Norvalinamide, N-[(2-naphthalenylamino)carbonyl]-4-(sulfomethyl)-L-phenylalanyl-L-norvalyl-2-methyl-L-prolyl-3-benzo[b]thien-3-yl-L-alanyl-5-carboxy-N-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 329274-01-3 CAPLUS

CN L-Norvalinamide, N-[(1-naphthalenylamino)carbonyl]-4-(sulfomethyl)-L-phenylalanyl-L-norvalyl-2-methyl-L-prolyl-3-benzo[b]thien-3-yl-L-alanyl-5-carboxy-N-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 329274-03-5 CAPLUS

CN L-Norvalinamide, N-[(phenylamino)carbonyl]-4-(sulfomethyl)-L-phenylalanyl-L-norvalyl-2-methyl-L-prolyl-3-benzo[b]thien-3-yl-L-alanyl-5-carboxy-N-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

—SO<sub>3</sub>H

L5 ANSWER 67 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2002:869567 CAPLUS  
 DOCUMENT NUMBER: 137:370356  
 TITLE: Preparation and use of bombesin receptor antagonists  
 for treatment of sexual dysfunction in males and  
 females  
 INVENTOR(S): Gonzalez, Maria Isabel; Higginbottom, Michael; Stock,  
 Herman Thijs; Pritchard, Martyn Clive; Pinnock, Robert  
 Denham; Van der Graaf, Pieter Hadewijn; Naylor,  
 Alisdair Mark; Wayman, Christopher Peter  
 PATENT ASSIGNEE(S): UK  
 SOURCE: U.S. Pat. Appl. Publ., 105 pp., Cont.-in-part of U.S.  
 Pat. Appl. 2002 58,606.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 10  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20020169101	A1	20021114	US 2001-999284	20011115
US 20020058606	A1	20020516	US 2001-759777	20010112
ZA 2003003249	A	20040623	ZA 2003-3249	20030425
PRIORITY APPLN. INFO.:			US 1999-133355P	P 19990510
			WO 2000-GB1787	W 20000510
			US 2000-700165	A2 20001109
			US 2001-759777	A2 20010112
			GB 2001-9910	A 20010423
			GB 2001-11037	A 20010504

OTHER SOURCE(S): MARPAT 137:370356  
 IT 204067-01-6 428864-38-4




RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)  
(preparation of as bombesin receptor antagonists for treatment of sexual  
dysfunction)

RN 204067-01-6 CAPLUS

CN 1H-Indole-3-propanamide, N-[[1-(5-methoxy-2-pyridinyl)cyclohexyl]methyl]-  
 $\alpha$ -methyl- $\alpha$ -[[[(4-nitrophenyl)amino]carbonyl]amino]-,  
( $\alpha$ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 428864-38-4 CAPLUS

CN 1H-Indole-3-propanamide, N-[[1-(4-aminophenyl)cyclohexyl]methyl]- $\alpha$ -  
methyl- $\alpha$ -[[[(4-nitrophenyl)amino]carbonyl]amino]-, ( $\alpha$ S)- (CA  
INDEX NAME)

Absolute stereochemistry.




IT 204066-72-8 204066-76-2 204066-78-4  
204066-79-5 204066-82-0 204066-83-1  
204066-84-2 204066-89-7 204066-95-5  
428864-39-5 428864-40-8 428864-41-9

428864-42-0 428864-49-7 428864-51-1  
 428864-53-3 428864-54-4 428864-56-6  
 428864-57-7 428864-58-8 428864-59-9  
 475247-11-1 475247-13-3 475247-25-7

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (preparation of as bombesin receptor antagonists for treatment of sexual  
 dysfunction)

RN 204066-72-8 CAPLUS


CN 1H-Indole-3-propanamide,  $\alpha$ -[[[2,6-bis(1-  
 methylethyl)phenyl]amino]carbonyl]amino]-N-(2-cyclohexylethyl)- $\alpha$ -  
 methyl- (CA INDEX NAME)



RN 204066-76-2 CAPLUS


CN 1H-Indole-3-propanamide, N-(cyclohexylmethyl)- $\alpha$ -methyl- $\alpha$ -[[[4-  
 nitrophenyl]amino]carbonyl]amino]-, ( $\alpha$ S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 204066-78-4 CAPLUS

CN 1H-Indole-3-propanamide,  $\alpha$ -[[[2,6-bis(1-  
 methylethyl)phenyl]amino]carbonyl]methylamino]-N-(cyclohexylmethyl)- (CA  
 INDEX NAME)




RN 204066-79-5 CAPLUS  
 CN 1H-Indole-3-propanamide,  $\alpha$ -[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]amino]-N-(cyclohexylmethyl)- $\alpha$ -methyl-, ( $\alpha$ S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 204066-82-0 CAPLUS  
 CN 1H-Indole-3-propanamide,  $\alpha$ -methyl- $\alpha$ -[[[(4-nitrophenyl)amino]carbonyl]amino]-N-[[1-(2-pyridinyl)cyclohexyl]methyl]-, ( $\alpha$ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 204066-83-1 CAPLUS

CN 1H-Indole-3-propanamide,  $\alpha$ -methyl-N-[[1-(2-pyridinyl)cyclohexyl]methyl]- $\alpha$ -[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]-, ( $\alpha$ S)- (CA INDEX NAME)


Absolute stereochemistry.




RN 204066-84-2 CAPLUS

CN Benzoic acid, 4-[[[(1S)-1-(1H-indol-3-ylmethyl)-1-methyl-2-oxo-2-[[[1-(2-pyridinyl)cyclohexyl]methyl]amino]ethyl]amino]carbonyl]amino]-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 204066-89-7 CAPLUS  
 CN Benzenepropanamide,  $\alpha$ -[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]amino]- $\alpha$ -methyl-N-[[1-(2-pyridinyl)cyclohexyl]methyl]-2-(trifluoromethyl)- (CA INDEX NAME)




RN 204066-95-5 CAPLUS  
 CN 1H-Imidazole-5-propanamide,  $\alpha$ -[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]amino]-N-[[1-(2-pyridinyl)cyclohexyl]methyl]- (CA INDEX NAME)




RN 428864-39-5 CAPLUS

CN 1H-Indole-3-propanamide, N-(cyclohexylmethyl)- $\alpha$ -[[[2-(1,1-dimethylethyl)phenyl]amino]carbonyl]amino]- $\alpha$ -methyl- (CA INDEX NAME)




RN 428864-40-8 CAPLUS


CN 1H-Indole-3-propanamide, N-(cyclohexylmethyl)- $\alpha$ -[[[2,6-dichlorophenyl]amino]carbonyl]amino]- $\alpha$ -methyl- (CA INDEX NAME)





RN 428864-41-9 CAPLUS  
 CN 1H-Indole-3-propanamide, N-(cyclohexylmethyl)- $\alpha$ -[[[2,6-dimethoxyphenyl)amino]carbonyl]amino]- $\alpha$ -methyl- (CA INDEX NAME)



RN 428864-42-0 CAPLUS  
 CN 1H-Indole-3-propanamide,  $\alpha$ -[[[[2,6-bis(dimethylamino)phenyl]amino]carbonyl]amino]-N-(cyclohexylmethyl)- $\alpha$ -methyl- (CA INDEX NAME)




RN 428864-49-7 CAPLUS  
 CN 1H-Indole-3-propanamide,  $\alpha$ -[[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]amino]- $\alpha$ -methyl-N-(3-phenylpropyl)- (CA INDEX NAME)




RN 428864-51-1 CAPLUS

CN 1H-Indole-3-propanamide,  $\alpha$ -[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]amino]- $\alpha$ -methyl-N-(2-phenylcyclohexyl)- (CA INDEX NAME)



RN 428864-53-3 CAPLUS


CN 1H-Indole-3-propanamide,  $\alpha$ -[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]amino]-N-[(1-hydroxycyclohexyl)methyl]- $\alpha$ -methyl- (CA INDEX NAME)






RN 428864-54-4 CAPLUS

CN 1H-Indole-3-propanamide,  $\alpha$ -[[[(2,6-bis(1-methylethyl)phenyl)amino]carbonyl]amino]- $\alpha$ -methyl-N-[[1-(2-pyridinyl)cyclohexyl]methyl]- (CA INDEX NAME)




RN 428864-56-6 CAPLUS

CN 1H-Indole-3-propanamide, N-[(1-hydroxycyclohexyl)methyl]- $\alpha$ -methyl- $\alpha$ -[[[(4-nitrophenyl)amino]carbonyl]amino]- (CA INDEX NAME)




RN 428864-57-7 CAPLUS

CN 1H-Indole-3-propanamide,  $\alpha$ -[[[(4-cyanophenyl)amino]carbonyl]amino]- $\alpha$ -methyl-N-[[1-(2-pyridinyl)cyclohexyl]methyl]- (CA INDEX NAME)




RN 428864-58-8 CAPLUS

CN Benzenepropanamide,  $\alpha$ -[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]amino]- $\alpha$ -methyl-2-nitro-N-[[1-(2-pyridinyl)cyclohexyl]methyl]- (CA INDEX NAME)




RN 428864-59-9 CAPLUS

CN 2-Pyridinepropanamide,  $\alpha$ -[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]amino]-N-(cyclohexylmethyl)- $\alpha$ -methyl- (CA INDEX NAME)




RN 475247-11-1 CAPLUS

CN 2-Pyridinepropanamide,  $\alpha$ -[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]methylamino]- $\alpha$ -methyl-N-[[1-(2-pyridinyl)cyclohexyl]methyl]-, 1-oxide (CA INDEX NAME)



RN 475247-13-3 CAPLUS


CN 2-Pyridinepropanamide,  $\alpha$ -[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]methylamino]- $\alpha$ -methyl-N-[[1-(2-pyridinyl)cyclohexyl]methyl]- (CA INDEX NAME)



RN 475247-25-7 CAPLUS


CN 1H-Indole-3-propanamide,  $\alpha$ -[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]methylamino]- $\alpha$ -methyl-N-[[1-(2-pyridinyl)cyclohexyl]methyl]-, 1-oxide (CA INDEX NAME)

methylethyl)phenyl]amino]carbonyl]amino]-N-(2,2-dimethyl-4-phenyl-1,3-dioxan-5-yl)- $\alpha$ -methyl- (CA INDEX NAME)



L5 ANSWER 68 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2002:813789 CAPLUS  
 DOCUMENT NUMBER: 138:280734  
 TITLE: 3D QSAR (COMFA) of a series of potent and highly selective VLA-4 antagonists  
 AUTHOR(S): Singh, Juswinder; Van Vlijmen, Herman; Lee, Wen-Cherng; Liao, Yusheng; Lin, Ko-Chung; Ateeq, Humayun; Cuervo, Julio; Zimmerman, Craig; Hammond, Charles; Karpusas, Michael; Palmer, Rex; Chattopadhyay, Tapan; Adams, Steven P.  
 CORPORATE SOURCE: Biogen Inc, Cambridge, MA, 02142, USA  
 SOURCE: Journal of Computer-Aided Molecular Design (2002), 16(3), 201-211  
 CODEN: JCADEQ; ISSN: 0920-654X  
 PUBLISHER: Kluwer Academic Publishers  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 IT 505082-10-0  
 RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (3D QSAR (COMFA) of a series of potent and highly selective VLA-4 antagonists)  
 RN 505082-10-0 CAPLUS  
 CN Benzenepropanoic acid, 3,4-dimethoxy- $\beta$ -[[[2S]-4-methyl-2-[[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]amino]carbonyl]amino]-1-oxopentyl]amino]-, ( $\beta$ S)- (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 69 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 2002:696111 CAPLUS  
DOCUMENT NUMBER: 137:228607  
TITLE: Crystal structure and three-dimensional structure of human Cdc25 catalytic domains and its use in designing peptidomimetic inhibitors  
INVENTOR(S): Taylor, Neil R.; Borhani, David; Epstein, David; Rudolph, Johannes; Ritter, Kurt; Fujimori, Taro; Robinson, Simon; Eckstein, Jens; Haupt, Andreas; Walker, Nigel; Dixon, Richard W.; Choquette, Deborah; Blanchard, Jill; Kluge, Arthur; Pal, Kollol; Bockovich, Nicholas; Come, Jon; Hediger, Mark  
PATENT ASSIGNEE(S): BASF Aktiengesellschaft, Germany; GPC Biotech Inc.  
SOURCE: PCT Int. Appl., 351 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
WO 2002070680	A1	20020912	WO 2001-US6587	20010301
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001241889	A1	20020919	AU 2001-241889	20010301
PRIORITY APPLN. INFO.:			WO 2001-US6587	W 20010301
OTHER SOURCE(S):	MARPAT	137:228607		
IT 329274-00-2P 329274-01-3P 329274-03-5P				
RL: SPN (Synthetic preparation); PREP (Preparation)				
(crystal structure and three-dimensional structure of human Cdc25 catalytic domains and its use in designing peptidomimetic inhibitors)				
RN 329274-00-2 CAPLUS				
CN L-Norvalinamide, N-[(2-naphthalenylamino)carbonyl]-4-(sulfomethyl)-L-phenylalanyl-L-norvalyl-2-methyl-L-prolyl-3-benzo[b]thien-3-yl-L-alanyl-5-carboxy-N-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.



RN 329274-03-5 CAPLUS  
CN L-Norvalinamide, N-[(phenylamino)carbonyl]-4-(sulfomethyl)-L-phenylalanyl-L-norvalyl-2-methyl-L-prolyl-3-benzo[b]thien-3-yl-L-alanyl-5-carboxy-N-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

```
L5      ANSWER 70 OF 188      CAPLUS  COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER:      2002:695975  CAPLUS
DOCUMENT NUMBER:      137:232913
TITLE:      Preparation of peptides for pharmaceutical use as
modulators of melanocortin receptors
INVENTOR(S):      Yu, Guixue; Macor, John; Herpin, Timothy; Lawrence, R.
Michael; Morton, George C.; Ruel, Rejean; Poindexter,
Graham S.; Ruediger, Edward H.; Thibault, Carl
PATENT ASSIGNEE(S):      Bristol-Myers Squibb Company, USA
SOURCE:      PCT Int. Appl., 107 pp.
CODEN: PIXXD2
DOCUMENT TYPE:      Patent
LANGUAGE:      English
FAMILY ACC. NUM. COUNT:      3
PATENT INFORMATION:
```

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002070511	A1	20020912	WO 2002-US6479	20020302
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2437594	A1	20020912	CA 2002-2437594	20020302
AU 2002254095	A1	20020919	AU 2002-254095	20020302

EP 1363898	A1	20031126	EP 2002-723310	20020302
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
HU 2004001544	A2	20041228	HU 2004-1544	20020302
JP 2005511475	T	20050428	JP 2002-569831	20020302
US 20030092732	A1	20030515	US 2002-90582	20020304
US 6979691	B2	20051227		
US 20030096827	A1	20030522	US 2002-90288	20020304
US 6713487	B2	20040330		
US 20040229882	A1	20041118	US 2003-696761	20031029
US 7067525	B2	20060627		
US 20060025403	A1	20060202	US 2005-199464	20050808
PRIORITY APPLN. INFO.:			US 2001-273206P	P 20010302
			US 2001-273291P	P 20010302
			WO 2002-US6479	W 20020302
			US 2002-90288	A3 20020304
			US 2002-90582	A3 20020304

OTHER SOURCE(S): MARPAT 137:232913

IT 457894-44-9P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of peptides for pharmaceutical use as modulators of melanocortin receptors)

RN 457894-44-9 CAPLUS

CN 1H-Imidazole-4-propanamide, N-[(1R)-1-[(4-methoxyphenyl)methyl]-2-oxo-2-[4-(1-oxobutyl)-4-phenyl-1-piperidinyl]ethyl]- $\alpha$ -[(phenylamino)carbonyl]amino]-, ( $\alpha$ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 71 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:695727 CAPLUS

DOCUMENT NUMBER: 137:226646

TITLE: Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-AMP associated disorders

INVENTOR(S): Macor, John E.; Carlson, Kenneth E.

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: PCT Int. Appl., 91 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English




FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002069905	A2	20020912	WO 2002-US6805	20020304
WO 2002069905	A3	20031009		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2439691	A1	20020912	CA 2002-2439691	20020304
AU 2002245601	A1	20020919	AU 2002-245601	20020304
US 20030069169	A1	20030410	US 2002-90258	20020304
EP 1370211	A2	20031217	EP 2002-713772	20020304
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2005506286	T	20050303	JP 2002-569083	20020304
HU 2006000103	A2	20060628	HU 2006-103	20020304
US 20040229882	A1	20041118	US 2003-696761	20031029
US 7067525	B2	20060627		
US 20060025403	A1	20060202	US 2005-199464	20050808
PRIORITY APPLN. INFO.:			US 2001-273206P	P 20010302
			US 2001-273291P	P 20010302
			US 2001-289719P	P 20010509
			US 2002-90288	A3 20020304
			US 2002-90582	A3 20020304
			WO 2002-US6805	W 20020304
OTHER SOURCE(S):	MARPAT 137:226646			
IT 457894-44-9P				
RL:	PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)			
	(Co-administration of melanocortin receptor agonist and cAMP phosphodiesterase inhibitor for treatment of cAMP-associated disorders)			
RN 457894-44-9	CAPLUS			
CN	1H-Imidazole-4-propanamide, N-[(1R)-1-[(4-methoxyphenyl)methyl]-2-oxo-2-[4-(1-oxobutyl)-4-phenyl-1-piperidinyl]ethyl]- $\alpha$ -[[(phenylamino)carbonyl]amino]-, ( $\alpha$ S)- (9CI) (CA INDEX NAME)			


Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 72 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2002:640061 CAPLUS  
 DOCUMENT NUMBER: 137:321739  
 TITLE: Homology-based model of the extracellular domain of the taste receptor T1R3  
 AUTHOR(S): Walters, D. Eric  
 CORPORATE SOURCE: Department of Biochemistry and Molecular Biology, Chicago Medical School, North Chicago, IL, 60064, USA  
 SOURCE: Pure and Applied Chemistry (2002), 74(7), 1117-1123  
 CODEN: PACHAS; ISSN: 0033-4545  
 PUBLISHER: International Union of Pure and Applied Chemistry  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 IT 135507-50-5, Superaspartame  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (mol. basis for ligand association with sweet receptor T1R3)  
 RN 135507-50-5 CAPLUS  
 CN L-Phenylalanine, N-[[[(4-cyanophenyl)amino]carbonyl]-L- $\alpha$ -aspartyl-, 2-methyl ester (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 73 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2002:595500 CAPLUS  
 DOCUMENT NUMBER: 137:150222  
 TITLE: Method for reducing or preventing the establishment, growth or metastasis of cancer by administering benzimidazolone peptidomimetics PAR-1 antagonist and


optionally PAR-2 antagonists  
 INVENTOR(S): D'Andrea, Michael; Derian, Claudia; Woodrow, Hal Brent  
 PATENT ASSIGNEE(S): USA  
 SOURCE: U.S. Pat. Appl. Publ., 44 pp., Cont.-in-part of U.S.  
 Ser. No. 599,826.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20020107204	A1	20020808	US 2001-865285	20010525
US 6630451	B1	20031007	US 2000-599826	20000622
US 20040063642	A1	20040401	US 2003-390098	20030317
US 6943149	B2	20050913		

PRIORITY APPLN. INFO.:  
 US 1999-141552P P 19990629  
 US 2000-599826 A2 20000622

OTHER SOURCE(S): MARPAT 137:150222  
 IT 315236-44-3  
 RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (benzimidazolone peptidomimetics PAR-1 antagonist and PAR-2 antagonists for inhibiting cancer and metastasis)  
 RN 315236-44-3 CAPLUS  
 CN L-Alaninamide, 3,4-difluoro-N-[[[3-[(4-fluorophenyl)methyl]-2,3-dihydro-2-oxo-1-[2-(1-pyrrolidinyl)ethyl]-1H-benzimidazol-5-yl]amino]carbonyl]-L-phenylalanyl-N-(2-aminoethyl)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 74 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2002:575744 CAPLUS  
 DOCUMENT NUMBER: 137:135069  
 TITLE: Method for reducing or preventing the establishment, growth or metastasis of cancer by administering indole peptidomimetics PAR-1 antagonist and optionally PAR-2 antagonists  
 INVENTOR(S): D'Andrea, Michael; Derian, Claudia; Woodrow, Hal Brent  
 PATENT ASSIGNEE(S): USA  
 SOURCE: U.S. Pat. Appl. Publ., 44 pp., Cont.-in-part of U.S.  
 Ser. No. 603,231.

DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

CODEN: USXXCO

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20020103138	A1	20020801	US 2001-865824	20010525
US 6858577	B1	20050222	US 2000-603231	20000626
US 20030224999	A1	20031204	US 2003-403542	20030331
US 7183252	B2	20070227		

PRIORITY APPLN. INFO.: US 1999-141550P P 19990629  
 US 2000-603231 A2 20000626

OTHER SOURCE(S): MARPAT 137:135069

IT 316150-87-5P, D-Histidinamide,  
 N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(phenylmethyl)-  
 316151-02-7P, L-Phenylalaninamide,  
 N2-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-arginyl-3,4-difluoro-N-(phenylmethyl)-  
 316151-51-6P, L-Alaninamide,  
 N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(phenylmethyl)-3-(4-pyridinyl)- 316151-53-8P, L-Phenylalaninamide,  
 N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-4-amino-N-(phenylmethyl)-  
 316151-69-6P, Benzenepropanamide,  
 N-[(1S)-4-amino-1-[(4-methyl-1-piperazinyl)carbonyl]butyl]- $\alpha$ -[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]amino]-3,4-difluoro-, ( $\alpha$ S)- 316151-71-0P  
 , Benzenepropanamide, N-[(1S)-4-amino-1-(1-piperidinylcarbonyl)butyl]-  
 $\alpha$ -[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]amino]-3,4-difluoro-, ( $\alpha$ S)-  
 316152-06-4P, L-Phenylalaninamide,  
 4-chloro-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(2-aminoethyl)-  
 316152-08-6P, L-Histidinamide,  
 4-chloro-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(2-aminoethyl)-  
 316152-10-0P, L-Alaninamide,  
 4-chloro-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(2-aminoethyl)-3-(4-pyridinyl)-  
 316152-11-1P, L-Alaninamide,  
 4-chloro-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(2-aminoethyl)-3-(2-thienyl)-  
 316152-13-3P, L-Alaninamide,  
 4-chloro-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(2-aminoethyl)-3-(4-thiazolyl)-  
 316152-15-5P, L-Phenylalaninamide,  
 N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(2-aminoethyl)-3-fluoro-  
 316152-17-7P, L-Alaninamide,  
 4-chloro-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-[2-[(1-iminoethyl)amino]ethyl]-  
 3-(4-pyridinyl)- 316152-25-7P, L-Alaninamide,  
 4-chloro-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(3-aminopropyl)-3-(4-pyridinyl)- 316152-37-1P, D-Alaninamide,  
 4-chloro-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-D-phenylalanyl-N-(2-aminoethyl)-3-(2-thienyl)-  
 316152-39-3P, L-Alaninamide,


3,4-difluoro-N-[[[1-[(3-methylphenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(3-aminopropyl)-3-(2-thienyl)-  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(inhibition of growth or metastasis of cancer by administering indole  
 peptidomimetics PAR-1 antagonists and combined with PAR-2 antagonists  
 and other agents in relation to immunostimulant activity)

RN 316150-87-5 CAPLUS

CN D-Histidinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316151-02-7 CAPLUS

CN L-Phenylalaninamide, N2-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-arginyl-3,4-difluoro-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316151-51-6 CAPLUS

CN L-Alaninamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(phenylmethyl)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316151-53-8 CAPLUS

CN L-Phenylalaninamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-4-amino-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316151-69-6 CAPLUS

CN Benzenepropanamide, N-[(1S)-4-amino-1-[(4-methyl-1-piperazinyl)carbonyl]butyl]-α-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]amino]-3,4-difluoro-, (αS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 316151-71-0 CAPLUS

CN Benzenepropanamide, N-[(1S)-4-amino-1-(1-piperidinylcarbonyl)butyl]-  
α-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-  
indol-6-yl]amino]carbonyl]amino]-3,4-difluoro-, (αS)- (CA INDEX  
NAME)


Absolute stereochemistry.



RN 316152-06-4 CAPLUS

CN L-Phenylalaninamide, 4-chloro-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-  
pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(2-  
aminoethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-08-6 CAPLUS

CN L-Histidinamide, 4-chloro-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(2-aminoethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 316152-10-0 CAPLUS

CN L-Alaninamide, 4-chloro-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(2-aminoethyl)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 316152-11-1 CAPLUS

CN L-Alaninamide, 4-chloro-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(2-aminoethyl)-3-(2-thienyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-13-3 CAPLUS

CN L-Alaninamide, 4-chloro-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(2-aminoethyl)-3-(4-thiazolyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-15-5 CAPLUS

CN L-Phenylalaninamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(2-aminoethyl)-3-fluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-17-7 CAPLUS

CN L-Alaninamide, 4-chloro-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-[2-[(1-iminoethyl)amino]ethyl]-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-25-7 CAPLUS

CN L-Alaninamide, 4-chloro-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(3-aminopropyl)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-37-1 CAPLUS

CN D-Alaninamide, 4-chloro-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-D-phenylalanyl-N-(2-aminoethyl)-3-(2-thienyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-39-3 CAPLUS

CN L-Alaninamide, 3,4-difluoro-N-[[[1-[(3-methylphenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(3-aminopropyl)-3-(2-thienyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 444160-88-7D, resin-bound


RL: RCT (Reactant); RACT (Reactant or reagent)

(inhibition of growth or metastasis of cancer by administering indole peptidomimetics PAR-1 antagonists and combined with PAR-2 antagonists and other agents in relation to immunostimulant activity)

RN 444160-88-7 CAPLUS

CN L-Alaninamide, 4-chloro-N-[[[1-[(2,6-dichlorophenyl)methyl]-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(2-aminoethyl)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 75 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:552324 CAPLUS

DOCUMENT NUMBER: 137:109488

TITLE: Preparation of peptidyl calcium channel blockers

INVENTOR(S): Booth, Richard John; Brogley, Louis; Cody, Wayne  
Livingston; Connor, David Thomas; Hamilton, Harriet  
Wall; He, John Xiaoqiang; Hu, Lain-Yen; Lescosky,  
Leonard Joseph; Malone, Thomas Charles; Nadasdi,  
Laszlo; Rafferty, Michael Francis; Roth, Bruce David;  
Silva, Diego F.; Song, Yuntao; Szoke, Balazs G.; Urge,  
Laszlo

PATENT ASSIGNEE(S): Warner-Lambert Company, USA; Neurex Corporation

SOURCE: U.S., 86 pp.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6423689	B1	20020723	US 1998-212785	19981216
PRIORITY APPLN. INFO.:			US 1997-68485P	P 19971222
OTHER SOURCE(S):	CASREACT 137:109488; MARPAT 137:109488			

IT 443690-43-5P 443690-44-6P 443690-46-8P  
443690-47-9P 443690-50-4P 443690-51-5P  
443690-53-7P 443690-54-8P 443690-56-0P  
443690-57-1P 443690-58-2P 443690-59-3P  
443690-60-6P 443690-61-7P 443690-62-8P  
443690-63-9P 443690-65-1P 443690-66-2P  
443690-67-3P 443690-68-4P 443690-69-5P  
443690-70-8P 443690-71-9P 443690-72-0P  
443690-73-1P 443690-74-2P 443690-75-3P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
(Uses)

(preparation of peptidyl calcium channel blockers)

RN 443690-43-5 CAPLUS

CN L-Tyrosine, N-[(phenylamino)carbonyl]-L-leucyl-O-(phenylmethyl)-,  
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 443690-44-6 CAPLUS

CN L-Tyrosine, N-[[ (4-nitrophenyl)amino]carbonyl]-L-leucyl-O-(phenylmethyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 443690-46-8 CAPLUS

CN L-Tyrosine, N-[[ (3-methoxyphenyl)amino]carbonyl]-L-leucyl-O-(phenylmethyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 443690-47-9 CAPLUS

CN L-Tyrosine, N-[[ (4-methylphenyl)amino]carbonyl]-L-leucyl-O-(phenylmethyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 443690-50-4 CAPLUS

CN L-Tyrosine, N-[[ (2-methylphenyl)amino]carbonyl]-L-leucyl-O-(phenylmethyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 443690-51-5 CAPLUS

CN L-Tyrosine, N-[[ (2,6-dimethylphenyl)amino]carbonyl]-L-leucyl-O-(phenylmethyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 443690-53-7 CAPLUS

CN L-Tyrosine, N-[[ [4-(methylthio)phenyl]amino]carbonyl]-L-leucyl-O-(phenylmethyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 443690-54-8 CAPLUS

CN L-Tyrosine, N-[[4-phenoxyphenyl]amino]carbonyl-L-leucyl-O-(phenylmethyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 443690-56-0 CAPLUS

CN L-Tyrosine, N-[[3,4,5-trimethoxyphenyl]amino]carbonyl-L-leucyl-O-(phenylmethyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 443690-57-1 CAPLUS

CN L-Tyrosine, N-[[4-methoxyphenyl]amino]carbonyl-L-leucyl-O-(phenylmethyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




Absolute stereochemistry.



RN 443690-58-2 CAPLUS

CN L-Tyrosine, N-[[ (2,4-difluorophenyl)amino]carbonyl]-L-leucyl-O-(phenylmethyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 443690-59-3 CAPLUS

CN L-Tyrosine, N-[[ [4-(trifluoromethyl)phenyl]amino]carbonyl]-L-leucyl-O-(phenylmethyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 443690-60-6 CAPLUS

CN L-Tyrosine, N-[[ (2-methoxyphenyl)amino]carbonyl]-L-leucyl-O-(phenylmethyl)-

, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 443690-61-7 CAPLUS

CN L-Tyrosine, N-[[ (3,5-dimethylphenyl)amino]carbonyl]-L-leucyl-O-(phenylmethyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 443690-62-8 CAPLUS

CN L-Tyrosine, N-[[ (2-chlorophenyl)amino]carbonyl]-L-leucyl-O-(phenylmethyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 443690-63-9 CAPLUS

CN L-Tyrosine, N-[[ (3-chlorophenyl)amino]carbonyl]-L-leucyl-O-(phenylmethyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 443690-65-1 CAPLUS

CN L-Tyrosine, N-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]-L-leucyl-O-(phenylmethyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 443690-66-2 CAPLUS


CN L-Tyrosine, N-[[[4-(ethoxycarbonyl)phenyl]amino]carbonyl]-L-leucyl-O-(phenylmethyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 443690-67-3 CAPLUS  
 CN L-Tyrosine, N-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]-L-leucyl-O-(phenylmethyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 443690-68-4 CAPLUS  
 CN L-Tyrosine, N-[(1-naphthalenylamino)carbonyl]-L-leucyl-O-(phenylmethyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 443690-69-5 CAPLUS  
 CN L-Tyrosine, N-[[[4-chlorophenyl]amino]carbonyl]-L-leucyl-O-(phenylmethyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 443690-70-8 CAPLUS

CN L-Tyrosine, N-[[ (2,3-dichlorophenyl)amino]carbonyl]-L-leucyl-O-(phenylmethyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 443690-71-9 CAPLUS

CN L-Tyrosine, N-[[ (2,4-dichlorophenyl)amino]carbonyl]-L-leucyl-O-(phenylmethyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 443690-72-0 CAPLUS

CN L-Tyrosine, N-[[[3,5-bis(trifluoromethyl)phenyl]amino]carbonyl]-L-leucyl-O-(phenylmethyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 443690-73-1 CAPLUS

CN L-Tyrosine, N-[[ (4-bromophenyl)amino]carbonyl]-L-leucyl-O-(phenylmethyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 443690-74-2 CAPLUS

CN L-Tyrosine, N-[[ (3,4-dichlorophenyl)amino]carbonyl]-L-leucyl-O-(phenylmethyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 443690-75-3 CAPLUS

CN L-Tyrosine, N-[[ (3,5-dichlorophenyl)amino]carbonyl]-L-leucyl-O-

(phenylmethyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 76 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:487398 CAPLUS

DOCUMENT NUMBER: 137:41784

TITLE: Nonpeptide bombesin receptor antagonists for treatment and diagnosis of anxiety, panic disorders, cancers, ulcers, and other conditions

INVENTOR(S): Pinnock, Robert Denham; Pritchard, Martyn Clive

PATENT ASSIGNEE(S): Warner-Lambert Company, USA; Lucas, Brian Ronald

SOURCE: PCT Int. Appl., 48 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
WO 2002049644	A1	20020627	WO 2000-GB4915	20001220
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2432066	A1	20020627	CA 2000-2432066	20001220
AU 2001023816	A	20020701	AU 2001-23816	20001220
EP 1343498	A1	20030917	EP 2000-987567	20001220
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
HU 2003002496	A2	20031229	HU 2003-2496	20001220
BR 2000017393	A	20040203	BR 2000-17393	20001220
ZA 2003003723	A	20040514	ZA 2003-3723	20030514
MX 2003005567	A	20031006	MX 2003-5567	20030619
PRIORITY APPLN. INFO.:			WO 2000-GB4915	W 20001220
OTHER SOURCE(S):	MARPAT 137:41784			
IT 204067-01-6				
RL:	DGN (Diagnostic use); PAC (Pharmacological activity); THU (Therapeutic			


use); BIOL (Biological study); USES (Uses)

(nonpeptide bombesin receptor antagonists for treatment and diagnosis of anxiety, panic disorders, cancers, ulcers, and other conditions)

RN 204067-01-6 CAPLUS

CN 1H-Indole-3-propanamide, N-[[1-(5-methoxy-2-pyridinyl)cyclohexyl)methyl]- $\alpha$ -methyl- $\alpha$ -[[[(4-nitrophenyl)amino]carbonyl]amino]-, ( $\alpha$ S)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 77 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:465965 CAPLUS

DOCUMENT NUMBER: 137:47128

TITLE: Preparation of of ureido- and carbamoyloxy-substituted amides as inhibitors of factor Xa for the treatment of clotting disorders and tumors.

INVENTOR(S): Dorsch, Dieter; Mederski, Werner; Tsaklakidis, Christos; Cezanne, Bertram; Gleitz, Johannes; Barnes, Christopher

PATENT ASSIGNEE(S): Merck Patent G.m.b.H., Germany

SOURCE: PCT Int. Appl., 92 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002048099	A1	20020620	WO 2001-EP13545	20011121
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			



DE 10063008	A1	20020620	DE 2000-10063008	20001216
CA 2431766	A1	20020620	CA 2001-2431766	20011121
AU 2002021881	A	20020624	AU 2002-21881	20011121
EP 1341755	A1	20030910	EP 2001-270524	20011121
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001016115	A	20031223	BR 2001-16115	20011121
HU 2003003296	A2	20040128	HU 2003-3296	20011121
HU 2003003296	A3	20060428		
JP 2004515538	T	20040527	JP 2002-549632	20011121
NO 2003002695	A	20030613	NO 2003-2695	20030613
MX 2003005342	A	20031006	MX 2003-5342	20030613
US 20040038858	A1	20040226	US 2003-450651	20030616
IN 2003KN00896	A	20050311	IN 2003-KN896	20030714
ZA 2003005455	A	20040826	ZA 2003-5455	20030715
US 20050137230	A1	20050623	US 2005-59655	20050217

PRIORITY APPLN. INFO.:

DE 2000-10063008	A	20001216
WO 2001-EP13545	W	20011121
US 2003-450651	A3	20030616

OTHER SOURCE(S): MARPAT 137:47128

IT 438053-48-6P 438053-49-7P 438053-50-0P  
438053-51-1P 438053-52-2P 438053-53-3P  
438053-54-4P 438053-55-5P 438053-57-7P  
438053-58-8P 438053-59-9P 438053-60-2P  
438053-61-3P 438053-62-4P 438053-63-5P  
438053-64-6P 438053-65-7P 438053-66-8P  
438053-68-0P 438053-69-1P 438053-70-4P  
438053-71-5P 438053-72-6P 438053-73-7P  
438053-74-8P 438053-75-9P 438053-76-0P  
438053-77-1P 438053-78-2P 438053-79-3P  
438053-80-6P 438053-81-7P 438053-82-8P  
438053-83-9P 438053-84-0P 438053-86-2P  
438053-87-3P 438053-88-4P 438053-89-5P  
438053-91-9P 438053-92-0P 438053-93-1P  
438053-94-2P 438053-95-3P 438053-96-4P  
438053-97-5P 438053-98-6P 438053-99-7P  
438054-00-3P 438054-01-4P 438054-02-5P  
438054-03-6P 438054-04-7P 438054-05-8P  
438054-06-9P 438054-07-0P 438054-08-1P  
438054-09-2P 438054-10-5P 438054-11-6P  
438054-12-7P 438054-13-8P 438054-14-9P  
438054-15-0P 438054-17-2P 438054-18-3P  
438054-19-4P 438054-20-7P 438054-21-8P  
438054-22-9P 438054-23-0P 438054-24-1P  
438054-26-3P 438054-27-4P 438054-29-6P  
438054-31-0P 438054-32-1P 438054-39-8P  
438054-40-1P 438054-42-3P 438054-43-4P  
438054-44-5P 438054-45-6P 438054-46-7P  
438054-47-8P 438054-48-9P 438054-50-3P  
438054-51-4P 438054-52-5P 438054-53-6P  
438054-54-7P 438054-59-2P 438054-61-6P  
438054-62-7P 438054-63-8P 438054-68-3P  
438054-73-0P 438054-74-1P 438054-76-3P  
438054-77-4P 438054-78-5P 438054-79-6P  
438054-86-5P 438054-87-6P 438054-88-7P  
438054-89-8P 438054-91-2P 438054-92-3P  
438054-93-4P 438054-94-5P 438054-99-0P  
438055-00-6P 438055-01-7P 438055-02-8P  
438055-03-9P 438055-04-0P 438055-12-0P  
438055-20-0P 438055-52-8P 438055-59-5P  
438055-60-8P 438055-61-9P 438055-62-0P  
438055-63-1P 438055-64-2P 438055-65-3P

438056-74-7P 438056-75-8P 438056-76-9P

438056-77-0P 438056-84-9P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(claimed compound; preparation of ureido- and carbamoyloxy-substituted amides as inhibitors of factor Xa for the treatment of clotting disorders such as strokes and cancer)

RN 438053-48-6 CAPLUS

CN Benzenepropanamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-, ( $\alpha$ R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 438053-49-7 CAPLUS

CN Propanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 438053-50-0 CAPLUS

CN Pentanamide, N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-[[[(2-pyridinylamino)carbonyl]amino]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 438053-51-1 CAPLUS


CN Pentanamide, N-[2'-(methanesulfonyl)[1,1'-biphenyl]-4-yl]-2-  
[[[(phenylamino)carbonyl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 438053-52-2 CAPLUS

CN 2-Thiophenepropanamide, N-[2'-(methanesulfonyl)[1,1'-biphenyl]-4-yl]-  
 $\alpha$ -[[[(phenylamino)carbonyl]amino]- (CA INDEX NAME)



RN 438053-53-3 CAPLUS


CN 1H-Imidazole-5-propanamide, N-[2'-(methanesulfonyl)[1,1'-biphenyl]-4-yl]-  
 $\alpha$ -[[[(phenylamino)carbonyl]amino]- (CA INDEX NAME)



RN 438053-54-4 CAPLUS


CN Hexanamide, N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-[[phenylamino]carbonyl]amino-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 438053-55-5 CAPLUS


CN Butanamide, N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-4-(methylthio)-2-[[phenylamino]carbonyl]amino- (CA INDEX NAME)



RN 438053-57-7 CAPLUS

CN Benzenepropanamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-, ( $\alpha$ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 438053-58-8 CAPLUS

CN Benzenepropanamide,  $\alpha$ -[[[(4-methylphenyl)amino]carbonyl]amino]-N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-, ( $\alpha$ R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 438053-59-9 CAPLUS

CN Pentanamide, N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-[[ (4-pyridinylamino)carbonyl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 438053-60-2 CAPLUS

CN Pentanamide, N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-[[ (4-

pyridinylamino)carbonyl]amino]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 438053-61-3 CAPLUS

CN Pentanamide, N-[2'-(methanesulfonyl)[1,1'-biphenyl]-4-yl]-2-[[2-(pyridinylamino)carbonyl]amino]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 438053-62-4 CAPLUS

CN Pentanamide, N-[2'-(methanesulfonyl)[1,1'-biphenyl]-4-yl]-2-[[2-(phenylamino)carbonyl]amino]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 438053-63-5 CAPLUS

CN Pentanamide, N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-[[ (3-pyridinylamino)carbonyl]amino]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 438053-64-6 CAPLUS

CN 3-Pyridinepropanamide, N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- $\alpha$ -[[ (phenylamino)carbonyl]amino]-, ( $\alpha$ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 438053-65-7 CAPLUS


CN 1H-Indole-3-propanamide, N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- $\alpha$ -[[ (phenylamino)carbonyl]amino]-, ( $\alpha$ S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 438053-66-8 CAPLUS


CN Propanamide, N-[2'-(methanesulfonyl)[1,1'-biphenyl]-4-yl]-2-[[ (phenylamino)carbonyl]amino]- (CA INDEX NAME)



RN 438053-68-0 CAPLUS

CN Benzenepropanamide,  $\alpha$ -[[[(3-chlorophenyl)amino]carbonyl]amino]-N-[2'-(methanesulfonyl)[1,1'-biphenyl]-4-yl]-, ( $\alpha$ S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 438053-69-1 CAPLUS

CN Benzenepropanamide, N-[2'-(methanesulfonyl)[1,1'-biphenyl]-4-yl]- $\alpha$ -[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]-, ( $\alpha$ S)- (CA INDEX NAME)

Absolute stereochemistry.






RN 438053-70-4 CAPLUS

CN Benzenepropanamide,  $\alpha$ -[[[(2-chlorophenyl)amino]carbonyl]amino]-N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-, ( $\alpha S$ )- (CA INDEX NAME)


Absolute stereochemistry.



RN 438053-71-5 CAPLUS

CN Benzenepropanamide,  $\alpha$ -[[[(4-ethoxyphenyl)amino]carbonyl]amino]-N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-, ( $\alpha S$ )- (CA INDEX NAME)

Absolute stereochemistry.




RN 438053-72-6 CAPLUS

CN Benzenepropanamide,  $\alpha$ -[[[(4-methylphenyl)amino]carbonyl]amino]-N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-, ( $\alpha S$ )- (CA INDEX NAME)

(methylsulfonyl)[1,1'-biphenyl]-4-yl]-, ( $\alpha$ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 438053-73-7 CAPLUS

CN Benzenepropanamide,  $\alpha$ -[[[(2-methoxyphenyl)amino]carbonyl]amino]-N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-, ( $\alpha$ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 438053-74-8 CAPLUS

CN Benzoic acid, 4-[[[[(1S)-2-[[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]amino]-2-oxo-1-(phenylmethyl)ethyl]amino]carbonyl]amino]-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 438053-75-9 CAPLUS

CN Benzenepropanamide, α-[[[(3-chlorophenyl)amino]carbonyl]amino]-N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-, (αR)- (CA INDEX NAME)


Absolute stereochemistry.



RN 438053-76-0 CAPLUS

CN Benzenepropanamide, N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-α-[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]-, (αR)- (CA INDEX NAME)


Absolute stereochemistry.



RN 438053-77-1 CAPLUS

CN Benzenepropanamide,  $\alpha$ -[[[(2-chlorophenyl)amino]carbonyl]amino]-N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-, ( $\alpha$ R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 438053-78-2 CAPLUS

CN Benzenepropanamide,  $\alpha$ -[[[(4-ethoxyphenyl)amino]carbonyl]amino]-N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-, ( $\alpha$ R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 438053-79-3 CAPLUS

CN Benzenepropanamide,  $\alpha$ -[[[(2-methoxyphenyl)amino]carbonyl]amino]-N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-, ( $\alpha$ R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 438053-80-6 CAPLUS


CN Benzoic acid, 4-[[[(1R)-2-[[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]amino]-2-oxo-1-(phenylmethyl)ethyl]amino]carbonyl]amino]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 438053-81-7 CAPLUS


CN Carbamic acid, [5-[[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]amino]-5-oxo-4-[[[(phenylamino)carbonyl]amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 438053-82-8 CAPLUS

CN Benzenepropanamide, N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-α-[[[(phenylamino)carbonyl]amino]-, (αS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 438053-83-9 CAPLUS

CN Benzenepropanamide, N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-α-  
[[ (phenylamino)carbonyl]amino]-, (αR)- (CA INDEX NAME)


Absolute stereochemistry.



RN 438053-84-0 CAPLUS


CN Cyclopropanepropanamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-  
N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 438053-86-2 CAPLUS


CN Benzenepropanamide,  $\alpha$ -[[[(5-chloro-2-pyridinyl)amino]carbonyl]amino]-N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)



RN 438053-87-3 CAPLUS

CN Benzenepropanamide,  $\alpha$ -[[[(4-bromophenyl)amino]carbonyl]amino]-N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-, ( $\alpha$ R)- (CA INDEX NAME)


Absolute stereochemistry.




RN 438053-88-4 CAPLUS

CN Benzenepropanamide,  $\alpha$ -[[[(3-fluoro-4-methoxyphenyl)amino]carbonyl]amino]-N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-, ( $\alpha$ R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 438053-89-5 CAPLUS  
 CN Hexanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)




RN 438053-91-9 CAPLUS  
 CN Pentanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-4-methyl-N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 438053-92-0 CAPLUS  
 CN Pentanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-4-methyl-N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 438053-93-1 CAPLUS  
 CN Benzenepropanamide,  $\alpha$ -[[[(4-methoxyphenyl)amino]carbonyl]amino]-N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-, ( $\alpha$ S)- (CA INDEX NAME)




Absolute stereochemistry.



RN 438053-94-2 CAPLUS

CN Benzenepropanamide,  $\alpha$ -[[[(4-bromophenyl)amino]carbonyl]amino]-N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-, ( $\alpha$ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 438053-95-3 CAPLUS

CN Benzenepropanamide,  $\alpha$ -[[[(4-iodophenyl)amino]carbonyl]amino]-N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-, ( $\alpha$ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 438053-96-4 CAPLUS

CN Benzenepropanamide,  $\alpha$ -[[[(4-fluorophenyl)amino]carbonyl]amino]-N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-, ( $\alpha S$ )- (CA INDEX NAME)


Absolute stereochemistry.



RN 438053-97-5 CAPLUS

CN Benzenepropanamide,  $\alpha$ -[[[(3-fluoro-4-methoxyphenyl)amino]carbonyl]amino]-N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-, ( $\alpha S$ )- (CA INDEX NAME)


Absolute stereochemistry.



RN 438053-98-6 CAPLUS

CN Benzenepropanamide,  $\alpha$ -[[[(4-methoxyphenyl)amino]carbonyl]amino]-N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-, ( $\alpha R$ )- (CA INDEX NAME)


Absolute stereochemistry.



RN 438053-99-7 CAPLUS

CN Benzenepropanamide,  $\alpha$ -[[[(4-iodophenyl)amino]carbonyl]amino]-N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-, ( $\alpha$ R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 438054-00-3 CAPLUS

CN Benzenepropanamide,  $\alpha$ -[[[(4-fluorophenyl)amino]carbonyl]amino]-N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-, ( $\alpha$ R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 438054-01-4 CAPLUS

CN Benzenepropanamide, N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- $\alpha$ -  
[[[3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-, ( $\alpha$ S)- (CA  
INDEX NAME)


Absolute stereochemistry.



RN 438054-02-5 CAPLUS


CN Benzenepropanamide, N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- $\alpha$ -  
[[[3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-, ( $\alpha$ R)- (CA  
INDEX NAME)

Absolute stereochemistry.



RN 438054-03-6 CAPLUS


CN Pentanamide, 5-amino-N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-  
[[phenylamino]carbonyl]amino]- (CA INDEX NAME)



RN 438054-04-7 CAPLUS


CN Benzenepropanamide, N-[4-(4-morpholinyl)phenyl]- $\alpha$ -  
[[phenylamino]carbonyl]amino]-, ( $\alpha$ S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 438054-05-8 CAPLUS


CN Pentanamide, N-[4-(4-morpholinyl)phenyl]-2-[[1-(phenylamino)carbonyl]amino]-  
(CA INDEX NAME)



RN 438054-06-9 CAPLUS


CN Benzenepropanamide, N-[4-(4-morpholinyl)phenyl]- $\alpha$ -  
[[1-(phenylamino)carbonyl]amino]-, ( $\alpha$ R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 438054-07-0 CAPLUS

CN Benzenepropanamide, 3-cyano-N-[4-(4-morpholinyl)phenyl]- $\alpha$ -  
[[1-(phenylamino)carbonyl]amino]- (CA INDEX NAME)




RN 438054-08-1 CAPLUS

CN Hexanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(4-morpholinyl)phenyl]- (CA INDEX NAME)



RN 438054-09-2 CAPLUS


CN Butanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-4-(methylthio)-N-[4-(4-morpholinyl)phenyl]- (CA INDEX NAME)



RN 438054-10-5 CAPLUS

CN Propanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(4-morpholinyl)phenyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 438054-11-6 CAPLUS

CN Pentanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-4-methyl-N-[4-(4-morpholinyl)phenyl]- (CA INDEX NAME)

morpholinyl)phenyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 438054-12-7 CAPLUS

CN Pentanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-4-methyl-N-[4-(4-morpholinyl)phenyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 438054-13-8 CAPLUS

CN Benzenepropanamide,  $\alpha$ -[[ (phenylamino)carbonyl]amino]-N-[[1-(4-pyridinyl)-4-piperidinyl]methyl]-, ( $\alpha$ S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 438054-14-9 CAPLUS

CN Benzenepropanamide,  $\alpha$ -[[ (phenylamino)carbonyl]amino]-N-[[1-(4-


pyridinyl)-4-piperidinyl)methyl]-, ( $\alpha$ R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 438054-15-0 CAPLUS


CN Pentanamide, 2-[[[(phenylamino)carbonyl]amino]-N-[[1-(4-pyridinyl)-4-piperidinyl)methyl]]- (CA INDEX NAME)



RN 438054-17-2 CAPLUS


CN Hexanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[[1-(4-pyridinyl)-4-piperidinyl)methyl]]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 438054-18-3 CAPLUS

CN Butanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-4-(methylthio)-N-[[1-(4-pyridinyl)-4-piperidinyl)methyl]]- (CA INDEX NAME)




RN 438054-19-4 CAPLUS




CN Propanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[[1-(4-pyridinyl)-4-piperidinyl]methyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 438054-20-7 CAPLUS

CN 2-Thiophenepropanamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 438054-21-8 CAPLUS


CN 1H-Indole-3-propanamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 438054-22-9 CAPLUS

CN Pentanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[[1-(4-


pyridinyl)-4-piperidinyl)methyl]- (CA INDEX NAME)



RN 438054-23-0 CAPLUS

CN Pentanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-4-methyl-N-[[1-(4-pyridinyl)-4-piperidinyl)methyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 438054-24-1 CAPLUS

CN Pentanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-4-methyl-N-[[1-(4-pyridinyl)-4-piperidinyl)methyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 438054-26-3 CAPLUS

CN Butanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-3-methyl-N-[[1-(4-pyridinyl)-4-piperidinyl)methyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 438054-27-4 CAPLUS


CN Butanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-3-methyl-N-[[1-(4-pyridinyl)-4-piperidinyl]methyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 438054-29-6 CAPLUS


CN Propanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-3,3,3-trifluoro-N-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 438054-31-0 CAPLUS

CN Butanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-3,3-dimethyl-N-[[1-(4-pyridinyl)-4-piperidinyl]methyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 438054-32-1 CAPLUS

CN Butanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-3,3-dimethyl-N-[[1-(4-pyridinyl)-4-piperidinyl]methyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 438054-39-8 CAPLUS

CN Benzenepropanamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[[1-(4-pyridinyl)-4-piperidinyl]methyl]-, ( $\alpha$ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 438054-40-1 CAPLUS

CN Benzenepropanamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[[1-(4-pyridinyl)-4-piperidinyl]methyl]-, ( $\alpha$ R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 438054-42-3 CAPLUS

CN Benzenepropanamide, N-([1,1'-biphenyl]-2-ylmethyl)- $\alpha$ -[[[(phenylamino)carbonyl]amino]-, ( $\alpha$ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 438054-43-4 CAPLUS


CN Benzenepropanamide, N-([1,1'-biphenyl]-2-ylmethyl)-α-  
[[1-(phenylamino)carbonyl]amino]-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 438054-44-5 CAPLUS


CN Pentanamide, N-([1,1'-biphenyl]-2-ylmethyl)-2-  
[[1-(phenylamino)carbonyl]amino]- (CA INDEX NAME)



RN 438054-45-6 CAPLUS


CN Benzenepropanamide, N-[[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]methyl]-  
α-[[1-(phenylamino)carbonyl]amino]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.




RN 438054-46-7 CAPLUS  
 CN Benzenepropanamide, N-[[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]methyl]-  
 $\alpha$ -[[ (phenylamino)carbonyl]amino]-, ( $\alpha$ R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 438054-47-8 CAPLUS  
 CN Pentanamide, N-[[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]methyl]-2-  
 [[ (phenylamino)carbonyl]amino]- (CA INDEX NAME)




RN 438054-48-9 CAPLUS  
 CN Benzenepropanamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[1-(4-pyridinyl)-4-piperidinyl]-, ( $\alpha$ R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 438054-50-3 CAPLUS  
 CN Pentanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[1-(4-pyridinyl)-4-piperidinyl]- (CA INDEX NAME)



RN 438054-51-4 CAPLUS

CN Benzenepropanamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[1-(4-pyridinyl)-4-piperidinyl]-, ( $\alpha S$ )- (CA INDEX NAME)


Absolute stereochemistry.



RN 438054-52-5 CAPLUS

CN Benzenepropanamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[2'-[[[(1,1'-dimethylethyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]-, ( $\alpha R$ )- (CA INDEX NAME)


Absolute stereochemistry.



RN 438054-53-6 CAPLUS

CN Benzenepropanamide, N-[2'-(aminosulfonyl)[1,1'-biphenyl]-4-yl]- $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-, ( $\alpha R$ )- (CA INDEX NAME)


Absolute stereochemistry.



RN 438054-54-7 CAPLUS

CN Benzenepropanamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[1-(tetrahydro-2H-pyran-4-yl)-4-piperidinyl]-, (αR)- (CA INDEX NAME)


Absolute stereochemistry.



RN 438054-59-2 CAPLUS

CN Benzenepropanamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[[1-(tetrahydro-2H-pyran-4-yl)-4-piperidinyl]methyl]-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.




RN 438054-61-6 CAPLUS

CN Benzenepropanamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-oxo-1-piperidinyl)phenyl]-, (αR)- (CA INDEX NAME)




Absolute stereochemistry.



RN 438054-62-7 CAPLUS

CN Benzenepropanamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-oxo-1-piperidinyl)phenyl]-, (αS)- (CA INDEX NAME)


Absolute stereochemistry.




RN 438054-63-8 CAPLUS

CN Benzenepropanamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(3-oxo-4-morpholinyl)phenyl]-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.




RN 438054-68-3 CAPLUS  
 CN Carbamic acid, (4-chlorophenyl)-, 1-methyl-2-oxo-2-[[[1-(4-pyridinyl)-4-piperidinyl]methyl]amino]ethyl ester (9CI) (CA INDEX NAME)




RN 438054-73-0 CAPLUS  
 CN Benzenepropanamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-(1-cyclopentyl-4-piperidinyl)-, ( $\alpha S$ )- (CA INDEX NAME)

Absolute stereochemistry.




RN 438054-74-1 CAPLUS  
 CN Benzenepropanamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-(1-cyclopentyl-4-piperidinyl)-, ( $\alpha R$ )- (CA INDEX NAME)

Absolute stereochemistry.



RN 438054-76-3 CAPLUS  
 CN Benzenepropanamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-oxo-1-pyrrolidinyl)phenyl]-, ( $\alpha R$ )- (CA INDEX NAME)


Absolute stereochemistry.



RN 438054-77-4 CAPLUS

CN Benzenepropanamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-oxo-1-pyrrolidiny)phenyl]-, (αS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 438054-78-5 CAPLUS


CN Benzenepropanamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(1-piperidiny)phenyl]-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.




RN 438054-79-6 CAPLUS  
CN Benzenepropanamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(1-piperidinyl)phenyl]-, ( $\alpha$ S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 438054-86-5 CAPLUS  
CN 1-Piperidinecarboxylic acid, 4-[[[(2S)-2-[[[(4-chlorophenyl)amino]carbonyl]amino]-1-oxo-3-phenylpropyl]amino]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 438054-87-6 CAPLUS  
CN 1-Piperidinecarboxylic acid, 4-[[[(2R)-2-[[[(4-chlorophenyl)amino]carbonyl]amino]-1-oxo-3-phenylpropyl]amino]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 438054-88-7 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[(2S)-2-[[[(4-chlorophenyl)amino]carbonyl]amino]-4-methyl-1-oxopentyl]amino]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 438054-89-8 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[(2R)-2-[[[(4-chlorophenyl)amino]carbonyl]amino]-4-methyl-1-oxopentyl]amino]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 438054-91-2 CAPLUS

CN Benzenepropanamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-(4-piperidinylmethyl)-, ( $\alpha$ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 438054-92-3 CAPLUS


CN Benzenepropanamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-(4-piperidinylmethyl)-, ( $\alpha$ R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 438054-93-4 CAPLUS  
 CN Pentanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-4-methyl-N-(4-piperidinylmethyl)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 438054-94-5 CAPLUS  
 CN Pentanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-4-methyl-N-(4-piperidinylmethyl)-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 438054-99-0 CAPLUS  
 CN 1-Piperazinecarboxylic acid, 4-[4-[[[(2R)-2-[[[(4-chlorophenyl)amino]carbonyl]amino]-1-oxo-3-phenylpropyl]amino]phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 438055-00-6 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[4-[[[(2S)-2-[[[(4-chlorophenyl)amino]carbonyl]amino]-1-oxo-3-phenylpropyl]amino]phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 438055-01-7 CAPLUS

CN Benzenepropanamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(1-piperazinyl)phenyl]-, (αR)- (CA INDEX NAME)


Absolute stereochemistry.



RN 438055-02-8 CAPLUS

CN Benzenepropanamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(1-piperazinyl)phenyl]-, ( $\alpha S$ )- (CA INDEX NAME)


Absolute stereochemistry.



RN 438055-03-9 CAPLUS

CN Benzenepropanamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-(1-cyclohexyl-4-piperidinyl)-, ( $\alpha S$ )- (CA INDEX NAME)

Absolute stereochemistry.




RN 438055-04-0 CAPLUS




CN Benzenepropanamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-(1-cyclohexyl-4-piperidinyl)-, ( $\alpha R$ )- (CA INDEX NAME)

Absolute stereochemistry.




RN 438055-12-0 CAPLUS

CN Carbamic acid, (4-chlorophenyl)-, 1-methyl-2-[[4-(4-morpholinyl)phenyl]amino]-2-oxoethyl ester (9CI) (CA INDEX NAME)




RN 438055-20-0 CAPLUS

CN Carbamic acid, (4-chlorophenyl)-, 1-methyl-2-[[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]amino]-2-oxoethyl ester (9CI) (CA INDEX NAME)




RN 438055-52-8 CAPLUS

CN Carbamic acid, (4-chlorophenyl)-, 2,2,2-trifluoro-1-[[[1-(4-pyridinyl)-4-piperidinyl]methyl]amino]carbonyl]ethyl ester (9CI) (CA INDEX NAME)




RN 438055-59-5 CAPLUS

CN Butanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-4,4,4-trifluoro-N-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (CA INDEX NAME)




RN 438055-60-8 CAPLUS

CN Benzenepropanamide, 4-cyano-N-[4-(2-oxo-1-piperidinyl)phenyl]-α-[[[(phenylamino)carbonyl]amino]- (CA INDEX NAME)




RN 438055-61-9 CAPLUS

CN Benzenepropanamide, 4-cyano-α-[[[(phenylamino)carbonyl]amino]-N-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (CA INDEX NAME)




RN 438055-62-0 CAPLUS

CN Benzenepropanamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-3-cyano-N-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (CA INDEX NAME)




RN 438055-63-1 CAPLUS

CN Benzenepropanamide, 3-(aminocarbonyl)-N-[4-(2-oxo-1-piperidinyl)phenyl]-α-[[[(phenylamino)carbonyl]amino]- (CA INDEX NAME)




RN 438055-64-2 CAPLUS

CN Benzenepropanamide, 3-(aminocarbonyl)- $\alpha$ -  
[[[(phenylamino)carbonyl]amino]-N-[[1-(4-pyridinyl)-4-piperidinyl]methyl]-  
(CA INDEX NAME)



RN 438055-65-3 CAPLUS


CN Benzenepropanamide, 3-(aminocarbonyl)- $\alpha$ -[[[(4-  
chlorophenyl)amino]carbonyl]amino]-N-[4-(2-oxo-1-piperidinyl)phenyl]- (CA  
INDEX NAME)



RN 438056-74-7 CAPLUS

CN Benzenepropanamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[[1-(1-  
methylethyl)-4-piperidinyl]methyl]-, ( $\alpha$ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 438056-75-8 CAPLUS

CN Benzenepropanamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[[1-(1-methylethyl)-4-piperidinyl]methyl]-, (αR)- (CA INDEX NAME)


Absolute stereochemistry.



RN 438056-76-9 CAPLUS

CN Pentanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-4-methyl-N-[[1-(1-methylethyl)-4-piperidinyl]methyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.




RN 438056-77-0 CAPLUS

CN Pentanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-4-methyl-N-[[1-(1-methylethyl)-4-piperidinyl]methyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 438056-84-9 CAPLUS  
 CN Butanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-4-(methylthio)- (CA INDEX NAME)




IT 438055-73-3P 438055-75-5P 438055-82-4P  
 438055-83-5P 438055-84-6P 438055-85-7P  
 438055-87-9P 438055-88-0P 438055-89-1P  
 438055-90-4P 438055-91-5P 438055-92-6P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)  
 (preparation of ureido- and carbamoyloxy-substituted amides as inhibitors of  
 factor Xa for the treatment of clotting disorders such as strokes and  
 cancer)  
 RN 438055-73-3 CAPLUS  
 CN Pentanamide, 5-amino-N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-  
 [[(phenylamino)carbonyl]amino]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 438055-75-5 CAPLUS  
 CN Benzenepropanamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[1-(4-pyridinyl)-4-piperidinyl]-, hydrochloride (1:?), ( $\alpha$ S)- (CA INDEX NAME)

Absolute stereochemistry.




● x HCl

RN 438055-82-4 CAPLUS

CN Benzenepropanamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-(4-piperidinylmethyl)-, hydrochloride (1:1), ( $\alpha$ S)- (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 438055-83-5 CAPLUS

CN Benzenepropanamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-(4-piperidinylmethyl)-, hydrochloride (1:1), ( $\alpha$ R)- (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 438055-84-6 CAPLUS  
 CN Pentanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-4-methyl-N-(4-piperidinylmethyl)-, hydrochloride (1:1), (2S)- (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 438055-85-7 CAPLUS  
 CN Pentanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-4-methyl-N-(4-piperidinylmethyl)-, hydrochloride (1:1), (2R)- (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 438055-87-9 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[4-[[[(2R)-2-[[[(4-chlorophenyl)amino]carbonyl]amino]-1-oxo-3-phenylpropyl]amino]phenyl]-, 1,1-dimethylethyl ester, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 438055-88-0 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[4-[[[(2S)-2-[[[(4-chlorophenyl)amino]carbonyl]amino]-1-oxo-3-phenylpropyl]amino]phenyl]-, 1,1-dimethylethyl ester, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 438055-89-1 CAPLUS

CN Benzenepropanamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(1-piperazinyl)phenyl]-, hydrochloride (1:?), ( $\alpha$ R)- (CA INDEX NAME)

Absolute stereochemistry.






● x HCl

RN 438055-90-4 CAPLUS

CN Benzenepropanamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(1-piperazinyl)phenyl]-, hydrochloride (1:?), (αS)- (CA INDEX NAME)

Absolute stereochemistry.




● x HCl

RN 438055-91-5 CAPLUS

CN Benzenepropanamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-(1-cyclohexyl-4-piperidinyl)-, hydrochloride (1:1), (αS)- (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 438055-92-6 CAPLUS  
 CN Benzenepropanamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-(1-cyclohexyl-4-piperidiny)-, hydrochloride (1:1), (αR)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 78 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2002:391535 CAPLUS  
 DOCUMENT NUMBER: 136:380143  
 TITLE: Treatment of sexual dysfunction using bombesin antagonist  
 INVENTOR(S): Gonzalez, Maria Isabel; Higginbottom, Michael; Pinnock, Robert Denham; Pritchard, Martyn Clive; Stock, Herman Thijs  
 PATENT ASSIGNEE(S): Warner-Lambert Company, USA  
 SOURCE: PCT Int. Appl., 151 pp.  
 CODEN: PIXXD2


DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 10  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002040022	A1	20020523	WO 2000-GB4380	20001117
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2426521	A1	20020523	CA 2000-2426521	20001117
AU 2001014046	A	20020527	AU 2001-14046	20001117
EP 1333829	A1	20030813	EP 2000-976165	20001117
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2000017374	A	20030930	BR 2000-17374	20001117
HU 2003003500	A2	20040128	HU 2003-3500	20001117
JP 2004525864	T	20040826	JP 2002-542395	20001117
CA 2429106	A1	20020523	CA 2001-2429106	20011114
WO 2002040008	A2	20020523	WO 2001-GB5018	20011114
WO 2002040008	A3	20020822		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002023802	A	20020527	AU 2002-23802	20011114
EP 1333824	A2	20030813	EP 2001-994552	20011114
EP 1333824	B1	20050907		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001015364	A	20030923	BR 2001-15364	20011114
HU 2003001892	A2	20031128	HU 2003-1892	20011114
HU 2003001892	A3	20050628		
JP 2004522710	T	20040729	JP 2002-542382	20011114
CN 1518445	A	20040804	CN 2001-821951	20011114
NZ 525415	A	20041126	NZ 2001-525415	20011114
AT 303804	T	20050915	AT 2001-994552	20011114
TW 220650	B	20040901	TW 2001-90128451	20011116
MX 2003003481	A	20040910	MX 2003-3481	20030416
MX 2003003482	A	20040910	MX 2003-3482	20030416
ZA 2003003250	A	20040426	ZA 2003-3250	20030425
US 20040087561	A1	20040506	US 2003-416934	20031204
PRIORITY APPLN. INFO.:			WO 2000-GB4380	W 20001117
			GB 2001-9910	A 20010423
			GB 2001-11037	A 20010504
			WO 2001-GB5018	W 20011114

IT 204067-01-6  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (bombesin antagonists for treatment of sexual dysfunction)

RN 204067-01-6 CAPLUS  
CN 1H-Indole-3-propanamide, N-[[1-(5-methoxy-2-pyridinyl)cyclohexyl]methyl]-  
 $\alpha$ -methyl- $\alpha$ -[[[(4-nitrophenyl)amino]carbonyl]amino]-,  
( $\alpha$ S)- (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 79 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 2002:391522 CAPLUS  
DOCUMENT NUMBER: 136:395983  
TITLE: Bombesin receptor antagonists, and combinations with  
other agents, for the treatment of sexual dysfunction  
INVENTOR(S): Gonzalez, Maria Isabel; Stock, Herman Thijs; Pinnock,  
Robert Denham; Pritchard, Martyn Clive; Wayman,  
Christopher Peter; Van der Graaf, Pieter Hadewijn;  
Naylor, Alisdair Mark; Higginbottom, Michael  
PATENT ASSIGNEE(S): Warner-Lambert Company, USA  
SOURCE: PCT Int. Appl., 225 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 10  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002040008	A2	20020523	WO 2001-GB5018	20011114
WO 2002040008	A3	20020822		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
WO 2002040022	A1	20020523	WO 2000-GB4380	20001117
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,			


CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,  
 HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,  
 LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,  
 SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,  
 YU, ZA, ZW  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,  
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,  
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG  
 CA 2429106 A1 20020523 CA 2001-2429106 20011114  
 AU 2002023802 A 20020527 AU 2002-23802 20011114  
 EP 1333824 A2 20030813 EP 2001-994552 20011114  
 EP 1333824 B1 20050907  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR  
 BR 2001015364 A 20030923 BR 2001-15364 20011114  
 HU 2003001892 A2 20031128 HU 2003-1892 20011114  
 HU 2003001892 A3 20050628  
 JP 2004522710 T 20040729 JP 2002-542382 20011114  
 NZ 525415 A 20041126 NZ 2001-525415 20011114  
 AT 303804 T 20050915 AT 2001-994552 20011114  
 MX 2003003482 A 20040910 MX 2003-3482 20030416  
 US 20040087561 A1 20040506 US 2003-416934 20031204  
 PRIORITY APPLN. INFO.: WO 2000-GB4380 W 20001117  
 GB 2001-9910 A 20010423  
 GB 2001-11037 A 20010504  
 WO 2001-GB5018 W 20011114  
 OTHER SOURCE(S): MARPAT 136:395983  
 IT 204066-72-8 204066-76-2 204066-78-4  
 204066-79-5 204066-82-0 204066-83-1  
 204066-84-2 204066-87-5 204066-89-7  
 204066-93-3 204066-95-5 204067-01-6  
 428864-38-4 428864-39-5 428864-40-8  
 428864-41-9 428864-42-0 428864-46-4  
 428864-49-7 428864-51-1 428864-53-3  
 428864-54-4 428864-56-6 428864-57-7  
 428864-58-8 428864-59-9  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
 (Biological study); USES (Uses)  
 (bombesin receptor antagonists, and combinations with other agents, for  
 treatment of sexual dysfunction)  
 RN 204066-72-8 CAPLUS  
 CN 1H-Indole-3-propanamide,  $\alpha$ -[[[2,6-bis(1-  
 methylethyl)phenyl]amino]carbonyl]amino]-N-(2-cyclohexylethyl)- $\alpha$ -  
 methyl- (CA INDEX NAME)



RN 204066-76-2 CAPLUS


CN 1H-Indole-3-propanamide, N-(cyclohexylmethyl)- $\alpha$ -methyl- $\alpha$ -[[[4-nitrophenyl)amino]carbonyl]amino]-, ( $\alpha$ S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 204066-78-4 CAPLUS

CN 1H-Indole-3-propanamide,  $\alpha$ -[[[[2,6-bis(1-methylethyl)phenyl)amino]carbonyl]methylamino]-N-(cyclohexylmethyl)- (CA INDEX NAME)




RN 204066-79-5 CAPLUS

CN 1H-Indole-3-propanamide,  $\alpha$ -[[[[2,6-bis(1-

methylethyl)phenyl]amino]carbonyl]amino]-N-(cyclohexylmethyl)- $\alpha$ -methyl-, ( $\alpha$ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 204066-82-0 CAPLUS

CN 1H-Indole-3-propanamide,  $\alpha$ -methyl- $\alpha$ -[[[4-nitrophenyl)amino]carbonyl]amino]-N-[[1-(2-pyridinyl)cyclohexyl)methyl]-, ( $\alpha$ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 204066-83-1 CAPLUS

CN 1H-Indole-3-propanamide,  $\alpha$ -methyl-N-[[1-(2-pyridinyl)cyclohexyl)methyl]- $\alpha$ -[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]-, ( $\alpha$ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 204066-84-2 CAPLUS


CN Benzoic acid, 4-[[[(1S)-1-(1H-indol-3-ylmethyl)-1-methyl-2-oxo-2-[[[1-(2-pyridinyl)cyclohexyl]methyl]amino]ethyl]amino]carbonyl]amino]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 204066-87-5 CAPLUS

CN 2-Pyridinepropanamide,  $\alpha$ -[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]amino]- $\alpha$ -methyl-N-[[1-(2-pyridinyl)cyclohexyl]methyl]-, 1-oxide (CA INDEX NAME)







RN 204066-89-7 CAPLUS  
 CN Benzenepropanamide,  $\alpha$ -[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]amino]- $\alpha$ -methyl-N-[[1-(2-pyridinyl)cyclohexyl]methyl]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 204066-93-3 CAPLUS  
 CN 2-Pyridinepropanamide,  $\alpha$ -[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]amino]- $\alpha$ -methyl-N-[[1-(2-pyridinyl)cyclohexyl]methyl]- (CA INDEX NAME)




RN 204066-95-5 CAPLUS  
 CN 1H-Imidazole-5-propanamide,  $\alpha$ -[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]amino]-N-[[1-(2-pyridinyl)cyclohexyl]methyl]- (CA INDEX NAME)



RN 204067-01-6 CAPLUS

CN 1H-Indole-3-propanamide, N-[[1-(5-methoxy-2-pyridinyl)cyclohexyl]methyl]-  
 $\alpha$ -methyl- $\alpha$ -[[[(4-nitrophenyl)amino]carbonyl]amino]-,  
 ( $\alpha$ S)- (CA INDEX NAME)


Absolute stereochemistry.




RN 428864-38-4 CAPLUS

CN 1H-Indole-3-propanamide, N-[[1-(4-aminophenyl)cyclohexyl]methyl]- $\alpha$ -  
 methyl- $\alpha$ -[[[(4-nitrophenyl)amino]carbonyl]amino]-, ( $\alpha$ S)- (CA  
 INDEX NAME)


Absolute stereochemistry.




RN 428864-39-5 CAPLUS  
 CN 1H-Indole-3-propanamide, N-(cyclohexylmethyl)-α-[[[2-(1,1-dimethylethyl)phenyl]amino]carbonyl]amino]-α-methyl- (CA INDEX NAME)




RN 428864-40-8 CAPLUS  
 CN 1H-Indole-3-propanamide, N-(cyclohexylmethyl)-α-[[[2,6-dichlorophenyl]amino]carbonyl]amino]-α-methyl- (CA INDEX NAME)



RN 428864-41-9 CAPLUS  
 CN 1H-Indole-3-propanamide, N-(cyclohexylmethyl)-α-[[[2,6-dimethoxyphenyl]amino]carbonyl]amino]-α-methyl- (CA INDEX NAME)




RN 428864-42-0 CAPLUS  
 CN 1H-Indole-3-propanamide, α-[[[[2,6-bis(dimethylamino)phenyl]amino]carbonyl]amino]-N-(cyclohexylmethyl)-α-methyl- (CA INDEX NAME)





RN 428864-46-4 CAPLUS  
 CN 1H-Indole-3-propanamide, α-[[[[2,6-bis(1-methyl-2-pyrrolidinyl)phenyl]amino]carbonyl]amino]-N-(cyclohexylmethyl)-α-methyl- (CA INDEX NAME)

methylethyl)phenyl]amino]carbonyl]amino]-N-(2,2-dimethyl-4-phenyl-1,3-benzodioxol-5-yl)- $\alpha$ -methyl- (CA INDEX NAME)




RN 428864-49-7 CAPLUS

CN 1H-Indole-3-propanamide,  $\alpha$ -[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]amino]- $\alpha$ -methyl-N-(3-phenylpropyl)- (CA INDEX NAME)




RN 428864-51-1 CAPLUS

CN 1H-Indole-3-propanamide,  $\alpha$ -[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]amino]- $\alpha$ -methyl-N-(2-phenylcyclohexyl)- (CA INDEX NAME)




RN 428864-53-3 CAPLUS

CN 1H-Indole-3-propanamide,  $\alpha$ -[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]amino]-N-[(1-hydroxycyclohexyl)methyl]- $\alpha$ -methyl- (CA INDEX NAME)




RN 428864-54-4 CAPLUS

CN 1H-Indole-3-propanamide,  $\alpha$ -[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]amino]- $\alpha$ -methyl-N-[[1-(2-pyridinyl)cyclohexyl)methyl]- (CA INDEX NAME)




RN 428864-56-6 CAPLUS

CN 1H-Indole-3-propanamide, N-[(1-hydroxycyclohexyl)methyl]- $\alpha$ -methyl- $\alpha$ -[[[4-nitrophenyl]amino]carbonyl]amino]- (CA INDEX NAME)




RN 428864-57-7 CAPLUS

CN 1H-Indole-3-propanamide, α-[[[(4-cyanophenyl)amino]carbonyl]amino]-α-methyl-N-[[1-(2-pyridinyl)cyclohexyl]methyl]- (CA INDEX NAME)




RN 428864-58-8 CAPLUS

CN Benzenepropanamide, α-[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]amino]-α-methyl-2-nitro-N-[[1-(2-pyridinyl)cyclohexyl]methyl]- (CA INDEX NAME)



RN 428864-59-9 CAPLUS  
 CN 2-Pyridinepropanamide,  $\alpha$ -[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]amino]-N-(cyclohexylmethyl)- $\alpha$ -methyl- (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 80 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2002:368981 CAPLUS  
 DOCUMENT NUMBER: 136:380137  
 TITLE: Bombesin receptor antagonists, and preparation thereof, for the treatment of sexual dysfunction  
 INVENTOR(S): Gonzalez, Maria Isabel; Pinnock, Robert Denham; Pritchard, Martyn Clive  
 PATENT ASSIGNEE(S): UK  
 SOURCE: U.S. Pat. Appl. Publ., 72 pp., Cont.-in-part of U. S. Ser. No. 700,165.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 10  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------




-----	-----	-----	-----	-----
US 20020058606	A1	20020516	US 2001-759777	20010112
US 20020169101	A1	20021114	US 2001-999284	20011115
ZA 2003003249	A	20040623	ZA 2003-3249	20030425
PRIORITY APPLN. INFO.:			US 1999-133355P	P 19990510
			WO 2000-GB1787	W 20000510
			US 2000-700165	A2 20001109
			US 2001-759777	A2 20010112
			GB 2001-9910	A 20010423
			GB 2001-11037	A 20010504

IT 204067-01-6  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
 (Biological study); USES (Uses)  
 (bombesin receptor antagonists, preparation, and use for sexual dysfunction  
 treatment, alone or with other agents)

RN 204067-01-6 CAPLUS

CN 1H-Indole-3-propanamide, N-[[1-(5-methoxy-2-pyridinyl)cyclohexyl)methyl]-  
 $\alpha$ -methyl- $\alpha$ -[[[(4-nitrophenyl)amino]carbonyl]amino]-,  
 ( $\alpha$ S)- (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 81 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:351144 CAPLUS

DOCUMENT NUMBER: 137:336847

TITLE: Gustatory responses of pigs to sixty compounds tasting sweet to humans

AUTHOR(S): Nofre, C.; Glaser, D.; Tinti, J.-M.; Wanner, M.

CORPORATE SOURCE: Faculty of Medicine of Lyon Laennec, University of Lyon, Lyon, Fr.

SOURCE: Journal of Animal Physiology and Animal Nutrition (2002), 86(3-4), 90-96  
 CODEN: JAPNEF; ISSN: 0931-2439

PUBLISHER: Blackwell Wissenschafts-Verlag GmbH

DOCUMENT TYPE: Journal


LANGUAGE: English

IT 135507-50-5, Superaspartame  
 RL: BSU (Biological study, unclassified); PRP (Properties); BIOL  
 (Biological study)  
 (gustatory responses of swine to compds. tasting sweet to humans)

RN 135507-50-5 CAPLUS

CN L-Phenylalanine, N-[[ (4-cyanophenyl) amino] carbonyl]-L- $\alpha$ -aspartyl-,  
2-methyl ester (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 82 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 2002:312019 CAPLUS  
DOCUMENT NUMBER: 136:325828  
TITLE: Preparation of dipeptide derivatives as cell adhesion  
inhibitors  
INVENTOR(S): Adams, Steven P.; Lin, Ko-Chung; Lee, Wen-Cherng;  
Castro, Alfredo C.; Zimmerman, Craig N.; Hammond,  
Charles E.; Liao, Yu-Sheng; Cuervo, Julio Hernan;  
Singh, Juswinder  
PATENT ASSIGNEE(S): Biogen, Inc., USA  
SOURCE: U.S., 50 pp., Cont.-in-part of U.S. 6,306,840.  
CODEN: USXXAM  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 2  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6376538	B1	20020423	US 1997-875321	19970919
US 6306840	B1	20011023	US 1995-376372	19950123
WO 9622966	A1	19960801	WO 1996-US1349	19960118
W:	AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI			
RW:	KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE			
EP 1142867	A2	20011010	EP 2001-107877	19960118
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI			
AU 766538	B2	20031016	AU 2000-62432	20001002
US 20030018016	A1	20030123	US 2001-2341	20011023
US 6630512	B2	20031007		
US 7001921	B1	20060221	US 2003-625626	20030724
US 20060166866	A1	20060727	US 2003-679478	20031007
JP 2008013574	A	20080124	JP 2007-217671	20070823
PRIORITY APPLN. INFO.:			US 1995-376372	A2 19950123
			WO 1996-US1349	W 19960118
			AU 1996-49115	A3 19960118
			EP 1996-905316	A3 19960118
			JP 1996-523071	A3 19960118
			US 1997-875321	A3 19970919

US 2001-935461 A1 20010822

US 2001-2341 A1 20011023

OTHER SOURCE(S): MARPAT 136:325828

IT 181521-39-1P 181521-73-3P 181521-74-4P

181521-76-6P 181522-77-0P 181522-88-3P

181522-89-4P 181522-90-7P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of  $\beta$ -amino acid dipeptide derivs. as cell adhesion inhibitors)

RN 181521-39-1 CAPLUS

CN Benzenepropanoic acid,  $\beta$ -[[ (2S)-4-methyl-1-oxo-2-[[ (phenylamino)carbonyl]amino]pentyl]amino]-, ( $\beta$ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 181521-73-3 CAPLUS

CN Benzenepropanoic acid,  $\beta$ -[[ (2S)-4-methyl-2-[[[(4-nitrophenyl)amino]carbonyl]amino]-1-oxopentyl]amino]-, ( $\beta$ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 181521-74-4 CAPLUS

CN Benzenepropanoic acid,  $\beta$ -[[ (2S)-2-[[[(4-aminophenyl)amino]carbonyl]amino]-4-methyl-1-oxopentyl]amino]-, ( $\beta$ S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 181521-76-6 CAPLUS

CN Benzenepropanoic acid,  $\beta$ -[[ (2S)-4-methyl-1-oxo-2-[[[(4-

[[ (phenylamino)carbonyl]amino]phenyl]amino]carbonyl]amino]pentyl]amino]-,  
(βS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 181522-77-0 CAPLUS

CN Benzenepropanoic acid, 4-methoxy-β-[[ (2S)-4-(methylsulfinyl)-1-oxo-2-  
[[ (phenylamino)carbonyl]amino]butyl]amino]-, (βS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 181522-88-3 CAPLUS

CN 1,3-Benzodioxole-5-propanoic acid,  
β-[[ (2S)-4-(dimethylamino)-1,4-dioxo-2-  
[[ (phenylamino)carbonyl]amino]butyl]amino]-, (βS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 181522-89-4 CAPLUS


CN 1,3-Benzodioxole-5-propanoic acid,  
β-[[ (2S)-4-(dimethylamino)-1-oxo-2-  
[[ (phenylamino)carbonyl]amino]butyl]amino]-, (βS)- (CA INDEX NAME)

Absolute stereochemistry.




RN 181522-90-7 CAPLUS  
 CN 1,3-Benzodioxole-5-propanoic acid,  
 $\beta$ -[[[(2S)-5-(4-morpholinyl)-1,5-dioxo-2-  
 [[[(phenylamino)carbonyl]amino]pentyl]amino]-, ( $\beta$ S)- (CA INDEX NAME)

Absolute stereochemistry.



IT 181518-83-2P 181518-89-8P 181518-97-8P  
 181519-72-2P 181519-73-3P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation of  $\beta$ -amino acid dipeptide derivs. as cell adhesion  
 inhibitors)  
 RN 181518-83-2 CAPLUS  
 CN 1,3-Benzodioxole-5-propanoic acid,  
 $\beta$ -[[[(2S)-4-(dimethylamino)-1,4-dioxo-2-  
 [[[(phenylamino)carbonyl]amino]butyl]amino]-, methyl ester, ( $\beta$ S)- (CA  
 INDEX NAME)


Absolute stereochemistry.



RN 181518-89-8 CAPLUS  
 CN 1,3-Benzodioxole-5-propanoic acid,  
 $\beta$ -[[[(2S)-4-(dimethylamino)-1-oxo-2-

[[ (phenylamino)carbonyl]amino]butyl]amino]-, methyl ester, ( $\beta$ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 181518-97-8 CAPLUS

CN Benzenepropanoic acid, 4-methoxy- $\beta$ -[[ (2S)-4-(methylthio)-1-oxo-2-[[ (phenylamino)carbonyl]amino]butyl]amino]-, 1,1-dimethylethyl ester, ( $\beta$ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 181519-72-2 CAPLUS

CN Benzenepropanoic acid,  $\beta$ -[[ (2S)-4-methyl-2-[[[(4-nitrophenyl)amino]carbonyl]amino]-1-oxopentyl]amino]-, 1,1-dimethylethyl ester, ( $\beta$ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 181519-73-3 CAPLUS

CN Benzenepropanoic acid,  $\beta$ -[[ (2S)-2-[[[(4-aminophenyl)amino]carbonyl]amino]-4-methyl-1-oxopentyl]amino]-, 1,1-dimethylethyl ester, ( $\beta$ S)- (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 83 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2002:241341 CAPLUS  
 DOCUMENT NUMBER: 136:257235  
 TITLE: Indazole peptidomimetic PAR-1 antagonists and PAR-2 antagonists as potential agents for controlling cancer metastasis  
 INVENTOR(S): D'Andrea, Michael; Derian, Claudia; Woodrow, Hal Brent  
 PATENT ASSIGNEE(S): USA  
 SOURCE: U.S. Pat. Appl. Publ., 44 pp., Cont.-in-part of U.S. Ser. No. 603,338.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20020037860	A1	20020328	US 2001-865511	20010525
US 20030199455	A1	20031023	US 2003-403218	20030331
US 7049297	B2	20060523		
US 20060166896	A1	20060727	US 2006-393350	20060330
US 20060166897	A1	20060727	US 2006-393529	20060330
US 7417030	B2	20080826		
PRIORITY APPLN. INFO.:			US 1999-141553P	P 19990629
			US 2000-603338	A2 20000626
			US 2003-403218	A3 20030331


OTHER SOURCE(S): MARPAT 136:257235  
 IT 315203-33-9D, resin-bound  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (indazole peptidomimetic PAR-1 antagonists and PAR-2 antagonists as potential agents for controlling cancer metastasis)  
 RN 315203-33-9 CAPLUS  
 CN L-Alaninamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indazol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(2-aminoethyl)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 315203-36-2P  
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (indazole peptidomimetic PAR-1 antagonists and PAR-2 antagonists as potential agents for controlling cancer metastasis)  
 RN 315203-36-2 CAPLUS  
 CN L-Alaninamide, 4-chloro-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indazol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(2-aminoethyl)-3-(2-thienyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 84 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2002:237356 CAPLUS  
 DOCUMENT NUMBER: 136:263090  
 TITLE: Preparation of cyclic amine derivatives for inhibition of the action of chemokines such as MIP-1 $\alpha$  and/or MCP-1 on target cells  
 INVENTOR(S): Shiota, Tatsuki; Kataoka, Ken-Ichiro; Imai, Minoru; Tsutsumi, Takaharu; Sudoh, Masaki; Sogawa, Ryo; Morita, Takuya; Hada, Takahiko; Muroga, Yumiko; Takenouchi, Osami; Furuya, Minoru; Endo, Noriaki; Tarby, Christine M.; Moree, Wilna; Teig, Steven  
 PATENT ASSIGNEE(S): Teijin Limited, Japan; Dupont Pharmaceuticals Research Laboratories  
 SOURCE: U.S., 364 pp., Cont. of U.S. Ser. No. 554,562.



DOCUMENT TYPE: CODEN: USXXAM  
 LANGUAGE: Patent  
 FAMILY ACC. NUM. COUNT: English 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6362177	B1	20020326	US 2001-905078	20010716
US 6451842	B1	20020917	US 2000-554562	20000516
US 6410566	B1	20020625	US 2001-905077	20010716
PRIORITY APPLN. INFO.:			US 2000-554562	A3 20000516
			US 1997-972484	B1 19971118
			US 1998-55285	B1 19980406
			US 1998-133434	B1 19980813
			WO 1998-US23254	W 19981117

OTHER SOURCE(S): MARPAT 136:263090


IT 226229-55-6P, Carbamic acid, (3-chlorophenyl)-,  
 2-[[[1-[(4-chlorophenyl)methyl]-2-pyrrolidinyl]methyl]amino]-1-methyl-2-  
 oxoethyl ester 226235-15-0P, Carbamic acid, (3-chlorophenyl)-,  
 2-[[[1-[(4-chlorophenyl)methyl]-4-piperidinyl]methyl]amino]-1-methyl-2-  
 oxoethyl ester

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(preparation of cyclic amine derivs. for inhibition of action of chemokines  
such as MIP-1 $\alpha$  and/or MCP-1 on target cells)


RN 226229-55-6 CAPLUS

CN Carbamic acid, (3-chlorophenyl)-, 2-[[[1-[(4-chlorophenyl)methyl]-2-  
 pyrrolidinyl]methyl]amino]-1-methyl-2-oxoethyl ester (9CI) (CA INDEX  
 NAME)



RN 226235-15-0 CAPLUS

CN Carbamic acid, (3-chlorophenyl)-, 2-[[[1-[(4-chlorophenyl)methyl]-4-  
 piperidinyl]methyl]amino]-1-methyl-2-oxoethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 85 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2001:900125 CAPLUS  
 DOCUMENT NUMBER: 136:19952  
 TITLE: Preparation of carbamimidoylphenylurea derivatives and thio analogs as factor VIIa inhibitors  
 INVENTOR(S): Klingler, Otmar; Schudok, Manfred; Nestler, Hans-Peter; Matter, Hans; Schreuder, Herman  
 PATENT ASSIGNEE(S): Aventis Pharma Deutschland G.m.b.H., Germany  
 SOURCE: Eur. Pat. Appl., 28 pp.  
 CODEN: EPXXDW  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1162194	A1	20011212	EP 2000-112116	20000606
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
CA 2410862	A1	20011213	CA 2001-2410862	20010526
WO 2001094301	A2	20011213	WO 2001-EP6029	20010526
WO 2001094301	A3	20020404		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1299354	A2	20030409	EP 2001-955291	20010526
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001011264	A	20030617	BR 2001-11264	20010526
HU 2003001631	A2	20030929	HU 2003-1631	20010526
JP 2003535844	T	20031202	JP 2002-501818	20010526
EE 200200617	A	20040415	EE 2002-617	20010526
NZ 522960	A	20040528	NZ 2001-522960	20010526
CN 1208314	C	20050629	CN 2001-808830	20010526
AU 2001277494	B2	20060504	AU 2001-277494	20010526
RU 2286337	C2	20061027	RU 2002-135308	20010526
IL 153220	A	20081103	IL 2001-153220	20010526
TW 283662	B	20070711	TW 2001-90113412	20010604
US 20020052417	A1	20020502	US 2001-874318	20010606
US 6743790	B2	20040601		
MX 2002009789	A	20030312	MX 2002-9789	20021004
ZA 2002009018	A	20031008	ZA 2002-9018	20021106
IN 2002CN01978	A	20050225	IN 2002-CN1978	20021202
HK 1055941	A1	20050923	HK 2003-108194	20031112
PRIORITY APPLN. INFO.:			EP 2000-112116	A 20000606
			WO 2001-EP6029	W 20010526

OTHER SOURCE(S): MARPAT 136:19952


IT 379260-18-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of carbamimidoylphenylurea derivs. and thio analogs as factor VIIa inhibitors useful in the treatment of cardiovascular disorders, thromboembolic diseases or restonses)

RN 379260-18-1 CAPLUS  
 CN Propanamide, 2-[[[(4-cyanophenyl)amino]carbonyl]amino]-N-[(4-cyanophenyl)methyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




IT 379259-62-8P 379259-63-9P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(target compound; preparation of carbamimidoylphenylurea derivs. and thio analogs as factor VIIa inhibitors useful in the treatment of cardiovascular disorders, thromboembolic diseases or restonses)

RN 379259-62-8 CAPLUS  
 CN Propanamide, 2-[[[4-(aminoiminomethyl)phenyl]amino]carbonyl]amino]-N-[[4-(aminoiminomethyl)phenyl]methyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 379259-63-9 CAPLUS  
 CN Benzenepropanamide, α-[[[[4-(aminoiminomethyl)phenyl]amino]carbonyl]amino]-N-[[4-(dimethylamino)phenyl]methyl]- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 86 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2001:713304 CAPLUS  
 DOCUMENT NUMBER: 135:257472  
 TITLE: Preparation of peptidomimetic ligands for cellular

receptors and ion channels  
 INVENTOR(S): Persons, Paul E.; Holland, Joanne M.; Hauske, James R.  
 PATENT ASSIGNEE(S): Sepracor, Inc., USA  
 SOURCE: PCT Int. Appl., 109 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001070684	A2	20010927	WO 2001-US6173	20010227
WO 2001070684	A3	20020307		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 20050080271	A1	20050414	US 2003-203279	20030304
US 7115664	B2	20061003		
US 20070093522	A1	20070426	US 2006-512056	20060829
US 7446115	B2	20081104		
PRIORITY APPLN. INFO.:			US 2000-190133P	P 20000316
			WO 2001-US6173	W 20010227
			US 2003-203279	A1 20030304

OTHER SOURCE(S): MARPAT 135:257472


IT 361347-23-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (preparation of peptidomimetic ligands for cellular receptors and ion channels)

RN 361347-23-1 CAPLUS

CN Butanamide, N-[(1S)-1-(aminomethyl)-2-phenylethyl]-3,3-dimethyl-2-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



IT 361347-42-4P 361347-45-7P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of peptidomimetic ligands for cellular receptors and ion channels)

RN 361347-42-4 CAPLUS

CN Butanamide, 3,3-dimethyl-N-[(1S)-2-oxo-1-(phenylmethyl)-2-(1-piperazinyl)ethyl]-2-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-,

(2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 361347-45-7 CAPLUS

CN Butanamide, N-[(1S)-1-[(dimethylamino)methyl]-2-phenylethyl]-3,3-dimethyl-2-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



IT 361347-24-2P 361347-58-2DP, resin-bound

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of peptidomimetic ligands for cellular receptors and ion channels)

RN 361347-24-2 CAPLUS


CN Butanamide, N-[(1S)-1-(aminomethyl)-2-phenylethyl]-3,3-dimethyl-2-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-, (2S)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 361347-23-1


CMF C23 H29 F3 N4 O2

Absolute stereochemistry.




CM 2

CRN 76-05-1  
CMF C2 H F3 O2



RN 361347-58-2 CAPLUS  
CN L-Phenylalaninamide, 3-methyl-N-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]-L-valyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 87 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 2001:612021 CAPLUS  
DOCUMENT NUMBER: 136:548  
TITLE: Thrombin receptor (PAR-1) antagonists. Solid-phase synthesis of indole-based peptide mimetics by anchoring to a secondary amide  
AUTHOR(S): Zhang, H.-C.; McComsey, D. F.; White, K. B.; Addo, M. F.; Andrade-Gordon, P.; Derian, C. K.; Oksenberg, D.; Maryanoff, B. E.  
CORPORATE SOURCE: Drug Discovery, The R. W. Johnson Pharmaceutical Research Institute, Spring House, PA, 19477-0776, USA  
SOURCE: Bioorganic & Medicinal Chemistry Letters (2001), 11(16), 2105-2109  
CODEN: BMCLE8; ISSN: 0960-894X  
PUBLISHER: Elsevier Science Ltd.  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
IT 375392-82-8P  
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC (Process) (solid-phase synthesis of indole-based peptidomimetic thrombin receptor (PAR-1) antagonists by anchoring to a secondary amide and structure activity studies)  
RN 375392-82-8 CAPLUS  
CN L-Histidinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 88 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2001:435041 CAPLUS  
 DOCUMENT NUMBER: 135:33431  
 TITLE: Preparation of cycloamine as CCR5 receptor antagonists  
 INVENTOR(S): Shiota, Tatsuki; Yokoyama, Tomonori; Kamimura, Takashi  
 PATENT ASSIGNEE(S): Teijin Limited, Japan  
 SOURCE: PCT Int. Appl., 271 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001042208	A1	20010614	WO 2000-JP8627	20001206
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2393757	A1	20010614	CA 2000-2393757	20001206
CA 2393757	C	20090407		
AU 2001017314	A	20010618	AU 2001-17314	20001206
AU 778173	B2	20041118		
EP 1238970	A1	20020911	EP 2000-979945	20001206
EP 1238970	B1	20061122		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
CN 1208318	C	20050629	CN 2000-818734	20001206
AT 346042	T	20061215	AT 2000-979945	20001206
ES 2276706	T3	20070701	ES 2000-979945	20001206
US 20070010509	A1	20070111	US 2002-148831	20020605
US 20070249701	A1	20071025	US 2007-730460	20070402
PRIORITY APPLN. INFO.:			JP 1999-348778	A 19991208
			WO 2000-JP8627	W 20001206

OTHER SOURCE(S): MARPAT 135:33431


IT 226235-15-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of cycloamine as CCR5 receptor antagonists for therapeutics or remedies of  $\beta$ -chemokine receptor CCR5-related diseases such as AIDS, rheumatoid arthritis, and nephritis)

RN 226235-15-0 CAPLUS

CN Carbamic acid, (3-chlorophenyl)-, 2-[[[1-[(4-chlorophenyl)methyl]-4-piperidinyl]methyl]amino]-1-methyl-2-oxoethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 89 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2001:380438 CAPLUS

DOCUMENT NUMBER: 135:24657

TITLE: Selective cellular targeting: multifunctional delivery vehicles

INVENTOR(S): Glazier, Arnold

PATENT ASSIGNEE(S): Drug Innovation &amp; Design, Inc., USA

SOURCE: PCT Int. Appl., 981 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001036003	A2	20010525	WO 2000-US31262	20001114
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2391534	A1	20010525	CA 2000-2391534	20001114
AU 2001016075	A	20010530	AU 2001-16075	20001114
EP 1255567	A1	20021113	EP 2000-978631	20001114
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
US 20030138432	A1	20030724	US 2000-738625	20001215
PRIORITY APPLN. INFO.:			US 1999-165485P	P 19991115
			US 2000-239478P	P 20001011
			US 2000-241937P	P 20001020
			WO 2000-US31262	W 20001114



IT 341551-20-0P 341551-29-9P 341990-74-7P

RL: PNU (Preparation, unclassified); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)


(multifunctional delivery vehicles for selective cellular targeting of drugs)

RN 341551-20-0 CAPLUS


CN 1H-Indole-1-carboxylic acid, 3-[3-[[[1-[5-[[[(16S)-13-[3-[bis(9H-fluoren-9-ylmethoxy)phosphinyl]propyl]-16-carboxy-20-(1,1-dioxidobenzo[b]thien-2-yl)-3,14,18-trioxo-7,10,19-trioxa-4,13,17-triazaeicos-1-yl]oxy]-2-pyridinyl]cyclohexyl]methyl]amino]-2-methyl-2-[[[(4-nitrophenyl)amino]carbonyl]amino]-3-oxopropyl]-, 1-(9H-fluoren-9-ylmethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A




PAGE 2-B



PAGE 3-A





PAGE 3-B



RN 341551-29-9 CAPLUS  
 CN 1H-Indole-1-carboxylic acid, 3-[3-[[[1-[5-(2-carboxyethoxy)-2-pyridinyl]cyclohexylmethyl]amino]-2-methyl-2-[[[(4-nitrophenyl)amino]carbonyl]amino]-3-oxopropyl]-, 1-(9H-fluoren-9-ylmethyl) ester (CA INDEX NAME)


PAGE 1-A






RN 341990-74-7 CAPLUS  
 CN L-Alaninamide, N12-[N-[3-[bis(9H-fluoren-9-ylmethoxy)phosphinyl]propyl]-N-[2-[2-[2-[3-[6-[1-[[3-[1-[(9H-fluoren-9-ylmethoxy)carbonyl]-1H-indol-3-yl]-2-methyl-2-[[[(4-nitrophenyl)amino]carbonyl]amino]-1-oxopropyl]amino]methyl]cyclohexyl]-3-pyridinyl]oxy]-1-oxopropyl]amino]ethoxy]ethoxy]ethyl]-L-asparaginy]l]-N23-[N-[2-[2-[[(1,1-dimethylethyl)dimethylsilyl]oxy]amino]-1-methyl-2-oxoethyl]-4-methyl-1-oxopentyl]-3-(5,6,7,8-tetrahydro-1-naphthalenyl)-L-alanyl]-23-amino-3,6,9,15,18,21-hexaoxa-12-azatricosanoyl-D-seryl-N-[1-[[[(1-[1,1'-biphenyl]-4-yl-1-methylethoxy)carbonyl]amino]iminomethyl]-2-[(1,1-dimethylethyl)dimethylsilyl]oxy]-3-piperidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.






PAGE 1-B




PAGE 2-A






PAGE 3-B



PAGE 4-A




PAGE 4-B



L5 ANSWER 90 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 2001:320839 CAPLUS  
DOCUMENT NUMBER: 135:74298  
TITLE: Responses of the ant lasius niger to various compounds  
perceived as sweet in humans: A structure-activity  
relationship study  
AUTHOR(S): Tinti, Jean-Marie; Nofre, Claude  
CORPORATE SOURCE: Faculty of Medicine of Lyon Laennec, University of

SOURCE: Lyon 1, Lyon, Fr.  
 Chemical Senses (2001), 26(3), 231-237  
 CODEN: CHSED8; ISSN: 0379-864X  
 PUBLISHER: Oxford University Press  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 IT 135507-50-5, Superaspartame  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)  
 (a structure-activity relationship study of responses of ants to various compds. perceived as sweet in humans)  
 RN 135507-50-5 CAPLUS  
 CN L-Phenylalanine, N-[(4-cyanophenyl)amino]carbonyl]-L- $\alpha$ -aspartyl-, 2-methyl ester (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 91 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2001:173744 CAPLUS  
 DOCUMENT NUMBER: 134:340694  
 TITLE: Solid-phase synthesis of ureas on microtubes  
 AUTHOR(S): Zhuang, Hui; Yang, En-Che; Xiao, Xiao-Yi; Czarnik, A. W.; Frye, Leah L.; Zindell, Renee  
 CORPORATE SOURCE: ChemRx / IRORI, San Diego, CA, 92121-1963, USA  
 SOURCE: Solid-Phase Organic Syntheses (2001), 1, 15-40  
 CODEN: SOSOCO  
 PUBLISHER: John Wiley & Sons, Inc.  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 134:340694  
 IT 337984-26-6P 337984-27-7P 337984-28-8P  
 337984-29-9P 337984-30-2P 337984-31-3P  
 337984-32-4P 337984-33-5P 337984-34-6P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (solid-phase synthesis of unsym. ureas on microtubes)  
 RN 337984-26-6 CAPLUS  
 CN Glycinamide, 3-cyclohexyl-N-[(phenylamino)carbonyl]-L-alanyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 337984-27-7 CAPLUS

CN Glycinamide, 3-cyclohexyl-N-[[4-methoxyphenyl]amino]carbonyl]-L-alanyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 337984-28-8 CAPLUS

CN Glycinamide, 3-cyclohexyl-N-[[4-nitrophenyl]amino]carbonyl]-L-alanyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 337984-29-9 CAPLUS


CN Glycinamide, N-[(phenylamino)carbonyl]-L-norleucyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 337984-30-2 CAPLUS  
 CN Glycinamide, N-[[ (4-methoxyphenyl)amino]carbonyl]-L-norleucyl-2-phenyl-,  
 (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 337984-31-3 CAPLUS  
 CN Glycinamide, N-[[ (4-nitrophenyl)amino]carbonyl]-L-norleucyl-2-phenyl-,  
 (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 337984-32-4 CAPLUS  
 CN Glycinamide, N-[(phenylamino)carbonyl]-L-phenylalanyl-2-phenyl-, (2S)-  
 (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 337984-33-5 CAPLUS

CN Glycinamide, N-[[ (4-methoxyphenyl)amino]carbonyl]-L-phenylalanyl-2-phenyl-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 337984-34-6 CAPLUS

CN Glycinamide, N-[[ (4-nitrophenyl)amino]carbonyl]-L-phenylalanyl-2-phenyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 92 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2001:168124 CAPLUS

DOCUMENT NUMBER: 134:218936

TITLE: Crystal structure of CDC25 proteins and its use in rational design of inhibitors

INVENTOR(S): Taylor, Neil R.; Borhani, David; Epstein, David; Rudolph, Johannes; Ritter, Kurt; Fujimori, Taro; Robinson, Simon; Eckstein, Jens; Haupt, Andreas; Walker, Nigel; Dixon, Richard W.; Choquette, Deborah; Blanchard, Jill; Kluge, Arthur; Pal, Kollol; Bockovich, Nicholas; Come, Jon; Hediger, Mark

PATENT ASSIGNEE(S): Basf Aktiengesellschaft, Germany

SOURCE: PCT Int. Appl., 314 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001016300	A2	20010308	WO 2000-US23473	20000825
WO 2001016300	A3	20020530		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,			


DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,  
 CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG  
 CA 2383603 A1 20010308 CA 2000-2383603 20000825  
 EP 1226237 A2 20020731 EP 2000-959449 20000825  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL  
 PRIORITY APPLN. INFO.: US 1999-172215P P 19990831  
 WO 2000-US23473 W 20000825  
 OTHER SOURCE(S): MARPAT 134:218936  
 IT 329274-00-2P 329274-01-3P 329274-03-5P  
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological  
 study); PREP (Preparation); USES (Uses)  
 (crystal structure of CDC25 proteins and its use in rational design of  
 inhibitors)  
 RN 329274-00-2 CAPLUS  
 CN L-Norvalinamide, N-[(2-naphthalenylamino)carbonyl]-4-(sulfomethyl)-L-  
 phenylalanyl-L-norvalyl-2-methyl-L-prolyl-3-benzo[b]thien-3-yl-L-alanyl-5-  
 carboxy-N-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 329274-01-3 CAPLUS  
 CN L-Norvalinamide, N-[(1-naphthalenylamino)carbonyl]-4-(sulfomethyl)-L-  
 phenylalanyl-L-norvalyl-2-methyl-L-prolyl-3-benzo[b]thien-3-yl-L-alanyl-5-  
 carboxy-N-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 329274-03-5 CAPLUS  
 CN L-Norvalinamide, N-[(phenylamino)carbonyl]-4-(sulfomethyl)-L-phenylalanyl-L-norvalyl-2-methyl-L-prolyl-3-benzo[b]thien-3-yl-L-alanyl-5-carboxy-N-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—SO<sub>3</sub>H

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 93 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2001:114982 CAPLUS  
 DOCUMENT NUMBER: 134:173028  
 TITLE: Cyclic amine CCR3 antagonists  
 INVENTOR(S): Shiota, Tatsuki; Sudoh, Masaki; Yokoyama, Tomonori;  
 Muroga, Yumiko; Kamimura, Takashi; Nakanishi, Akinobu  
 PATENT ASSIGNEE(S): Teijin Ltd., Japan  
 SOURCE: PCT Int. Appl., 263 pp.  
 CODEN: PIXXD2

DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001010439	A1	20010215	WO 2000-JP5260	20000804
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2378499	A1	20010215	CA 2000-2378499	20000804
EP 1201239	A1	20020502	EP 2000-950006	20000804
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, MC, IE, SI, LT, LV, FI, RO, MK, CY, AL				
AU 779610	B2	20050203	AU 2000-63193	20000804
CN 1192773	C	20050316	CN 2000-813241	20000804
PRIORITY APPLN. INFO.:			JP 1999-220864	A 19990804
			WO 2000-JP5260	W 20000804

OTHER SOURCE(S): MARPAT 134:173028


IT 226235-15-0 325964-15-6 325964-16-7  
 325964-30-5 325964-31-6 325964-32-7  
 325964-36-1 325964-58-7 325964-65-6  
 325964-79-2 325964-80-5 325964-87-2  
 325965-11-5

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(cyclic amine CCR3 antagonists as antiasthmatics and allergy inhibitors)

RN 226235-15-0 CAPLUS


CN Carbamic acid, (3-chlorophenyl)-, 2-[[[1-[(4-chlorophenyl)methyl]-4-piperidinyl]methyl]amino]-1-methyl-2-oxoethyl ester (9CI) (CA INDEX NAME)



RN 325964-15-6 CAPLUS

CN Pentanediamide, N1-[[1-[[4-(methylthio)phenyl]methyl]-4-piperidinyl]methyl]-2-[(phenylamino)carbonyl]amino]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 325964-16-7 CAPLUS

CN Pentanediamide, N1-[[1-[(4-chlorophenyl)methyl]-4-piperidinyl]methyl]-2-[[[(phenylamino)carbonyl]amino]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 325964-30-5 CAPLUS

CN Propanamide, N-[[1-[(3,4-dichlorophenyl)methyl]-4-piperidinyl]methyl]-2-[[[(phenylamino)carbonyl]amino]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 325964-31-6 CAPLUS


CN Butanamide, N-[[1-[(3,4-dichlorophenyl)methyl]-4-piperidinyl]methyl]-3-methyl-2-[[[(phenylamino)carbonyl]amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 325964-32-7 CAPLUS  
 CN Butanamide, N-[[1-[(4-chlorophenyl)methyl]-4-piperidinyl)methyl]-3-methyl-2-[[1-(phenylamino)carbonyl]amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 325964-36-1 CAPLUS  
 CN Propanamide, N-[[1-[(4-chlorophenyl)methyl]-4-piperidinyl)methyl]-3-hydroxy-2-[[1-(phenylamino)carbonyl]amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 325964-58-7 CAPLUS  
 CN Propanamide, N-[[1-[(3,4-dichlorophenyl)methyl]-4-piperidinyl)methyl]-2-[[1-(1-naphthalenylamino)carbonyl]amino]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 325964-65-6 CAPLUS  
 CN Propanamide, N-[[1-[(3,4-dichlorophenyl)methyl]-4-piperidinyl)methyl]-2-[[1-(4-methoxyphenyl)amino]carbonyl]amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.






RN 325964-79-2 CAPLUS

CN Pentanediamide, N1-[[1-[(3,4-dichlorophenyl)methyl]-4-piperidinyl]methyl]-2-[[[(phenylamino)carbonyl]amino]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 325964-80-5 CAPLUS

CN Propanamide, N-[[1-[(3,4-dichlorophenyl)methyl]-4-piperidinyl]methyl]-3-hydroxy-2-[[[(phenylamino)carbonyl]amino]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 325964-87-2 CAPLUS


CN Propanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[[1-[(3,4-dichlorophenyl)methyl]-4-piperidinyl]methyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 325965-11-5 CAPLUS  
 CN Propanamide, N-[[1-[(3,4-dichlorophenyl)methyl]-4-piperidiny]methyl]-3-hydroxy-2-[[[(4-methoxyphenyl)amino]carbonyl]amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 94 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2001:101101 CAPLUS  
 DOCUMENT NUMBER: 134:162834  
 TITLE: Preparation of ureas as inhibitors of CCR-3 receptor  
 INVENTOR(S): Padia, Janak; Hocker, Michael D.; Ohashi, Hiroshi; Nishitoba, Tsuyoshi; Sawa, Eiji  
 PATENT ASSIGNEE(S): Kirin Beer Kabushiki Kaisha, Japan  
 SOURCE: PCT Int. Appl., 177 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001009088	A1	20010208	WO 2000-US17868	20000728
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1200395	A1	20020502	EP 2000-950266	20000728
EP 1200395	B1	20060329		


R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL

AT 321751	T	20060415	AT 2000-950266	20000728
ES 2260036	T3	20061101	ES 2000-950266	20000728
US 6875884	B1	20050405	US 2002-19652	20020702

PRIORITY APPLN. INFO.:  
 US 1999-146219P P 19990728  
 US 2000-191094P P 20000322  
 US 1999-146216P P 19990728  
 WO 2000-US17868 W 20000728


OTHER SOURCE(S): MARPAT 134:162834  
 IT 325162-72-9P 325162-76-3P 325162-79-6P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of ureas as inhibitors of CCR-3 receptor)  
 RN 325162-72-9 CAPLUS  
 CN Butanoic acid, 4-[[[(3S)-3-[[[(4-bromophenyl)amino]carbonyl]amino]-4-oxo-4-[(phenylmethyl)amino]butyl](1,2,3,4-tetrahydro-1-naphthalenyl)amino]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 325162-76-3 CAPLUS  
 CN Butanoic acid, 4-[[[(3S)-3-[[[(4-bromophenyl)amino]carbonyl]amino]-4-oxo-4-[(phenylmethyl)amino]butyl][(1R)-1,2,3,4-tetrahydro-1-naphthalenyl]amino]-, (CA INDEX NAME)


Absolute stereochemistry.



RN 325162-79-6 CAPLUS

CN Butanoic acid, 4-[[[(3S)-3-[[[(4-bromophenyl)amino]carbonyl]amino]-4-oxo-4-  
[(phenylmethyl)amino]butyl][(1S)-1,2,3,4-tetrahydro-1-naphthalenyl]amino]-  
(CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 95 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2001:61090 CAPLUS

DOCUMENT NUMBER: 134:247168

TITLE: Tyrosine 220 in the 5th transmembrane domain of the  
neuromedin B receptor is critical for the high  
selectivity of the peptoid antagonist PD168368

AUTHOR(S): Tokita, Kenji; Hocart, Simon J.; Katsuno, Tatsuro;  
Mantey, Samuel A.; Coy, David H.; Jensen, Robert T.

CORPORATE SOURCE: Digestive Diseases Branch, NIDDK, National Institutes  
of Health, Bethesda, MD, 20892-1804, USA

SOURCE: Journal of Biological Chemistry (2001), 276(1),  
495-504

CODEN: JBCHA3; ISSN: 0021-9258

PUBLISHER: American Society for Biochemistry and Molecular  
Biology

DOCUMENT TYPE: Journal

LANGUAGE: English

IT 204066-82-0, PD168368


RL: BAC (Biological activity or effector, except adverse); BSU (Biological  
study, unclassified); BUU (Biological use, unclassified); BIOL (Biological  
study); USES (Uses)

(tyrosine 220 in the 5th transmembrane domain of neuromedin B receptor  
is critical for high selectivity of peptoid antagonist PD168368)

RN 204066-82-0 CAPLUS

CN 1H-Indole-3-propanamide,  $\alpha$ -methyl- $\alpha$ -[[[(4-  
nitrophenyl)amino]carbonyl]amino]-N-[[1-(2-pyridinyl)cyclohexyl]methyl]-,  
( $\alpha$ S)- (CA INDEX NAME)


Absolute stereochemistry.



REFERENCE COUNT: 80 THERE ARE 80 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 96 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2001:20384 CAPLUS  
 DOCUMENT NUMBER: 134:250079  
 TITLE: Cellular responses of NG108-15 and SK-N-MC lines to sweet and bitter tastants as measured by extracellular acidification rates  
 AUTHOR(S): Khare, Sangeeta; Gokulan, Kuppan; Linthicum, D. Scott  
 CORPORATE SOURCE: Departments of Pathobiology and Medical Physiology, Texas A and M University, College Station, TX, USA  
 SOURCE: Journal of Neuroscience Research (2001), 63(1), 64-71  
 CODEN: JNREDK; ISSN: 0360-4012  
 PUBLISHER: Wiley-Liss, Inc.  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 IT 135507-50-5, SC 40014  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)  
 (cellular responses of NG108-15 and SK-N-MC lines to sweet and bitter tastants as measured by extracellular acidification rates)  
 RN 135507-50-5 CAPLUS  
 CN L-Phenylalanine, N-[(4-cyanophenyl)amino]carbonyl]-L- $\alpha$ -aspartyl-, 2-methyl ester (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 97 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2001:12495 CAPLUS

DOCUMENT NUMBER: 134:91087  
 TITLE: Antifungal peptides derived from  
 bactericidal/permeability-increasing protein (BPI)  
 INVENTOR(S): Little, Roger G.; Lin, Jong-jye; Gikonyo, J. G. Kinyua  
 PATENT ASSIGNEE(S): Xoma Technology Ltd., USA  
 SOURCE: PCT Int. Appl., 106 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001000671	A1	20010104	WO 2000-US17383	20000623
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6355616	B1	20020312	US 1999-344541	19990625
PRIORITY APPLN. INFO.:			US 1999-344541	A2 19990625
OTHER SOURCE(S): MARPAT 134:91087				
IT 316135-10-1P, XMP.599				
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (amino acid sequence; antifungal peptides derived from bactericidal/permeability-increasing protein (BPI))				
RN 316135-10-1 CAPLUS				
CN D-Lysinamide, N2-[(3,5,6-trichloro-2-pyridinyl)amino]carbonyl]-D-lysyl-D- tryptophyl-D-leucyl-D-glutaminyl-D-leucyl-D-phenylalanyl-D-histidyl-D- lysyl- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-B



REFERENCE COUNT:

5


THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 98 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2001:12484 CAPLUS  
 DOCUMENT NUMBER: 134:71908  
 TITLE: Preparation of benzimidazolone peptidomimetics as  
 thrombin receptor antagonists  
 INVENTOR(S): Zhang, Han-cheng; Maryanoff, Bruce E.; Mccomsey, David  
 F.; White, Kimberly B.  
 PATENT ASSIGNEE(S): Ortho-Mcneil Pharmaceutical, Inc., USA; Cor  
 Therapeutics, Inc.  
 SOURCE: PCT Int. Appl., 53 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001000659	A1	20010104	WO 2000-US17751	20000628
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6630451	B1	20031007	US 2000-599826	20000622
US 20040063642	A1	20040401	US 2003-390098	20030317
US 6943149	B2	20050913		
PRIORITY APPLN. INFO.:			US 1999-141552P	P 19990629
			US 2000-599826	A 20000622
OTHER SOURCE(S):	MARPAT	134:71908		
IT 315236-44-3P				
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
(preparation of benzimidazolone peptidomimetics as thrombin receptor antagonists)				
RN 315236-44-3 CAPLUS				
CN L-Alaninamide, 3,4-difluoro-N-[[[3-[(4-fluorophenyl)methyl]-2,3-dihydro-2-oxo-1-[2-(1-pyrrolidinyl)ethyl]-1H-benzimidazol-5-yl]amino]carbonyl]-L-phenylalanyl-N-(2-aminoethyl)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.





REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 99 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2001:12482 CAPLUS  
 DOCUMENT NUMBER: 134:71906  
 TITLE: Preparation of novel indole peptidomimetics as thrombin receptor antagonists  
 INVENTOR(S): Zhang, Han-cheng; Hoekstra, William J.; Maryanoff, Bruce E.; McComsey, David F.  
 PATENT ASSIGNEE(S): Ortho-Mcneil Pharmaceutical, Inc., USA; Cor Therapeutics, Inc.  
 SOURCE: PCT Int. Appl., 76 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001000657	A2	20010104	WO 2000-US18018	20000629
WO 2001000657	A3	20010712		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6858577	B1	20050222	US 2000-603231	20000626
US 20030224999	A1	20031204	US 2003-403542	20030331
US 7183252	B2	20070227		

PRIORITY APPLN. INFO.: US 1999-141550P P 19990629  
 US 2000-603231 A 20000626


OTHER SOURCE(S): MARPAT 134:71906  
 IT 316150-87-5P 316151-02-7P 316151-51-6P  
 316151-53-8P 316151-69-6P 316151-71-0P  
 316152-06-4P 316152-08-6P 316152-10-0P  
 316152-11-1P 316152-13-3P 316152-15-5P  
 316152-17-7P 316152-25-7P 316152-37-1P  
 316152-39-3P 316153-13-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of novel indole peptidomimetics as thrombin receptor antagonists)

RN 316150-87-5 CAPLUS

CN D-Histidinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316151-02-7 CAPLUS

CN L-Phenylalaninamide, N2-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-arginyl-3,4-difluoro-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316151-51-6 CAPLUS

CN L-Alaninamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(phenylmethyl)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316151-53-8 CAPLUS

CN L-Phenylalaninamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidin-1-ylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-4-amino-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316151-69-6 CAPLUS

CN Benzenepropanamide, N-[(1S)-4-amino-1-[(4-methyl-1-piperazinyl)carbonyl]butyl]-alpha-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidin-1-ylmethyl)-1H-indol-6-yl]amino]carbonyl]amino]-3,4-difluoro-, (alphaS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 316151-71-0 CAPLUS

CN Benzenepropanamide, N-[(1S)-4-amino-1-(1-piperidinylcarbonyl)butyl]-  
α-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-  
indol-6-yl]amino]carbonyl]amino]-3,4-difluoro-, (αS)- (CA INDEX  
NAME)


Absolute stereochemistry.



RN 316152-06-4 CAPLUS

CN L-Phenylalaninamide, 4-chloro-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-  
pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(2-  
aminoethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-08-6 CAPLUS

CN L-Histidinamide, 4-chloro-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(2-aminoethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-10-0 CAPLUS

CN L-Alaninamide, 4-chloro-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(2-aminoethyl)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-11-1 CAPLUS

CN L-Alaninamide, 4-chloro-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(2-aminoethyl)-3-(2-thienyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-13-3 CAPLUS

CN L-Alaninamide, 4-chloro-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(2-aminoethyl)-3-(4-thiazolyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-15-5 CAPLUS

CN L-Phenylalaninamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(2-aminoethyl)-3-fluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-17-7 CAPLUS

CN L-Alaninamide, 4-chloro-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-[2-[(1-iminoethyl)amino]ethyl]-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-25-7 CAPLUS

CN L-Alaninamide, 4-chloro-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(3-aminopropyl)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 316152-37-1 CAPLUS

CN D-Alaninamide, 4-chloro-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-D-phenylalanyl-N-(2-aminoethyl)-3-(2-thienyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 316152-39-3 CAPLUS

CN L-Alaninamide, 3,4-difluoro-N-[[[1-[(3-methylphenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(3-aminopropyl)-3-(2-thienyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316153-13-6 CAPLUS

CN L-Alaninamide, 4-chloro-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(2-aminoethyl)-3-(4-pyridinyl)-, trihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●3 HCl

L5 ANSWER 100 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2001:12481 CAPLUS  
 DOCUMENT NUMBER: 134:71905  
 TITLE: Preparation of indazole peptidomimetics as thrombin  
 receptor antagonists  
 INVENTOR(S): Zhang, Han-cheng; Maryanoff, Bruce E.; Pandey, Anjali;  
 Scarborough, Robert M.  
 PATENT ASSIGNEE(S): Ortho-Mcneil Pharmaceutical, Inc., USA; Cor  
 Therapeutics, Inc.  
 SOURCE: PCT Int. Appl., 51 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001000656	A2	20010104	WO 2000-US17718	20000628
WO 2001000656	A3	20010525		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 20030199455	A1	20031023	US 2003-403218	20030331
US 7049297	B2	20060523		
US 20060166896	A1	20060727	US 2006-393350	20060330
US 20060166897	A1	20060727	US 2006-393529	20060330
US 7417030	B2	20080826		
PRIORITY APPLN. INFO.:			US 1999-141553P	P 19990629
			US 2000-603338	A 20000626
			US 2003-403218	A3 20030331


OTHER SOURCE(S): MARPAT 134:71905  
 IT 315203-33-9P 315203-36-2P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);  
BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of indazole peptidomimetics as thrombin receptor antagonists)

RN 315203-33-9 CAPLUS

CN L-Alaninamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indazol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(2-aminoethyl)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 315203-36-2 CAPLUS

CN L-Alaninamide, 4-chloro-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indazol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(2-aminoethyl)-3-(2-thienyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 101 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2000:854241 CAPLUS

DOCUMENT NUMBER: 134:172770

TITLE: Nonpeptide neuromedin B receptor antagonists inhibit the proliferation of C6 cells

AUTHOR(S): Moody, T. W.; Jensen, R. T.; Garcia, L.; Leyton, J.

CORPORATE SOURCE: Cell and Cancer Biology Department, Medicine Branch, National Cancer Institute, Bldg. KWC, Rm. 300, Rockville, MD, 20850, USA

SOURCE: European Journal of Pharmacology (2000), 409(2),

133-142

CODEN: EJPHAZ; ISSN: 0014-2999

PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

IT 185215-75-2, PD165929 204066-82-0, PD168368

204067-01-6, PD176252


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(nonpeptide neuromedin B receptor antagonists inhibit proliferation of C6 cells)

RN 185215-75-2 CAPLUS

CN 1H-Indole-3-propanamide,  $\alpha$ -[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]amino]- $\alpha$ -methyl-N-[[1-(2-pyridinyl)cyclohexyl]methyl]-, ( $\alpha$ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 204066-82-0 CAPLUS

CN 1H-Indole-3-propanamide,  $\alpha$ -methyl- $\alpha$ -[[[4-nitrophenyl]amino]carbonyl]amino]-N-[[1-(2-pyridinyl)cyclohexyl]methyl]-, ( $\alpha$ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 204067-01-6 CAPLUS

CN 1H-Indole-3-propanamide, N-[[1-(5-methoxy-2-pyridinyl)cyclohexyl]methyl]-  
 $\alpha$ -methyl- $\alpha$ -[[[(4-nitrophenyl)amino]carbonyl]amino]-,  
( $\alpha$ S)- (CA INDEX NAME)


Absolute stereochemistry.



REFERENCE COUNT: 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 102 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 2000:844925 CAPLUS  
DOCUMENT NUMBER: 134:187821  
TITLE: Solid-phase synthesis of di- and tripeptidic  
hydroxamic acids as inhibitors of procollagen  
C-proteinase  
AUTHOR(S): Dankwardt, Sharon M.; Billedeau, Roland J.; Lawley,  
Linda K.; Abbot, Sarah C.; Martin, Robert L.; Chan,  
Christine S.; Van Wart, Harold E.; Walker, Keith A. M.  
CORPORATE SOURCE: Inflammatory Diseases Unit, Roche Bioscience, Palo  
Alto, CA, 94304, USA  
SOURCE: Bioorganic & Medicinal Chemistry Letters (2000),  
10(22), 2513-2516  
CODEN: BMCLE8; ISSN: 0960-894X  
PUBLISHER: Elsevier Science Ltd.  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
OTHER SOURCE(S): CASREACT 134:187821  
IT 274936-94-6P 327031-77-6P 327031-80-1P  
327031-82-3P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological  
study, unclassified); SPN (Synthetic preparation); BIOL (Biological  
study); PREP (Preparation)  
(solid-phase synthesis of di- and tripeptidic hydroxamic acids as  
inhibitors of procollagen C-proteinase)  
RN 274936-94-6 CAPLUS  
CN L-Tryptophanamide, N-[[[(3,5-dichlorophenyl)amino]carbonyl]-L-isoleucyl-N-  
hydroxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 327031-77-6 CAPLUS

CN L-Tryptophanamide, N-[(2-nitrophenyl)amino]carbonyl]-L-isoleucyl-N-hydroxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 327031-80-1 CAPLUS

CN L-Tryptophanamide, N-[(2-chlorophenyl)amino]carbonyl]-L-isoleucyl-N-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 327031-82-3 CAPLUS

CN L-Tryptophanamide, N-[(3-bromophenyl)amino]carbonyl]-L-isoleucyl-N-

hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 103 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2000:824101 CAPLUS

DOCUMENT NUMBER: 134:5154

TITLE: Preparation of cyclic amine derivatives as remedies or preventives for diseases in association with chemokines or chemokine receptors

INVENTOR(S): Shiota, Tatsuki; Miyagi, Fuminori; Kamimura, Takashi; Ohta, Tomohiro; Takano, Yasuhiro; Horiuchi, Hideki

PATENT ASSIGNEE(S): Teijin Limited, Japan

SOURCE: PCT Int. Appl., 405 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000069432	A1	20001123	WO 2000-JP3203	20000518
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2373942	A1	20001123	CA 2000-2373942	20000518
EP 1179341	A1	20020213	EP 2000-927808	20000518
EP 1179341	B1	20051109		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, MC, PT, IE, SI, LT, LV, FI, RO			
NZ 515374	A	20040924	NZ 2000-515374	20000518
AU 779954	B2	20050224	AU 2000-46147	20000518
AT 308985	T	20051115	AT 2000-927808	20000518
CN 1240699	C	20060208	CN 2000-810490	20000518
ES 2250132	T3	20060416	ES 2000-927808	20000518
US 7390830	B1	20080624	US 2001-959635	20011101
PRIORITY APPLN. INFO.:			JP 1999-175856	A 19990518


OTHER SOURCE(S): MARPAT 134:5154

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

RN 226229-55-6 CAPLUS

Clc1ccc(cc1)CN(CC2CCCC2)CCNC(=O)C(C)OC(=O)Nc3ccc(Cl)cc3

CN Carbamic acid, (3-chlorophenyl)-, 2-[[[1-[(4-chlorophenyl)methyl]-4-piperidinyl]methyl]amino]-1-methyl-2-oxoethyl ester (9CI) (CA INDEX NAME)



L5 ANSWER 104 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN

DOCUMENT NUMBER: 133:252041

TITLE: Preparation of amine derivatives as cathepsin K and cathepsin S inhibitors and in treating pathology and/or symptomatology of diseases caused by cysteine protease activity

INVENTOR(S): Link, John O.; Martelli, Arnold J.; Martichonok, Valeri; Patterson, John W.; Saunders, Oliver L.; Zipfel, Sheila

PATENT ASSIGNEE(S): Axys Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 223 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1



## PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000055144	A1	20000921	WO 2000-US6885	20000315
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2367352	A1	20000921	CA 2000-2367352	20000315
AU 2000037507	A	20001004	AU 2000-37507	20000315
AU 774664	B2	20040701		
EP 1161422	A1	20011212	EP 2000-916397	20000315
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 2000009044	A	20020115	BR 2000-9044	20000315
TR 200103335	T2	20020422	TR 2001-3335	20000315
HU 2002000572	A2	20020629	HU 2002-572	20000315
HU 2002000572	A3	20040728		
JP 2002539201	T	20021119	JP 2000-605574	20000315
EE 200100486	A	20030217	EE 2001-486	20000315
US 6576630	B1	20030610	US 2000-525507	20000315
EP 1516877	A1	20050323	EP 2004-15656	20000315
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
IL 145428	A	20071031	IL 2000-145428	20000315
ZA 2001007496	A	20021211	ZA 2001-7496	20010911
MX 2001009240	A	20020108	MX 2001-9240	20010913
IN 2001KN00948	A	20050311	IN 2001-KN948	20010913
NO 2001004483	A	20011101	NO 2001-4483	20010914
BG 105969	A	20020531	BG 2001-105969	20011002
HR 2001000736	A1	20021231	HR 2001-736	20011012
US 20030232864	A1	20031218	US 2003-354888	20030128
AU 2004201071	A1	20040408	AU 2004-201071	20040315
PRIORITY APPLN. INFO.:				
			US 1999-124421P	P 19990315
			AU 2000-37507	A3 20000315
			EP 2000-916397	A3 20000315
			US 2000-525507	A1 20000315
			WO 2000-US6885	W 20000315

OTHER SOURCE(S): MARPAT 133:252041


IT 294883-28-6P 294883-37-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of amine derivs. as cathepsin K and cathepsin S inhibitors useful in disorders caused by cysteine protease activity)

RN 294883-28-6 CAPLUS

CN Cyclohexanepropanamide, N-[(1S)-1-(2-benzoxazolylhydroxymethyl)-3-phenylpropyl]- $\alpha$ -[[3-pyridinylamino)carbonyl]amino]-, ( $\alpha$ S)-  
 (CA INDEX NAME)


Absolute stereochemistry.



RN 294883-37-7 CAPLUS

CN Cyclohexanepropanamide, N-[(1S)-1-(2-benzoxazolylcarbonyl)-3-phenylpropyl]- $\alpha$ -[[3-pyridinylamino)carbonyl]amino]-, (aS)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 105 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2000:666699 CAPLUS  
 DOCUMENT NUMBER: 133:251875  
 TITLE: Preparation of esters as protease inhibitors  
 INVENTOR(S): Buysse, Ann M.; Mendonca, Rohan V.; Palmer, James T.;  
 Tian, Zong-Qiang; Venkatraman, Shankar  
 PATENT ASSIGNEE(S): Axy's Pharmaceuticals, Inc., USA  
 SOURCE: PCT Int. Appl., 108 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000055124	A2	20000921	WO 2000-US7145	20000315
WO 2000055124	A3	20010816		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW

RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,

DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,  
 CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG  
 CA 2367348 A1 20000921 CA 2000-2367348 20000315  
 EP 1159260 A1 20011205 EP 2000-918085 20000315  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO  
 JP 2002539190 T 20021119 JP 2000-605555 20000315  
 US 6506733 B1 20030114 US 2000-526300 20000315  
 AU 779177 B2 20050113 AU 2000-38959 20000315  
 US 20030092634 A1 20030515 US 2002-288103 20021104  
 PRIORITY APPLN. INFO.: US 1999-124529P P 19990315  
 US 2000-526300 A1 20000315  
 WO 2000-US7145 W 20000315

OTHER SOURCE(S): MARPAT 133:251875


IT 294870-01-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of esters as protease inhibitors)

RN 294870-01-2 CAPLUS

CN Pentanamide, 2-[[[(3-methoxyphenyl)amino]carbonyl]amino]-3-methyl-N-[(1S)-2-oxo-1-(2-phenylethyl)-3-(phenylmethoxy)propyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 106 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2000:401856 CAPLUS

DOCUMENT NUMBER: 133:43814

TITLE: Preparation of peptides as procollagen C-proteinase inhibitors

INVENTOR(S): Dankwardt, Sharon Marie; Van Wart, Harold Edgar; Walker, Keith Adrian Murray

PATENT ASSIGNEE(S): F. Hoffmann-La Roche A.-G., Switz.

SOURCE: PCT Int. Appl., 78 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000034313	A1	20000615	WO 1999-EP9519	19991206
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG,				

MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL,  
 TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW  
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,  
 DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,  
 CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG  
 CA 2352740 A1 20000615 CA 1999-2352740 19991206  
 BR 9916004 A 20011002 BR 1999-16004 19991206  
 EP 1137661 A1 20011004 EP 1999-968338 19991206  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO  
 TR 200101663 T2 20011121 TR 2001-1663 19991206  
 JP 2002531576 T 20020924 JP 2000-586755 19991206  
 AU 772575 B2 20040429 AU 2000-25375 19991206  
 US 6426402 B1 20020730 US 1999-459201 19991210  
 MX 2001005750 A 20011001 MX 2001-5750 20010607  
 ZA 2001004672 A 20020909 ZA 2001-4672 20010607  
 US 20020169133 A1 20021114 US 2002-72730 20020207  
 US 6951918 B2 20051004  
 PRIORITY APPLN. INFO.: US 1998-111661P P 19981210  
 WO 1999-EP9519 W 19991206  
 US 1999-459201 A3 19991210


OTHER SOURCE(S): MARPAT 133:43814  
 IT 274936-88-8P 274936-90-2P 274936-91-3P  
 274936-94-6P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological  
 study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);  
 BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of peptides as procollagen C-proteinase inhibitors)  
 RN 274936-88-8 CAPLUS  
 CN L-Tryptophanamide, N-[(phenylamino)carbonyl]-L-isoleucyl-N-hydroxy- (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.



RN 274936-90-2 CAPLUS  
 CN L-Tryptophanamide, N-[(2-fluorophenyl)amino]carbonyl]-L-isoleucyl-N-  
 hydroxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274936-91-3 CAPLUS

CN L-Tryptophanamide, N-[(2-methoxyphenyl)amino]carbonyl]-L-isoleucyl-N-hydroxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274936-94-6 CAPLUS

CN L-Tryptophanamide, N-[(3,5-dichlorophenyl)amino]carbonyl]-L-isoleucyl-N-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT:

6

THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 107 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2000:142694 CAPLUS  
 DOCUMENT NUMBER: 132:306178  
 TITLE: Active Conformations of Neotame and Other High-Potency Sweeteners  
 AUTHOR(S): Walters, D. Eric; Prakash, Indra; Desai, Nitin  
 CORPORATE SOURCE: Department of Biochemistry and Molecular Biology, Finch University of Health Sciences/The Chicago Medical School, North Chicago, IL, 60064, USA  
 SOURCE: Journal of Medicinal Chemistry (2000), 43(6), 1242-1245  
 CODEN: JMCMAR; ISSN: 0022-2623  
 PUBLISHER: American Chemical Society  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 IT 135507-50-5, Superspartame  
 RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)  
 (receptor-active conformations of high-potency dipeptide and guanidine sweeteners)  
 RN 135507-50-5 CAPLUS  
 CN L-Phenylalanine, N-[(4-cyanophenyl)amino]carbonyl]-L- $\alpha$ -aspartyl-, 2-methyl ester (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 108 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1999:819353 CAPLUS  
 DOCUMENT NUMBER: 132:64534  
 TITLE: Preparation of cyclic amino acid compounds for inhibiting  $\beta$ -amyloid peptide release and/or its synthesis  
 INVENTOR(S): Thompson, Richard C.; Wilkie, Stephen; Stack, Douglas R.; Vanmeter, Eldon E.; Shi, Qing; Britton, Thomas C.; Audia, James E.; Reel, Jon K.; Mabry, Thomas E.; Dressman, Bruce A.; Cwi, Cynthia L.; Henry, Steven S.; Mcdaniel, Stacey L.; Stucky, Russell D.; Porter, Warren J.  
 PATENT ASSIGNEE(S): Elan Pharmaceuticals, Inc., USA; Eli Lilly & Company; et al.  
 SOURCE: PCT Int. Appl., 714 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 4  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9967221	A1	19991229	WO 1999-US14193	19990622
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2325389	A1	19991229	CA 1999-2325389	19990622
AU 9947101	A	20000110	AU 1999-47101	19990622
EP 1089980	A1	20010411	EP 1999-930594	19990622
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002518483	T	20020625	JP 2000-555875	19990622
US 20050192265	A1	20050901	US 2004-2922	20041203
PRIORITY APPLN. INFO.:				
			US 1998-102507	A2 19980622
			WO 1999-US14193	W 19990622
			US 2003-392332	A3 20030320

OTHER SOURCE(S): MARPAT 132:64534

IT 253323-23-8P 253323-26-1P 253323-27-2P  
 253323-28-3P 253323-29-4P 253323-30-7P  
 253323-31-8P 253323-32-9P 253323-33-0P  
 253323-34-1P 253323-35-2P 253323-36-3P  
 253323-37-4P 253323-39-6P 253323-41-0P  
 253323-42-1P 253323-44-3P 253323-45-4P  
 253323-47-6P 253323-48-7P 253323-49-8P  
 253323-50-1P 253323-51-2P 253323-52-3P  
 253323-53-4P 253323-54-5P 253323-55-6P  
 253323-56-7P 253323-57-8P 253323-58-9P  
 253323-59-0P 253323-60-3P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of cyclic amino acid compds. for inhibiting  $\beta$ -amyloid peptide release)

RN 253323-23-8 CAPLUS


CN Propanamide, 2-[[[(3,4-dichlorophenyl)amino]carbonyl]amino]-N-[(3S)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 253323-26-1 CAPLUS  
 CN Propanamide, 2-[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]amino]-N-  
 [(3S)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-,  
 (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 253323-27-2 CAPLUS  
 CN Propanamide, N-[(3S)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-  
 benzodiazepin-3-yl]-2-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-,  
 (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 253323-28-3 CAPLUS  
 CN Propanamide, N-[(3S)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-  
 benzodiazepin-3-yl]-2-[(phenylamino)carbonyl]amino]-, (2S)- (CA INDEX  
 NAME)

Absolute stereochemistry.






RN 253323-29-4 CAPLUS

CN Benzoic acid, 4-[[[(1S)-2-[[[(3S)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]amino]-1-methyl-2-oxoethyl]amino]carbonyl]amino]-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 253323-30-7 CAPLUS

CN Propanamide, 2-[[[(2-bromophenyl)amino]carbonyl]amino]-N-[(3S)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 253323-31-8 CAPLUS


CN Propanamide, N-[(3S)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-[[[(2-methylphenyl)amino]carbonyl]amino]-, (2S)-  
(CA INDEX NAME)

Absolute stereochemistry.




RN 253323-32-9 CAPLUS  
CN Propanamide, N-[(3S)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-[[[(2-ethyl-6-methylphenyl)amino]carbonyl]amino]-, (2S)-  
(CA INDEX NAME)

Absolute stereochemistry.



RN 253323-33-0 CAPLUS  
CN Propanamide, N-[(3S)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-[[[(2-fluorophenyl)amino]carbonyl]amino]-, (2S)-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 253323-34-1 CAPLUS

CN Propanamide, 2-[[[(2,4-difluorophenyl)amino]carbonyl]amino]-N-[(3S)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 253323-35-2 CAPLUS

CN Propanamide, N-[(3S)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-[[[(2-ethoxyphenyl)amino]carbonyl]amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 253323-36-3 CAPLUS

CN Propanamide, 2-[[[(3-acetylphenyl)amino]carbonyl]amino]-N-[(3S)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-, (2S)- (CA INDEX NAME)

dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 253323-37-4 CAPLUS

CN Propanamide, 2-[[[(3-cyanophenyl)amino]carbonyl]amino]-N-[(3S)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 253323-39-6 CAPLUS

CN Propanamide, 2-[[[(4-butylphenyl)amino]carbonyl]amino]-N-[(3S)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 253323-41-0 CAPLUS

CN Propanamide, 2-[[[1,1'-biphenyl]-4-ylamino]carbonyl]amino]-N-[(3S)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 253323-42-1 CAPLUS

CN Propanamide, N-[(3S)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-[[[4-(1-methylethyl)phenyl]amino]carbonyl]amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 253323-44-3 CAPLUS

CN Propanamide, N-[(3S)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-

benzodiazepin-3-yl]-2-[[[2-(1-methylethyl)phenyl]amino]carbonyl]amino]-,  
(2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 253323-45-4 CAPLUS

CN Propanamide, 2-[[[2,6-difluorophenyl]amino]carbonyl]amino]-N-[(3S)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 253323-47-6 CAPLUS

CN Propanamide, N-[(3S)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-[[[4-(trifluoromethoxy)phenyl]amino]carbonyl]amino]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 253323-48-7 CAPLUS

CN Propanamide, 2-[[[(2,4-dichlorophenyl)amino]carbonyl]amino]-N-[(3S)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 253323-49-8 CAPLUS

CN Benzoic acid, 3-[[[(1S)-2-[[[(3S)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]amino]-1-methyl-2-oxoethyl]amino]carbonyl]amino]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 253323-50-1 CAPLUS

CN Propanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[(3S)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-, (2S)- (CA INDEX NAME)

dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-, (2S)- (CA  
INDEX NAME)


Absolute stereochemistry.



RN 253323-51-2 CAPLUS

CN Propanamide, 2-[[[(4-butoxyphenyl)amino]carbonyl]amino]-N-[(3S)-2,3-  
dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-, (2S)- (CA  
INDEX NAME)

Absolute stereochemistry.




RN 253323-52-3 CAPLUS

CN Propanamide, N-[(3S)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-  
benzodiazepin-3-yl]-2-[[[(4-phenoxyphenyl)amino]carbonyl]amino]-, (2S)-  
(CA INDEX NAME)

Absolute stereochemistry.






RN 253323-53-4 CAPLUS

CN Propanamide, N-[(3S)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-[[[(1-naphthalenylamino)carbonyl]amino]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 253323-54-5 CAPLUS

CN Propanamide, 2-[[[(1,1'-biphenyl)-2-ylamino)carbonyl]amino]-N-[(3S)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 253323-55-6 CAPLUS


CN Propanamide, N-[(3S)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-[[[2-(methylthio)phenyl]amino]carbonyl]amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 253323-56-7 CAPLUS  
CN Propanamide, N-[(3S)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-[[[(2-ethylphenyl)amino]carbonyl]amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 253323-57-8 CAPLUS  
CN Propanamide, N-[(3S)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-[[[(3-methoxyphenyl)amino]carbonyl]amino]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 253323-58-9 CAPLUS


CN Propanamide, N-[(3S)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-[[[(3,4,5-trimethoxyphenyl)amino]carbonyl]amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 253323-59-0 CAPLUS  
CN Propanamide, N-[(3S)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-[[[(2,4,6-trimethylphenyl)amino]carbonyl]amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 253323-60-3 CAPLUS  
CN Propanamide, N-[(3S)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-[[[2-(1,1-dimethylethyl)-6-methylphenyl]amino]carbonyl]amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 109 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1999:811266 CAPLUS  
 DOCUMENT NUMBER: 132:50253  
 TITLE: Preparation of tetrapeptides and their analogs that selectively bind mammalian opioid receptors  
 INVENTOR(S): Persons, Paul E.; Hauske, James; Hussoin, Roushan A.  
 PATENT ASSIGNEE(S): Sepracor, Inc., USA  
 SOURCE: PCT Int. Appl., 225 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9965932	A1	19991223	WO 1999-US13638	19990618
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9945729	A	20000105	AU 1999-45729	19990618
US 6548637	B1	20030415	US 1999-336314	19990618
PRIORITY APPLN. INFO.:			US 1998-89792P	P 19980618
			WO 1999-US13638	W 19990618

OTHER SOURCE(S): MARPAT 132:50253  
 IT 252766-30-6P 252766-35-1P 252766-36-2P  
 252766-37-3P 252766-38-4P 252766-39-5P  
 252766-40-8P 252766-41-9P 252766-42-0P  
 252766-43-1P 252766-44-2P 252766-45-3P  
 252766-46-4P 252766-47-5P 252766-58-8P  
 252766-59-9P 252766-60-2P 252766-62-4P  
 252766-64-6P 252766-65-7P 252766-66-8P  
 252766-67-9P 252766-68-0P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of tetrapeptides and their analogs that selectively bind mammalian opioid receptors)

RN 252766-30-6 CAPLUS

CN Benzenebutanamide, N-[[ (2,5-difluorophenyl)amino]carbonyl]-3-methyl-L-valyl-L-phenylalanyl- $\alpha$ -amino-, ( $\alpha$ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252766-35-1 CAPLUS

CN L-Phenylalaninamide, N-[[ (3-methoxyphenyl)amino]carbonyl]-3-methyl-L-valyl-L-phenylalanyl-3-chloro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252766-36-2 CAPLUS

CN L-Phenylalaninamide, 3-methyl-N-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]-L-valyl-L-phenylalanyl-3-chloro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252766-37-3 CAPLUS

CN L-Phenylalaninamide, N-[[ (2,5-difluorophenyl)amino]carbonyl]-3-methyl-L-valyl-L-phenylalanyl-3-chloro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252766-38-4 CAPLUS

CN L-Phenylalalaninamide, N-[[ (3-methoxyphenyl)amino]carbonyl]-3-methyl-L-valyl-L-phenylalanyl-β-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252766-39-5 CAPLUS

CN L-Phenylalaninamide, 3-methyl-N-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]-L-valyl-L-phenylalanyl-β-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252766-40-8 CAPLUS

CN L-Phenylalaninamide, N-[[[(2,5-difluorophenyl)amino]carbonyl]-3-methyl-L-valyl-L-phenylalanyl-β-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252766-41-9 CAPLUS

CN L-Phenylalaninamide, 3-methyl-N-[[[4-(methylthio)phenyl]amino]carbonyl]-L-valyl-L-phenylalanyl-3,4-dichloro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252766-42-0 CAPLUS

CN L-Alaninamide, N-[[[(3-methoxyphenyl)amino]carbonyl]-3-methyl-L-valyl-L-phenylalanyl-3-(3-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252766-43-1 CAPLUS

CN L-Alaninamide, 3-methyl-N-[[[4-(methylthio)phenyl]amino]carbonyl]-L-valyl-L-phenylalanyl-3-(3-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252766-44-2 CAPLUS

CN Benzenebutanamide, 3-methyl-N-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]-L-valyl-L-phenylalanyl- $\alpha$ -amino-, ( $\alpha$ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252766-45-3 CAPLUS

CN Benzenebutanamide, N-[[[3-methoxyphenyl]amino]carbonyl]-3-methyl-L-valyl-L-phenylalanyl- $\alpha$ -amino-, ( $\alpha$ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252766-46-4 CAPLUS

CN L-Alaninamide, N-[[[3-methoxyphenyl]amino]carbonyl]-3-methyl-L-valyl-L-phenylalanyl-3-[1,1'-biphenyl]-4-yl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 252766-47-5 CAPLUS

CN L-Phenylalanyl-L-phenylalanyl-3,4-dichloro-L-phenylalaninamide, N-[[[(3-methoxyphenyl)amino]carbonyl]-3-methyl-L-valyl-L-phenylalanyl-3,4-dichloro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252766-58-8 CAPLUS

CN Benzenebutanamide, N-[[[(2,6-dimethylphenyl)amino]carbonyl]-3-methyl-L-valyl-L-phenylalanyl-α-amino-, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252766-59-9 CAPLUS

CN Benzenebutanamide, N-[[[(3,4-dichlorophenyl)amino]carbonyl]-3-methyl-L-valyl-L-phenylalanyl-α-amino-, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252766-60-2 CAPLUS

CN Benzenebutanamide, N-[[[(2,5-difluorophenyl)amino]carbonyl]-3-methyl-L-valyl-L-phenylalanyl- $\alpha$ -amino-, ( $\alpha$ R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252766-62-4 CAPLUS

CN Benzenebutanamide, N-[[[(2,5-difluorophenyl)amino]carbonyl]-3-methyl-L-valyl-D-phenylalanyl- $\alpha$ -amino-, ( $\alpha$ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252766-64-6 CAPLUS

CN Benzenebutanamide, N-[[[(2,5-difluorophenyl)amino]carbonyl]-3-methyl-D-valyl-L-phenylalanyl- $\alpha$ -amino-, ( $\alpha$ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252766-65-7 CAPLUS

CN Benzenebutanamide, N-[(2,5-difluorophenyl)amino]carbonyl]-3-methyl-L-valyl-D-phenylalanyl- $\alpha$ -amino-, ( $\alpha$ R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252766-66-8 CAPLUS

CN Benzenebutanamide, N-[(2,5-difluorophenyl)amino]carbonyl]-3-methyl-D-valyl-L-phenylalanyl- $\alpha$ -amino-, ( $\alpha$ R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252766-67-9 CAPLUS

CN Benzenebutanamide, N-[(2,5-difluorophenyl)amino]carbonyl]-3-methyl-D-valyl-D-phenylalanyl- $\alpha$ -amino-, ( $\alpha$ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252766-68-0 CAPLUS

CN Benzenebutanamide, N-[[[(2,5-difluorophenyl)amino]carbonyl]-3-methyl-D-valyl-D-phenylalanyl- $\alpha$ -amino-, ( $\alpha$ R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 110 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1999:708752 CAPLUS

DOCUMENT NUMBER: 131:322921

TITLE: Preparation of hydroxypropylamide peptidomimetics as inhibitors of aspartyl proteases

INVENTOR(S): Dolle, Roland Ellwood, III; Cavallaro, Cullen Lee; Herpin, Timothee Felix

PATENT ASSIGNEE(S): Pharmacoopia, Inc., USA

SOURCE: PCT Int. Appl., 48 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9955687	A2	19991104	WO 1999-US9070	19990427
WO 9955687	A3	20000224		
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 5986102	A	19991116	US 1998-69380	19980429

AU 9938684	A	19991116	AU 1999-38684	19990427
US 6191277	B1	20010220	US 1999-408237	19990929
PRIORITY APPLN. INFO.:			US 1998-69380	A 19980429
			WO 1999-US9070	W 19990427

OTHER SOURCE(S): MARPAT 131:322921

IT 248596-64-7P 248596-66-9P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of hydroxypropylamide peptidomimetics as inhibitors of aspartyl proteases)

RN 248596-64-7 CAPLUS

CN Butanamide, N-[(1S)-4-(4-acetyl-1-piperazinyl)-2-hydroxy-1-(2-phenylethyl)butyl]-3-methyl-2-[[[(phenylamino)carbonyl]oxy]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 248596-66-9 CAPLUS

CN D-glycero-Pentitol, 5-(4-acetyl-1-piperazinyl)-1-[1,1'-biphenyl]-4-yl-1,2,4,5-tetradeoxy-2-[[[(2S)-3-methyl-1-oxo-2-[[[(4-phenoxyphenyl)amino]carbonyl]oxy]butyl]amino]-, (3ξ)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 111 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1999:659784 CAPLUS  
 DOCUMENT NUMBER: 131:284566  
 TITLE: Taste in domestic pig, *Sus scrofa*  
 AUTHOR(S): Hellekant, G.; Danilova, V.

CORPORATE SOURCE: Dep. Animal Health Biomedical Sciences, Univ.  
 Wisconsin, Madison, WI, 53705, USA  
 SOURCE: Journal of Animal Physiology and Animal Nutrition  
 (1999), 82(1), 8-24  
 CODEN: JAPNEF; ISSN: 0931-2439  
 PUBLISHER: Blackwell Wissenschafts-Verlag GmbH  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 IT 135507-50-5, Super-aspartame  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological  
 study, unclassified); BIOL (Biological study)  
 (taste sense in domestic swine)  
 RN 135507-50-5 CAPLUS  
 CN L-Phenylalanine, N-[[ (4-cyanophenyl) amino] carbonyl] -L- $\alpha$ -aspartyl-,  
 2-methyl ester (CA INDEX NAME)


Absolute stereochemistry.



REFERENCE COUNT: 64 THERE ARE 64 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 112 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1999:547942 CAPLUS  
 DOCUMENT NUMBER: 131:281759  
 TITLE: Comparative pharmacology of the nonpeptide neuromedin  
 B receptor antagonist PD 168368  
 AUTHOR(S): Ryan, Richard R.; Katsuno, Tatsuro; Mantey, Samuel A.;  
 Pradhan, Tapas K.; Weber, H. Christian; Coy, David H.;  
 Battey, James F.; Jensen, Robert T.  
 CORPORATE SOURCE: Digestive Diseases Branch, National Institute of  
 Diabetes and Digestive and Kidney Diseases, National  
 Institutes of Health, Bethesda, MD, USA  
 SOURCE: Journal of Pharmacology and Experimental Therapeutics  
 (1999), 290(3), 1202-1211  
 CODEN: JPETAB; ISSN: 0022-3565  
 PUBLISHER: American Society for Pharmacology and Experimental  
 Therapeutics  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 IT 204066-82-0, PD 168368  
 RL: BAC (Biological activity or effector, except adverse); BPR (Biological  
 process); BSU (Biological study, unclassified); BUU (Biological use,  
 unclassified); BIOL (Biological study); PROC (Process); USES (Uses)  
 (comparative pharmacol. of nonpeptide neuromedin B receptor antagonist  
 PD 168368 in human, mouse, rat and frog)  
 RN 204066-82-0 CAPLUS  
 CN 1H-Indole-3-propanamide,  $\alpha$ -methyl- $\alpha$ -[[[(4-  
 nitrophenyl) amino] carbonyl] amino]-N-[[1-(2-pyridinyl) cyclohexyl] methyl]-,  
 ( $\alpha$ S)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 113 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1999:487262 CAPLUS  
 DOCUMENT NUMBER: 131:116519  
 TITLE: Preparation of N-(phenylcarbamoyl)-amino acid amides as calcitonin mimetics  
 INVENTOR(S): Petrie, Charles; Mckernan, Patricia A.; Moore, Emma E.; Ostrech, John M.; Meyer, Jean-Philippe; Houghten, Richard A.; Pinella, Clemencia  
 PATENT ASSIGNEE(S): Zymogenetics, Inc., USA; Trega Biosciences, Inc.  
 SOURCE: PCT Int. Appl., 55 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9937604	A2	19990729	WO 1999-US1151	19990120
WO 9937604	A3	19991014		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2284864	A1	19990729	CA 1999-2284864	19990120
AU 9922381	A	19990809	AU 1999-22381	19990120
AU 743631	B2	20020131		
EP 975589	A2	20000202	EP 1999-902386	19990120
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2001501979	T	20010213	JP 1999-538414	19990120
US 6221913	B1	20010424	US 1999-233893	19990120
US 6255351	B1	20010703	US 1999-410115	19990930
US 6391917	B1	20020521	US 2001-838726	20010419
PRIORITY APPLN. INFO.:				
			US 1998-72987P	P 19980121
			US 1999-233893	A3 19990120
			WO 1999-US1151	W 19990120

OTHER SOURCE(S): MARPAT 131:116519

IT 232603-35-9P 232603-36-0P 232603-37-1P  
 232603-38-2P 232603-39-3P 232603-40-6P  
 232603-41-7P 232603-43-9P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of N-(phenylcarbamoyl)-amino acid amides as calcitonin mimetics for treating bone resorption-related disorders)

RN 232603-35-9 CAPLUS

CN Benzenepropanamide,  $\alpha$ -[[[2,5-bis(1,1-dimethylethyl)phenyl]amino]carbonyl]amino]-4-chloro-N-(phenylmethyl)-, ( $\alpha$ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 232603-36-0 CAPLUS

CN Benzenepropanamide,  $\alpha$ -[[[2,5-bis(1,1-dimethylethyl)phenyl]amino]carbonyl]amino]-4-fluoro-N-(phenylmethyl)-, ( $\alpha$ S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 232603-37-1 CAPLUS

CN Benzenepropanamide,  $\alpha$ -[[[2,5-bis(1,1-dimethylethyl)phenyl]amino]carbonyl]amino]-4-iodo-N-(phenylmethyl)-, ( $\alpha$ S)- (CA INDEX NAME)

Absolute stereochemistry.






RN 232603-38-2 CAPLUS

CN 2-Naphthalenepropanamide,  $\alpha$ -[[[2,5-bis(1,1-dimethylethyl)phenyl]amino]carbonyl]amino]-N-(phenylmethyl)-, ( $\alpha$ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 232603-39-3 CAPLUS

CN Benzenepropanamide,  $\alpha$ -[[[2,5-bis(1,1-dimethylethyl)phenyl]amino]carbonyl]amino]-4-chloro-N-(2-naphthalenylmethyl)-, ( $\alpha$ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 232603-40-6 CAPLUS

CN Benzenepropanamide,  $\alpha$ -[[[2,5-bis(1,1-dimethylethyl)phenyl]amino]carbonyl]amino]-4-fluoro-N-(2-naphthalenylmethyl)-, ( $\alpha$ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 232603-41-7 CAPLUS

CN Benzenepropanamide,  $\alpha$ -[[[2,5-bis(1,1-dimethylethyl)phenyl]amino]carbonyl]amino]-4-iodo-N-(2-naphthalenylmethyl)-, ( $\alpha$ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 232603-43-9 CAPLUS

CN 2-Naphthalenepropanamide,  $\alpha$ -[[[2,5-bis(1,1-dimethylethyl)phenyl]amino]carbonyl]amino]-N-(2-naphthalenylmethyl)-, ( $\alpha$ S)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

6

THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 114 OF 188

CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER:

1999:350650 CAPLUS

DOCUMENT NUMBER:

131:18925

TITLE:

Preparation of cyclic amine derivatives for inhibition of the action of chemokines such as MIP-1 $\alpha$

and/or MCP-1 on target cells

INVENTOR(S): Shiota, Tatsuki; Kataoka, Kenichiro; Imai, Minoru; Tsutsumi, Takaharu; Sudoh, Masaki; Sogawa, Ryo; Morita, Takuya; Hada, Takahiko; Muroga, Yumiko; Takenouchi, Osami; Furuya, Monoru; Endo, Noriaki; Tarby, Christine M.; Moree, Wil A.; Teig, Steven L.

PATENT ASSIGNEE(S): Teijin Ltd., Japan; Combichem, Inc.

SOURCE: PCT Int. Appl., 374 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9925686	A1	19990527	WO 1998-US23254	19981117
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2309328	A1	19990527	CA 1998-2309328	19981117
CA 2309328	C	20081014		
AU 9913741	A	19990607	AU 1999-13741	19981117
AU 744685	B2	20020228		
EP 1030840	A1	20000830	EP 1998-957495	19981117
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200001399	T2	20001121	TR 2000-1399	19981117
HU 2000004200	A2	20010328	HU 2000-4200	19981117
HU 2000004200	A3	20010428		
BR 9814645	A	20010731	BR 1998-14645	19981117
EE 200000294	A	20010815	EE 2000-294	19981117
JP 2001523661	T	20011127	JP 2000-521070	19981117
JP 3786578	B2	20060614		
RU 2216540	C2	20031120	RU 2000-112403	19981117
CN 1496981	A	20040519	CN 2002-2002118546	19981117
CN 100418951	C	20080917		
EP 1535909	A2	20050601	EP 2005-75285	19981117
EP 1535909	A3	20050713		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY				
EP 1553085	A1	20050713	EP 2005-75283	19981117
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, LV, FI, MK, CY				
CN 1660815	A	20050831	CN 2004-10082013	19981117
IL 135488	A	20060820	IL 1998-135488	19981117
PL 192083	B1	20060831	PL 1998-342207	19981117
SK 285729	B6	20070706	SK 2000-553	19981117
HR 2000000214	A1	20011231	HR 2000-214	20000413
BG 104441	A	20010131	BG 2000-104441	20000516
BG 64848	B1	20060630		
US 6451842	B1	20020917	US 2000-554562	20000516
MX 2000004851	A	20010328	MX 2000-4851	20000518
HK 1062827	A1	20090116	HK 2004-105633	20040730
PRIORITY APPLN. INFO.:			US 1997-972484	A 19971118
			US 1998-55285	A 19980406
			US 1998-133434	A 19980813


OTHER SOURCE(S) : MARPAT 131:18925

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of cyclic amine derivs. for inhibition of the action of chemokines such as MIP-1 $\alpha$  and/or MCP-1 on target cells)

CN Carbamic acid, (3-chlorophenyl)-, 2-[[[1-[(4-chlorophenyl)methyl]-2-pyrrolidinyl]methyl]amino]-1-methyl-2-oxoethyl ester (9CI) (CA INDEX NAME)



CN Carbamic acid, (3-chlorophenyl)-, 2-[[[1-[(4-chlorophenyl)methyl]-4-piperidinyl]methyl]amino]-1-methyl-2-oxoethyl ester (9CI) (CA INDEX NAME)



L5 ANSWER 115 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN

DOCUMENT NUMBER: 130:267727

AUTHOR(S): Hamuro, Yoshitomo; Scialdone, Mark A.; DeGrado, William F.


SOURCE: Journal of the American Chemical Society (1999),  
121(8), 1636-1644

CODEN: JACSAT; ISSN: 0002-7863

DOCUMENT TYPE: Journal


LANGUAGE: English  
 IT 221898-46-0P 221898-50-6P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of peptides, amides, and ureas via resin-to-resin acyl and  
 aminoacyl transfer reactions using oxime supports)  
 RN 221898-46-0 CAPLUS  
 CN L-Phenylalanine, N-[[ (4-methoxyphenyl)amino]carbonyl]-L-alanyl- (9CI) (CA  
 INDEX NAME)

Absolute stereochemistry.



RN 221898-50-6 CAPLUS  
 CN L-Phenylalanine, N-[[ (4-methoxyphenyl)amino]carbonyl]-L-valyl- (9CI) (CA  
 INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 65 THERE ARE 65 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 116 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1999:64682 CAPLUS  
 DOCUMENT NUMBER: 130:125407  
 TITLE: Preparation of glycol and hydroxyphosphonate  
 peptidomimetics as inhibitors of aspartyl proteases  
 INVENTOR(S): Carroll, Carolyn Dilanni; Dolle, Roland Ellwood, III;  
 Shimshock, Yvonne Class; Herpin, Timothee Felix  
 PATENT ASSIGNEE(S): Pharmacoepia, Inc., USA  
 SOURCE: PCT Int. Appl., 47 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9902153	A1	19990121	WO 1998-US13973	19980706
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,				
DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG,				
KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX,				
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,				
UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,				

	FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG		
US 5962506	A	19991005	US 1997-888957 19970707
AU 9883842	A	19990208	AU 1998-83842 19980706
US 6150344	A	20001121	US 1999-318970 19990526
US 6326393	B1	20011204	US 2000-597025 20000620
US 6432933	B1	20020813	US 2000-597024 20000620

PRIORITY APPLN. INFO.:

		US 1997-888957	A	19970707
		WO 1998-US13973	W	19980706
		US 1999-318970	A3	19990526

OTHER SOURCE(S): MARPAT 130:125407


IT 219799-15-2P 219799-16-3P 219799-18-5P  
219799-22-1P 219799-25-4P 219799-31-2P  
219799-32-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of glycol and hydroxyphosphonate peptidomimetics as inhibitors of aspartyl proteases)

RN 219799-15-2 CAPLUS

CN L-Leucinamide, (2S)-3-methyl-2-[[[(4-phenoxyphenyl)amino]carbonyl]oxy]butanoyl-(2ξ,3ξ)-4-amino-4,5-dideoxy-5-(4-methoxyphenyl)-L-glycero-pentonoyl-L-alanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 219799-16-3 CAPLUS

CN L-Leucinamide, (2S)-3-methyl-2-[[[(4-phenoxyphenyl)amino]carbonyl]oxy]butanoyl-(2ξ,3ξ)-4-amino-4,5-dideoxy-5-(3,4-dichlorophenyl)-L-glycero-pentonoyl-L-alanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 219799-18-5 CAPLUS

CN L-glycero-Pentonamide, 5-[1,1'-biphenyl]-4-yl-4,5-dideoxy-4-[[ (2S)-3-methyl-1-oxo-2-[[[(4-phenoxyphenyl)amino]carbonyl]oxy]butyl]amino]-N-[(3S)-1-(phenylmethyl)-3-pyrrolidinyl]-, (2ξ,3ξ)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 219799-22-1 CAPLUS

CN L-glycero-Pentonamide, 4,5-dideoxy-5-(3,4-dichlorophenyl)-4-[[ (2S)-3-methyl-1-oxo-2-[[[(4-phenoxyphenyl)amino]carbonyl]oxy]butyl]amino]-N-[(3S)-1-(phenylmethyl)-3-pyrrolidinyl]-, (2ξ,3ξ)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 219799-25-4 CAPLUS

CN L-glycero-Pentonamide, N-butyl-5-(4-chlorophenyl)-4,5-dideoxy-4-[[ (2S)-3-methyl-1-oxo-2-[[[(4-phenoxyphenyl)amino]carbonyl]oxy]butyl]amino]-, (2ξ,3ξ)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 219799-31-2 CAPLUS

CN L-glycero-Pentonamide, N-butyl-4,5-dideoxy-5-(3,4-dichlorophenyl)-4-[[ (2S)-3-methyl-1-oxo-2-[[[(4-phenoxyphenyl)amino]carbonyl]oxy]butyl]amino]-, (2ξ,3ξ)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.





RN 219799-32-3 CAPLUS  
CN L-glycero-Pentonamide, 5-(4-chlorophenyl)-4,5-dideoxy-4-[[ (2S)-3-methyl-1-oxo-2-[[[(4-phenoxyphenyl)amino]carbonyl]oxy]butyl]amino]-N-[2-[[ (4-methylphenyl)sulfonyl]amino]ethyl]-, (2ξ,3ξ)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 117 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 1999:28392 CAPLUS  
DOCUMENT NUMBER: 130:329078  
TITLE: Use of Caco-2 cells and LC/MS/MS to screen a peptide combinatorial library for permeable structures  
AUTHOR(S): Stevenson, Cynthia L.; Augustijns, Patrick F.; Hendren, R. Wayne  
CORPORATE SOURCE: Oligomer Development, Glaxo Wellcome, Research Triangle Park, NC, 27709, USA  
SOURCE: International Journal of Pharmaceutics (1999), 177(1), 103-115  
CODEN: IJPHDE; ISSN: 0378-5173  
PUBLISHER: Elsevier Science B.V.  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
IT 223902-57-6  
RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PROC (Process)  
(Caco-2 cells and LC/MS/MS for screening a peptide combinatorial library for permeable structures)  
RN 223902-57-6 CAPLUS  
CN L-Histidinamide, N-[(phenylamino)carbonyl]-L-tryptophyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 118 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1998:704703 CAPLUS  
 DOCUMENT NUMBER: 130:93315  
 TITLE: Gustatory responses of the hamster *Mesocricetus auratus* to various compounds considered sweet by humans  
 AUTHOR(S): Danilova, Vicktoria; Hellekant, Goran; Tinti, Jean-Marie; Nofre, Claude  
 CORPORATE SOURCE: Animal Health and Biomedical Sciences, The University of Wisconsin-Madison, Madison, WI, 53706, USA  
 SOURCE: Journal of Neurophysiology (1998), 80(4), 2102-2112  
 CODEN: JONEA4; ISSN: 0022-3077  
 PUBLISHER: American Physiological Society  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 IT 129864-45-5 135507-50-5, Superaspartame  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)  
 (sweet taste responses in hamster and humans)  
 RN 129864-45-5 CAPLUS  
 CN Butanoic acid, 3-[[[(4-cyanophenyl)amino]carbonyl]amino]-4-oxo-4-[[ (1R)-1-phenylethyl]amino]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 135507-50-5 CAPLUS  
 CN L-Phenylalanine, N-[[[(4-cyanophenyl)amino]carbonyl]-L- $\alpha$ -aspartyl-, 2-methyl ester (CA INDEX NAME)


Absolute stereochemistry.



REFERENCE COUNT: 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 119 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1998:660097 CAPLUS  
 DOCUMENT NUMBER: 130:20201  
 TITLE: PD 176252 - the first high affinity non-peptide  
 gastrin-releasing peptide (BB2) receptor antagonist  
 AUTHOR(S): Ashwood, V.; Brownhill, V.; Higginbottom, M.; Horwell,  
 D. C.; Hughes, J.; Lewthwaite, R. A.; McKnight, A. T.;  
 Pinnock, R. D.; Pritchard, M. C.; Suman-Chauhan, N.;  
 Webb, C.; Williams, S. C.  
 CORPORATE SOURCE: Parke-Davis Neuroscience Research Centre, CAMBRIDGE,  
 CB2 2QB, UK  
 SOURCE: Bioorganic & Medicinal Chemistry Letters (1998),  
 8(18), 2589-2594  
 CODEN: BMCLE8; ISSN: 0960-894X  
 PUBLISHER: Elsevier Science Ltd.  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 IT 185215-75-2, PD 165929 204066-81-9 204066-82-0  
 , PD 168368 204066-83-1 204067-01-6, PD 176252  
 216318-92-2 216319-01-6 216319-06-1  
 216319-16-3 216319-26-5 216319-32-3  
 216319-38-9 216319-44-7 216319-50-5  
 216319-55-0 216319-57-2 216319-58-3  
 216319-60-7 216319-62-9 216319-64-1  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological  
 study, unclassified); BIOL (Biological study)  
 (PD 176252 as first high affinity non-peptide gastrin-releasing peptide  
 (BB2) receptor antagonist and structure-activity relations)  
 RN 185215-75-2 CAPLUS  
 CN 1H-Indole-3-propanamide,  $\alpha$ -[[[2,6-bis(1-  
 methylethyl)phenyl]amino]carbonyl]amino]- $\alpha$ -methyl-N-[[1-(2-  
 pyridinyl)cyclohexyl]methyl]-, ( $\alpha$ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 204066-81-9 CAPLUS

CN 1H-Indole-3-propanamide,  $\alpha$ -[[[(4-cyanophenyl)amino]carbonyl]amino]-  
 $\alpha$ -methyl-N-[[1-(2-pyridinyl)cyclohexyl]methyl]-, ( $\alpha$ S)- (CA  
 INDEX NAME)


Absolute stereochemistry.



RN 204066-82-0 CAPLUS


CN 1H-Indole-3-propanamide,  $\alpha$ -methyl- $\alpha$ -[[[(4-  
 nitrophenyl)amino]carbonyl]amino]-N-[[1-(2-pyridinyl)cyclohexyl]methyl]-,  
 ( $\alpha$ S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 204066-83-1 CAPLUS  
 CN 1H-Indole-3-propanamide,  $\alpha$ -methyl-N-[[1-(2-pyridinyl)cyclohexyl]methyl]- $\alpha$ -[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]-, ( $\alpha$ S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 204067-01-6 CAPLUS  
 CN 1H-Indole-3-propanamide, N-[[1-(5-methoxy-2-pyridinyl)cyclohexyl]methyl]- $\alpha$ -methyl- $\alpha$ -[[[4-nitrophenyl]amino]carbonyl]amino]-, ( $\alpha$ S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 216318-92-2 CAPLUS  
 CN 1H-Indole-3-propanamide,  $\alpha$ -methyl- $\alpha$ -  
 [[ (phenylamino)carbonyl]amino]-N-[[1-(2-pyridinyl)cyclohexyl]methyl]-,  
 ( $\alpha$ S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 216319-01-6 CAPLUS  
 CN 1H-Indole-3-propanamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-  
 $\alpha$ -methyl-N-[[1-(2-pyridinyl)cyclohexyl]methyl]-, ( $\alpha$ S)- (CA  
 INDEX NAME)


Absolute stereochemistry.



RN 216319-06-1 CAPLUS

CN 1H-Indole-3-propanamide,  $\alpha$ -[[[(3,4-dichlorophenyl)amino]carbonyl]amino]- $\alpha$ -methyl-N-[[1-(2-pyridinyl)cyclohexyl]methyl]-, ( $\alpha$ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 216319-16-3 CAPLUS

CN 1H-Indole-3-propanamide,  $\alpha$ -methyl- $\alpha$ -[[[4-(1-methylethyl)phenyl]amino]carbonyl]amino]-N-[[1-(2-pyridinyl)cyclohexyl]methyl]-, ( $\alpha$ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 216319-26-5 CAPLUS

CN 1H-Indole-3-propanamide,  $\alpha$ -methyl- $\alpha$ -[[[(3-nitrophenyl)amino]carbonyl]amino]-N-[[1-(2-pyridinyl)cyclohexyl]methyl]-, ( $\alpha$ S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 216319-32-3 CAPLUS

CN 1H-Indole-3-propanamide,  $\alpha$ -methyl- $\alpha$ -[[[(2-nitrophenyl)amino]carbonyl]amino]-N-[[1-(2-pyridinyl)cyclohexyl]methyl]-, ( $\alpha$ S)- (CA INDEX NAME)

Absolute stereochemistry.






RN 216319-38-9 CAPLUS

CN 1H-Indole-3-propanamide,  $\alpha$ -methyl- $\alpha$ -[[[(4-nitrophenyl)amino]carbonyl]amino]-N-[(1-phenylcyclohexyl)methyl]-, ( $\alpha$ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 216319-44-7 CAPLUS


CN 1H-Indole-3-propanamide, N-[[[1-(4-hydroxyphenyl)cyclohexyl)methyl]- $\alpha$ -methyl- $\alpha$ -[[[(4-nitrophenyl)amino]carbonyl]amino]-, ( $\alpha$ S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 216319-50-5 CAPLUS  
 CN 1H-Indole-3-propanamide,  $\alpha$ -methyl- $\alpha$ -[[[(4-nitrophenyl)amino]carbonyl]amino]-N-[[1-(4-nitrophenyl)cyclohexyl]methyl]-, ( $\alpha$ S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 216319-55-0 CAPLUS  
 CN 1H-Indole-3-propanamide, N-[[1-[4-(dimethylamino)phenyl]cyclohexyl]methyl]- $\alpha$ -methyl- $\alpha$ -[[[(4-nitrophenyl)amino]carbonyl]amino]-, ( $\alpha$ S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 216319-57-2 CAPLUS  
 CN 1H-Indole-3-propanamide,  $\alpha$ -methyl-N-[[1-[4-(1-methylethyl)phenyl]cyclohexyl]methyl]- $\alpha$ -[[[4-nitrophenyl]amino]carbonyl]amino]-, ( $\alpha$ S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 216319-58-3 CAPLUS  
 CN 1H-Indole-3-propanamide, N-[[1-(4-methoxyphenyl)cyclohexyl]methyl]- $\alpha$ -methyl- $\alpha$ -[[[4-nitrophenyl]amino]carbonyl]amino]-, ( $\alpha$ S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 216319-60-7 CAPLUS  
 CN 1H-Indole-3-propanamide, N-[[1-(4-ethoxyphenyl)cyclohexyl]methyl]-α-methyl-α-[[[(4-nitrophenyl)amino]carbonyl]amino]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.




RN 216319-62-9 CAPLUS  
 CN 1H-Indole-3-propanamide, N-[[1-(2-methoxyphenyl)cyclohexyl]methyl]-α-methyl-α-[[[(4-nitrophenyl)amino]carbonyl]amino]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 216319-64-1 CAPLUS  
 CN 1H-Indole-3-propanamide, N-[[1-(3,4-dimethoxyphenyl)cyclohexyl]methyl]-  
 α-methyl-α-[[[(4-nitrophenyl)amino]carbonyl]amino]-,  
 (αS)- (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 120 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1998:635996 CAPLUS  
 DOCUMENT NUMBER: 130:52710  
 TITLE: Synthesis of Peptide Aldehyde Derivatives as Selective  
 Inhibitors of Human Cathepsin L and Their Inhibitory  
 Effect on Bone Resorption  
 AUTHOR(S): Yasuma, Tsuneo; Oi, Satoru; Choh, Nobuo; Nomura,  
 Toshiyuki; Furuyama, Naoki; Nishimura, Atsushi;  
 Fujisawa, Yukio; Sohda, Takashi  
 CORPORATE SOURCE: Pharmaceutical Research Division, Takeda Chemical  
 Industries Ltd., Yodogawa-ku Osaka, 532-8686, Japan  
 SOURCE: Journal of Medicinal Chemistry (1998), 41(22),  
 4301-4308  
 CODEN: JMCMAR; ISSN: 0022-2623


PUBLISHER: American Chemical Society  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
IT 161709-52-0P 161709-68-8P 161709-82-6P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
(preparation of peptide aldehyde derivs. as inhibitors of cathepsin L and bone resorption)  
RN 161709-52-0 CAPLUS  
CN Pentanamide, N-[(1S)-1-formyl-2-(1H-indol-3-yl)ethyl]-3-methyl-2-[[[(3-methylphenyl)amino]carbonyl]amino]-, (2S,3S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 161709-68-8 CAPLUS  
CN Pentanamide, N-[(1S)-1-formyl-2-(1H-indol-3-yl)ethyl]-3-methyl-2-[[[2-(trifluoromethyl)phenyl]amino]carbonyl]amino]-, (2S,3S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 161709-82-6 CAPLUS  
CN Pentanamide, N-[(1S)-1-formyl-2-(1H-indol-3-yl)ethyl]-3-methyl-2-[[[1-naphthalenylamino]carbonyl]amino]-, (2S,3S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




IT 161708-77-6P 161708-81-2P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation of peptide aldehyde derivs. as inhibitors of cathepsin L and  
 bone resorption)  
 RN 161708-77-6 CAPLUS  
 CN Pentanamide, N-[(1S)-2-hydroxy-1-(1H-indol-3-ylmethyl)ethyl]-3-methyl-2-  
 [[[(3-methylphenyl)amino]carbonyl]amino]-, (2S,3S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 161708-81-2 CAPLUS  
 CN Pentanamide, N-[(1S)-2-hydroxy-1-(1H-indol-3-ylmethyl)ethyl]-3-methyl-2-  
 [[[[2-(trifluoromethyl)phenyl]amino]carbonyl]amino]-, (2S,3S)- (CA INDEX  
 NAME)

Absolute stereochemistry. Rotation (-).



REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 1998:268513 CAPLUS  
 DOCUMENT NUMBER: 128:321945  
 ORIGINAL REFERENCE NO.: 128:63829a,63832a  
 TITLE: Preparation of peptide analogs as inhibitors of serine proteases, particularly hepatitis C virus NS3 protease  
 INVENTOR(S): Tung, Roger D.; Harbeson, Scott L.; Deininger, David D.; Murcko, Mark A.; Bhisetti, Govinda Rao; Farmer, Luc J.  
 PATENT ASSIGNEE(S): Vertex Pharmaceuticals Inc., USA; Tung, Roger D.; Harbeson, Scott L.; Deininger, David D.; Murcko, Mark A.; Bhisetti, Govinda Rao; Farmer, Luc J.  
 SOURCE: PCT Int. Appl., 128 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9817679	A1	19980430	WO 1997-US18968	19971017
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2268391	A1	19980430	CA 1997-2268391	19971017
ZA 9709327	A	19980511	ZA 1997-9327	19971017
AU 9851477	A	19980515	AU 1998-51477	19971017
AU 719984	B2	20000518		
EP 932617	A1	19990804	EP 1997-946273	19971017
EP 932617	B1	20020116		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
IN 183120	A1	19990911	IN 1997-CA1951	19971017
BR 9712544	A	19991019	BR 1997-12544	19971017
CN 1238780	A	19991215	CN 1997-180151	19971017
CN 1133649	C	20040107		
HU 2000000152	A2	20000728	HU 2000-152	19971017
HU 2000000152	A3	20000928		
NZ 335276	A	20000929	NZ 1997-335276	19971017
JP 2001502694	T	20010227	JP 1998-519568	19971017
JP 4080541	B2	20080423		
EP 1136498	A1	20010926	EP 2001-109433	19971017
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
AP 1019	A	20011016	AP 1999-1512	19971017
W: GH, KE, LS, MW, SD, SZ, UG, ZW				
AT 212037	T	20020215	AT 1997-946273	19971017
ES 2169880	T3	20020716	ES 1997-946273	19971017
EE 4023	B1	20030415	EE 1999-161	19971017
PL 192280	B1	20060929	PL 1997-332872	19971017
IN 1997CA01952	A	20061229	IN 1997-CA1952	19971017
PL 194025	B1	20070430	PL 1997-372333	19971017
CZ 298749	B6	20080116	CZ 1999-1340	19971017
SK 286105	B6	20080305	SK 1999-510	19971017
IL 129407	A	20081103	IL 1997-129407	19971017
TW 530065	B	20030501	TW 1997-86115382	19971018
US 6265380	B1	20010724	US 1999-293247	19990416



MX 2005003026	A	20050615	MX 2005-200503026	19990416
KR 2000049263	A	20000725	KR 1999-703372	19990417
HK 1023779	A1	20020927	HK 2000-100690	20000203
US 20020032175	A1	20020314	US 2001-875390	20010606
US 6617309	B2	20030909		
US 20040266731	A1	20041230	US 2003-607716	20030627
US 7388017	B2	20080617		
JP 2008063341	A	20080321	JP 2007-290832	20071108
IN 2008KO00531	A	20080829	IN 2008-KO531	20080317
PRIORITY APPLN. INFO.:			US 1996-28290P	P 19961018
			EP 1997-946273	A3 19971017
			IN 1997-CA1952	A3 19971017
			JP 1998-519568	A3 19971017
			WO 1997-US18968	W 19971017
			US 1999-293247	A 19990416
			US 2001-875390	A3 20010606

OTHER SOURCE(S): MARPAT 128:321945

IT 207001-67-0P 207001-68-1P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of peptide analogs as hepatitis C virus NS3 protease inhibitors)

RN 207001-67-0 CAPLUS

CN L-Prolinamide, N-[[[(3,5-dicarboxyphenyl)amino]carbonyl]-L-valyl-L-valyl-N-[(1S)-1-formylpropyl]-4-(phenylmethoxy)-, (4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 207001-68-1 CAPLUS

CN L-Prolinamide, N-[[[(2-carboxyphenyl)amino]carbonyl]-L-valyl-L-valyl-N-[(1S)-1-formylpropyl]-4-(phenylmethoxy)-, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 122 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 1998:147326 CAPLUS  
DOCUMENT NUMBER: 128:205147  
ORIGINAL REFERENCE NO.: 128:40583a,40584a  
TITLE: Preparation of non-peptide bombesin receptor antagonists  
INVENTOR(S): Horwell, David Christopher; Pritchard, Martyn Clive  
PATENT ASSIGNEE(S): Warner-Lambert Company, USA; Horwell, David Christopher; Pritchard, Martyn Clive  
SOURCE: PCT Int. Appl., 112 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 9807718	A1	19980226	WO 1997-US13871	19970806
W: AL, AU, BA, BB, BG, BR, CA, CN, CZ, EE, GE, GH, HU, IL, IS, JP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
BR 9711342	A	19990817	BR 1997-11342	19970222
CA 2255966	A1	19980226	CA 1997-2255966	19970806
AU 9741466	A	19980306	AU 1997-41466	19970806
AU 733226	B2	20010510		
EP 920424	A1	19990609	EP 1997-939359	19970806
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
HU 9903968	A2	20000228	HU 1999-3968	19970806
HU 9903968	A3	20011128		
NZ 333038	A	20001027	NZ 1997-333038	19970806
JP 2001500850	T	20010123	JP 1998-510779	19970806
AT 311383	T	20051215	AT 1997-939359	19970806
ES 2253782	T3	20060601	ES 1997-939359	19970806
ZA 9707526	A	19980219	ZA 1997-7526	19970821
US 6194437	B1	20010227	US 1999-230933	19990203
NO 312669	B1	20020617	NO 1999-788	19990219
PRIORITY APPLN. INFO.:			US 1996-24323P	P 19960822
			WO 1997-US13871	W 19970806

OTHER SOURCE(S): MARPAT 128:205147


IT 204066-87-5P 204067-04-9P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(preparation of non-peptide bombesin receptor antagonists)  
RN 204066-87-5 CAPLUS  
CN 2-Pyridinepropanamide,  $\alpha$ -[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]amino]- $\alpha$ -methyl-N-[[1-(2-pyridinyl)cyclohexyl]methyl]-, 1-oxide (CA INDEX NAME)



RN 204067-04-9 CAPLUS

CN 1H-Indole-3-propanamide,  $\alpha$ -methyl- $\alpha$ -[[[4-nitrophenyl)amino]carbonyl]amino]-N-[[1-[1-(triphenylmethyl)-1H-imidazol-4-yl]cyclohexyl]methyl]-, ( $\alpha$ S)- (CA INDEX NAME)

Absolute stereochemistry.




IT 142627-75-6P 185215-75-2P 204066-72-8P  
 204066-74-0P 204066-76-2P 204066-77-3P  
 204066-78-4P 204066-79-5P 204066-81-9P  
 204066-82-0P 204066-83-1P 204066-84-2P  
 204066-85-3P 204066-89-7P 204066-91-1P  
 204066-93-3P 204066-95-5P 204066-99-9P  
 204067-01-6P 204067-02-7P 204067-03-8P  
 204067-05-0P 204067-06-1P 204067-40-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of non-peptide bombesin receptor antagonists)

RN 142627-75-6 CAPLUS

CN 1H-Indole-3-propanamide,  $\alpha$ -[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]amino]-N-(2,2-dimethyl-4-phenyl-1,3-dioxan-5-yl)- $\alpha$ -methyl-, [4S-[4 $\alpha$ ,5 $\alpha$ (R\*)]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 185215-75-2 CAPLUS


CN 1H-Indole-3-propanamide,  $\alpha$ -[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]amino]- $\alpha$ -methyl-N-[[1-(2-pyridinyl)cyclohexyl]methyl]-, (*αS*)- (CA INDEX NAME)

Absolute stereochemistry.



RN 204066-72-8 CAPLUS


CN 1H-Indole-3-propanamide,  $\alpha$ -[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]amino]-N-(2-cyclohexylethyl)- $\alpha$ -methyl- (CA INDEX NAME)



RN 204066-74-0 CAPLUS

CN 1H-Indole-3-propanamide,  $\alpha$ -[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]amino]- $\alpha$ -methyl-N-[(1S,2S)-2-phenylcyclohexyl]-, ( $\alpha$ R)- (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 204066-76-2 CAPLUS

CN 1H-Indole-3-propanamide, N-(cyclohexylmethyl)- $\alpha$ -methyl- $\alpha$ -[[[4-nitrophenyl]amino]carbonyl]amino]-, ( $\alpha$ S)- (CA INDEX NAME)


Absolute stereochemistry.




RN 204066-77-3 CAPLUS

CN 1H-Indole-3-propanamide, N-[(1-hydroxycyclohexyl)methyl]- $\alpha$ -methyl-  
 $\alpha$ -[[[(4-nitrophenyl)amino]carbonyl]amino]-, ( $\alpha$ S)- (CA INDEX  
 NAME)

Absolute stereochemistry.




RN 204066-78-4 CAPLUS  
 CN 1H-Indole-3-propanamide,  $\alpha$ -[[[[2,6-bis(1-  
 methylethyl)phenyl]amino]carbonyl]methylamino]-N-(cyclohexylmethyl)- (CA  
 INDEX NAME)



RN 204066-79-5 CAPLUS  
 CN 1H-Indole-3-propanamide,  $\alpha$ -[[[[2,6-bis(1-  
 methylethyl)phenyl]amino]carbonyl]amino]-N-(cyclohexylmethyl)- $\alpha$ -  
 methyl-, ( $\alpha$ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 204066-81-9 CAPLUS

CN 1H-Indole-3-propanamide,  $\alpha$ -[[[(4-cyanophenyl)amino]carbonyl]amino]- $\alpha$ -methyl-N-[[1-(2-pyridinyl)cyclohexyl]methyl]-, ( $\alpha$ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 204066-82-0 CAPLUS

CN 1H-Indole-3-propanamide,  $\alpha$ -methyl- $\alpha$ -[[[(4-nitrophenyl)amino]carbonyl]amino]-N-[[1-(2-pyridinyl)cyclohexyl]methyl]-, ( $\alpha$ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 204066-83-1 CAPLUS

CN 1H-Indole-3-propanamide,  $\alpha$ -methyl-N-[[1-(2-pyridinyl)cyclohexyl]methyl]- $\alpha$ -[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]-, ( $\alpha$ S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 204066-84-2 CAPLUS

CN Benzoic acid, 4-[[[(1S)-1-(1H-indol-3-ylmethyl)-1-methyl-2-oxo-2-[[[1-(2-pyridinyl)cyclohexyl]methyl]amino]ethyl]amino]carbonyl]amino]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.






RN 204066-85-3 CAPLUS


CN 1H-Indole-3-propanamide, N-(cyclohexylmethyl)- $\alpha$ -[[[2,6-dimethoxyphenyl)amino]carbonyl]amino]- $\alpha$ -methyl-, ( $\alpha$ S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 204066-89-7 CAPLUS

CN Benzenepropanamide,  $\alpha$ -[[[2,6-bis(1-methylethyl)phenyl)amino]carbonyl]amino]- $\alpha$ -methyl-N-[[1-(2-pyridinyl)cyclohexyl)methyl]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 204066-91-1 CAPLUS  
 CN Benzenepropanamide,  $\alpha$ -methyl-2-nitro- $\alpha$ -[[[4-nitrophenyl)amino]carbonyl]amino]-N-[[1-(2-pyridinyl)cyclohexyl)methyl]-  
 (CA INDEX NAME)


PAGE 1-A






RN 204066-93-3 CAPLUS

CN 2-Pyridinepropanamide,  $\alpha$ -[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]amino]- $\alpha$ -methyl-N-[[1-(2-pyridinyl)cyclohexyl]methyl]- (CA INDEX NAME)



RN 204066-95-5 CAPLUS

CN 1H-Imidazole-5-propanamide,  $\alpha$ -[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]amino]-N-[[1-(2-pyridinyl)cyclohexyl]methyl]- (CA INDEX NAME)




RN 204066-99-9 CAPLUS

CN 1H-Indole-3-propanamide,  $\alpha$ -methyl-N-[[1-(2-methyl-4-thiazolyl)cyclohexyl]methyl]- $\alpha$ -[[[4-

nitrophenyl)amino]carbonyl]amino]-, ( $\alpha$ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 204067-01-6 CAPLUS

CN 1H-Indole-3-propanamide, N-[[1-(5-methoxy-2-pyridinyl)cyclohexyl]methyl]-  
 $\alpha$ -methyl- $\alpha$ -[[[4-nitrophenyl)amino]carbonyl]amino]-,  
( $\alpha$ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 204067-02-7 CAPLUS


CN 1H-Indole-3-propanamide, N-[[1-[4-(dimethylamino)methyl]phenyl]cyclohexyl]methyl]- $\alpha$ -methyl- $\alpha$ -  
[[[4-nitrophenyl)amino]carbonyl]amino]-, ( $\alpha$ S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 204067-03-8 CAPLUS  
 CN 1H-Indole-3-propanamide,  $\alpha$ -methyl- $\alpha$ -[[[(4-nitrophenyl)amino]carbonyl]amino]-N-[2-phenyl-2-(1-piperidiny)ethyl]-, ( $\alpha$ S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 204067-05-0 CAPLUS  
 CN 1H-Indole-3-propanamide, N-[[[1-(1H-imidazol-5-yl)cyclohexyl]methyl]- $\alpha$ -methyl- $\alpha$ -[[[(4-nitrophenyl)amino]carbonyl]amino]-, ( $\alpha$ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 204067-06-1 CAPLUS


CN 1H-Indole-3-propanamide,  $\alpha$ -[[[(4-cyanophenyl)amino]carbonyl]amino]-N-[[1-(5-methoxy-2-pyridinyl)cyclohexyl]methyl]- $\alpha$ -methyl-, ( $\alpha$ S)-  
(CA INDEX NAME)

Absolute stereochemistry.




RN 204067-40-3 CAPLUS

CN 1H-Indole-3-propanamide,  $\alpha$ -[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]amino]-N-(cyclohexylmethyl)- $\alpha$ -methyl- (CA INDEX NAME)



IT 204067-26-5P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation of non-peptide bombesin receptor antagonists)  
 RN 204067-26-5 CAPLUS  
 CN 1H-Imidazole-4-propanamide,  $\alpha$ -[[[2,6-bis(1-  
 methylethyl)phenyl]amino]carbonyl]amino]-N-[[1-(2-  
 pyridinyl)cyclohexyl]methyl]-1-(triphenylmethyl)- (CA INDEX NAME)




REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 123 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1997:615095 CAPLUS  
 DOCUMENT NUMBER: 127:288296  
 ORIGINAL REFERENCE NO.: 127:56165a, 56168a  
 TITLE: Construction of chimeric human bombesin receptors to  
 identify neuromedin B and gastrin-releasing peptide  
 receptor binding sites  
 AUTHOR(S): Maughfling, Edward J. R.; Boden, Philip; Hall, Matthew  
 D.  
 CORPORATE SOURCE: Parke-Davis Neuroscience Research Centre, Cambridge,  
 CB2 2QB, UK  
 SOURCE: Biochemical Society Transactions (1997), 25(3), 455S  
 CODEN: BCSTB5; ISSN: 0300-5127  
 PUBLISHER: Portland Press

DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 IT 185215-75-2, PD 165929  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)  
 (construction of chimeric human bombesin receptors to identify neuromedin B and gastrin-releasing peptide receptor binding sites)  
 RN 185215-75-2 CAPLUS  
 CN 1H-Indole-3-propanamide,  $\alpha$ -[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]- $\alpha$ -methyl-N-[[1-(2-pyridinyl)cyclohexyl]methyl]-, ( $\alpha$ S)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 124 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1997:473595 CAPLUS  
 DOCUMENT NUMBER: 127:81788  
 ORIGINAL REFERENCE NO.: 127:15693a,15696a  
 TITLE: Preparation of amino acid derivatives as neuropeptide Y antagonists  
 INVENTOR(S): Engel, Wolfhard; Eberlein, Wolfgang; Rudolf, Klaus; Doods, Henri; Wieland, Heike-Andrea; Willim, Klaus-Dieter; Entzeroth, Michael; Wienen, Wolfgang  
 PATENT ASSIGNEE(S): Dr. Karl Thomae Gmbh, Germany  
 SOURCE: Ger. Offen., 117 pp.  
 CODEN: GWXXBX  
 DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
DE 19544687	A1	19970605	DE 1995-19544687	19951130
CA 2238859	C	19970605	CA 1996-2238859	19961126
CA 2238859	A1	19970605		
WO 9719911	A1	19970605	WO 1996-EP5222	19961126
W: CA, JP, MX, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 885186	A1	19981223	EP 1996-941032	19961126
EP 885186	B1	20030326		



JP 2000501390	T	20000208	JP 1997-520166		19961126
AT 235459	T	20030415	AT 1996-941032		19961126
US 6114390	A	20000905	US 1997-950113		19971014
PRIORITY APPLN. INFO.:			DE 1995-19544687	A	19951130
			WO 1996-EP5222	W	19961126
			US 1998-945048	A	19980210

OTHER SOURCE(S): MARPAT 127:81788


IT 191870-66-3P 191870-67-4P 191870-71-0P  
191870-72-1P 191870-85-6P 191870-86-7P  
191871-43-9P 191871-60-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of amino acid derivs. as neuropeptide Y antagonists)

RN 191870-66-3 CAPLUS

CN Benzenepropanamide, N-[[4-[[[(aminocarbonyl)amino]methyl]phenyl]methyl]-3-(aminoiminomethyl)- $\alpha$ -[[[(2-butyl-1H-benzimidazol-6-yl)amino]carbonyl]amino]- (CA INDEX NAME)




RN 191870-67-4 CAPLUS

CN Benzenepropanamide, N-[[4-[[[(aminocarbonyl)amino]methyl]phenyl]methyl]-3-(aminoiminomethyl)- $\alpha$ -[[[(2-butyl-1H-benzimidazol-5-yl)amino]carbonyl]amino]-, monoacetate (9CI) (CA INDEX NAME)

CM 1


CRN 191870-66-3

CMF C31 H37 N9 O3




CM 2

CRN 64-19-7  
CMF C2 H4 O2



RN 191870-71-0 CAPLUS  
CN Pentanamide, N-[[4-[[ (aminocarbonyl)amino]methyl]phenyl]methyl]-5-  
[(aminoiminomethyl)amino]-2-[[ (1-naphthalenylamino)carbonyl]amino]-, (2R)-  
(CA INDEX NAME)

Absolute stereochemistry.




RN 191870-72-1 CAPLUS  
CN Pentanamide, N-[[4-[[ (aminocarbonyl)amino]methyl]phenyl]methyl]-5-  
[(aminoiminomethyl)amino]-2-[[ (1-naphthalenylamino)carbonyl]amino]-,  
acetate (1:1), (2R)- (CA INDEX NAME)

CM 1


CRN 191870-71-0  
CMF C26 H32 N8 O3

Absolute stereochemistry.




CM 2

CRN 64-19-7  
CMF C2 H4 O2



RN 191870-85-6 CAPLUS  
CN Pentanamide, N-[[4-[[ (aminocarbonyl)amino]methyl]phenyl]methyl]-5-  
[(aminoiminomethyl)amino]-2-[[[(3,4-dichlorophenyl)amino]carbonyl]amino]-,  
(2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 191870-86-7 CAPLUS  
CN Pentanamide, N-[[4-[[ (aminocarbonyl)amino]methyl]phenyl]methyl]-5-  
[(aminoiminomethyl)amino]-2-[[[(3,4-dichlorophenyl)amino]carbonyl]amino]-,  
(2R)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 191870-85-6  
CMF C22 H28 Cl2 N8 O3


Absolute stereochemistry.



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 191871-43-9 CAPLUS


CN Benzeneacetamide, 4-[[[2-[[[(3,4-dichlorophenyl)amino]carbonyl]amino]-5-(1H-imidazol-2-ylamino)-1-oxopentyl]amino]methyl]- (CA INDEX NAME)




RN 191871-60-0 CAPLUS

CN Benzeneacetamide, 4-[[[(2R)-2-[[[(2,4-dichlorophenyl)amino]carbonyl]amino]-5-(1H-imidazol-2-ylamino)-1-oxopentyl]amino]methyl]- (CA INDEX NAME)


Absolute stereochemistry.



IT 191870-64-1P 191870-65-2P 191870-70-9P  
 191870-84-5P 191871-41-7P 191871-42-8P  
 191871-58-6P 191871-59-7P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation of amino acid derivs. as neuropeptide Y antagonists)  
 RN 191870-64-1 CAPLUS  
 CN Benzenepropanamide, N-[[4-[[[(aminocarbonyl)amino]methyl]phenyl]methyl]-  
 $\alpha$ -[[[(2-butyl-1H-benzimidazol-6-yl)amino]carbonyl]amino]-3-cyano-  
 (CA INDEX NAME)




RN 191870-65-2 CAPLUS  
 CN Benzenepropanamide, N-[[4-[[[(aminocarbonyl)amino]methyl]phenyl]methyl]-  
 $\alpha$ -[[[(2-butyl-1H-benzimidazol-6-yl)amino]carbonyl]amino]-3-  
 [(hydroxyamino)iminomethyl]- (CA INDEX NAME)




RN 191870-70-9 CAPLUS  
 CN Pentanamide, N-[[4-[[ (aminocarbonyl)amino]methyl]phenyl]methyl]-5-  
 [[imino(nitroamino)methyl]amino]-2-[[ (1-naphthalenylamino)carbonyl]amino]-  
 , (2R)- (CA INDEX NAME)

Absolute stereochemistry.





RN 191870-84-5 CAPLUS  
 CN Pentanamide, N-[[4-[[ (aminocarbonyl)amino]methyl]phenyl]methyl]-2-[[[(3,4-dichlorophenyl)amino]carbonyl]amino]-5-[[[(3,4-dihydro-2,2,5,7,8-pentamethyl-2H-1-benzopyran-6-yl)sulfonyl]amino]iminomethyl]amino]-, (2R)-  
 (CA INDEX NAME)


Absolute stereochemistry.



RN 191871-41-7 CAPLUS  
 CN Carbamic acid, [5-[[[4-(2-amino-2-oxoethyl)phenyl]methyl]amino]-4-[[[(3,4-dichlorophenyl)amino]carbonyl]amino]-5-oxopentyl]-, phenylmethyl ester  
 (9CI) (CA INDEX NAME)




RN 191871-42-8 CAPLUS  
 CN Benzeneacetamide, 4-[[[5-amino-2-[[[(3,4-dichlorophenyl)amino]carbonyl]amino]-1-oxopentyl]amino]methyl]- (CA INDEX NAME)




RN 191871-58-6 CAPLUS  
 CN Carbamic acid, [5-[[[4-(2-amino-2-oxoethyl)phenyl]methyl]amino]-4-[[[(2,4-dichlorophenyl)amino]carbonyl]amino]-5-oxopentyl]-, phenylmethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 191871-59-7 CAPLUS  
 CN Benzeneacetamide, 4-[[[(2R)-5-amino-2-[[[(2,4-dichlorophenyl)amino]carbonyl]amino]-1-oxopentyl]amino]methyl]- (CA INDEX NAME)

Absolute stereochemistry.




L5 ANSWER 125 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1997:231368 CAPLUS  
 DOCUMENT NUMBER: 126:305783  
 ORIGINAL REFERENCE NO.: 126:59235a,59238a  
 TITLE: Preparation of endothelin antagonistic peptides  
 INVENTOR(S): Fujita, Kagari; Ihara, Masaki; Ikemoto, Fumihiko;  
 Yano, Mitsuo; Nishikibe, Masaru; Ishikawa, Kiyofumi;  
 Fukami, Takehiro; Hayama, Takeshi; Niiyama, Kenji;  
 Nagase, Toshio; Mase, Toshiaki  
 PATENT ASSIGNEE(S): Banyu Pharmaceutical Co., Ltd., Japan  
 SOURCE: U.S., 46 pp., Cont.-in-part of U.S. Ser. No. 884,642,  
 abandoned.  
 CODEN: USXXAM  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 3  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5614498	A	19970325	US 1992-945414	19920916
KR 230630	B1	19991115	KR 1992-23363	19921204
US 5470833	A	19951128	US 1994-213829	19940314
US 5444152	A	19950822	US 1994-214679	19940321
US 5496928	A	19960305	US 1994-230534	19940420
US 5691315	A	19971125	US 1995-494818	19950626
PRIORITY APPLN. INFO.:			JP 1990-149105	A 19900607
			US 1991-712095	B3 19910607
			JP 1991-347670	A 19911204
			JP 1991-353738	A 19911218
			US 1992-884642	B2 19920518
			JP 1992-234207	A 19920810
			US 1992-884189	B1 19920518
			US 1992-945414	A2 19920916
			US 1992-981424	B1 19921125
			US 1994-213829	A3 19940314

OTHER SOURCE(S): MARPAT 126:305783  
 IT 158739-63-0P 158739-64-1P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (preparation of endothelin antagonistic peptides)  
 RN 158739-63-0 CAPLUS  
 CN D-Norleucine, N-[1-(methoxycarbonyl)-N-[[[(2-nitrophenyl)amino]carbonyl]-L-leucyl]-D-tryptophyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 158739-64-1 CAPLUS

CN D-Norleucine, N-[N-[N-[[2-(aminophenyl)amino]carbonyl]-L-leucyl]-1-(methoxycarbonyl)-D-tryptophyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 158739-43-6P 158739-57-2P 158739-58-3P  
158739-59-4P 158739-60-7P 158739-61-8P  
158739-62-9P 158739-65-2P 158739-85-6P  
158739-91-4P 189104-64-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of endothelin antagonistic peptides)

RN 158739-43-6 CAPLUS

CN D-Norleucine, N-[N-[N-[[2-(chlorophenyl)amino]carbonyl]-L-leucyl]-1-(methoxycarbonyl)-D-tryptophyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 158739-57-2 CAPLUS

CN D-Norleucine, N-[3-benzo[b]thien-3-yl-N-[N-[(2-chlorophenyl)amino]carbonyl]-L-leucyl]-D-alanyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 158739-58-3 CAPLUS

CN D-Norleucine, N-[(2-chlorophenyl)amino]carbonyl]-L-leucyl-3-(ethoxycarbonyl)phenylalanyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 158739-59-4 CAPLUS

CN D-Norleucine, N-[[[(2-chlorophenyl)amino]carbonyl]-L-leucyl-3-(methoxycarbonyl)phenylalanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 158739-60-7 CAPLUS

CN D-Norleucine, N-[N-[N-[[[(2,6-dichlorophenyl)amino]carbonyl]-L-leucyl]-1-(methoxycarbonyl)-D-tryptophyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 158739-61-8 CAPLUS


CN D-Norleucine, N-[N-[N-[[[(2-fluorophenyl)amino]carbonyl]-L-leucyl]-1-(methoxycarbonyl)-D-tryptophyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 158739-62-9 CAPLUS  
 CN D-Norleucine, N-[1-(methoxycarbonyl)-N-[N-[[2-(trifluoromethyl)phenyl]amino]carbonyl]-L-leucyl]-D-tryptophyl]- (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.




RN 158739-65-2 CAPLUS  
 CN D-Norleucine, N-[N-[N-[[[2-(formylamino)phenyl]amino]carbonyl]-L-leucyl]-1-(methoxycarbonyl)-D-tryptophyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 158739-85-6 CAPLUS  
 CN D-Norleucine, N-[1-(methoxycarbonyl)-N-[N-[(2-pyridinylamino)carbonyl]-L-leucyl]-D-tryptophyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 158739-91-4 CAPLUS  
 CN D-Norleucine, N-[N-[2-[[[(2-chlorophenyl)amino]carbonyl]oxy]-4-methyl-1-oxopentyl]-1-(methoxycarbonyl)-D-tryptophyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 189104-64-1 CAPLUS  
 CN D-Norvaline, N-[[[(2-chlorophenyl)amino]carbonyl]-L-leucyl-1-(ethoxycarbonyl)-D-tryptophyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 158741-09-4P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation of endothelin antagonistic peptides)  
 RN 158741-09-4 CAPLUS  
 CN D-Norleucine, N-[3-benzo[b]thien-3-yl-N-[N-[(2-  
 chlorophenyl)amino]carbonyl]-L-leucyl]-D-alanyl]-, 1,1-dimethylethyl ester  
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 126 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1997:218870 CAPLUS  
 DOCUMENT NUMBER: 126:301403  
 ORIGINAL REFERENCE NO.: 126:58209a, 58212a  
 TITLE: Discovery of endothelin antagonists  
 AUTHOR(S): Neya, Masahiro  
 CORPORATE SOURCE: Exploratory Res. Lab., Fujisawa Pharm. Co., Ltd.,  
 Ibaraki, 300-26, Japan  
 SOURCE: Pure and Applied Chemistry (1997), 69(3), 441-446  
 CODEN: PACHAS; ISSN: 0033-4545  
 PUBLISHER: Blackwell  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English

IT 189237-25-0  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (discovery of peptides as endothelin antagonists specific for ETA and ETB receptors in relation to structure and antihypertensive and bronchoconstrictor activities)  
 RN 189237-25-0 CAPLUS  
 CN D-Alanine, N-[(phenylamino)carbonyl]-L-leucyl-1-methyl-D-tryptophyl-3-(2-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 127 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1997:85045 CAPLUS  
 DOCUMENT NUMBER: 126:104427  
 ORIGINAL REFERENCE NO.: 126:20165a,20168a  
 TITLE: Preparation of tripeptides as endothelin antagonists and vasodilators  
 INVENTOR(S): Hirata, Mitsuteru; Tamura, Masahiro; Suzuki, Chotaka; Ooshima, Takeshi; Oda, Toshiaki; Sogi, Hiroyuki; Shirato, Shozo; Hamada, Masa; Maeda, Kenji; Takeuchi, Tomio  
 PATENT ASSIGNEE(S): Kowa Co, Japan; Microbial Chemistry Research Foundation  
 SOURCE: Jpn. Kokai Tokkyo Koho, 29 pp.  
 CODEN: JKXXAF  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 08311097	A	19961126	JP 1995-119937	19950518
PRIORITY APPLN. INFO.:			JP 1995-119937	19950518
OTHER SOURCE(S):		MARPAT 126:104427		

IT 185816-97-1P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of tripeptides (leucyltryptophylaspartic acid) as endothelin antagonists and vasodilators)

RN 185816-97-1 CAPLUS

CN L-Aspartic acid, N-[(phenylamino)carbonyl]-L-leucyl-1-formyl-D-tryptophyl-, 31-butyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 185819-16-3P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of tripeptides (leucyltryptophylaspartic acid) as endothelin antagonists and vasodilators)

RN 185819-16-3 CAPLUS

CN L-Aspartic acid, N-[(phenylamino)carbonyl]-L-leucyl-1-formyl-D-tryptophyl-, 31-butyl 34-(phenylmethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 128 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1997:84874 CAPLUS

DOCUMENT NUMBER: 126:89160

ORIGINAL REFERENCE NO.: 126:17215a,17218a

TITLE: Preparation of polycyclic aromatics with linked chiral moieties as chiral stationary phases

INVENTOR(S): Ramage, Robert; Knox, John Henderson; Radisson, Xavier; Dutton, Jonathan Keith

PATENT ASSIGNEE(S): Rhone-Poulenc Limited, UK; Life Science International (Europe) Limited

SOURCE: Brit. UK Pat. Appl., 73 pp.



CODEN: BAXXDU  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 2299993	A	19961023	GB 1996-8277	19960422
WO 9633162	A1	19961024	WO 1996-GB966	19960422
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN				
AU 9653437	A	19961107	AU 1996-53437	19960422
PRIORITY APPLN. INFO.:			GB 1995-8118	A 19950421
			WO 1996-GB966	W 19960422

OTHER SOURCE(S): MARPAT 126:89160


IT 185816-09-5P

RL: MOA (Modifier or additive use); SPN (Synthetic preparation); PREP (Preparation); USES (Uses)  
(preparation of polycyclic aroms. with linked chiral moieties as chiral stationary phases)

RN 185816-09-5 CAPLUS

CN Butanediamide, N-[6-(17H-cyclopenta[1,2-l:3,4-l']diphenanthren-17-yl)hexyl]-N'-(1-methylethyl)-2,3-bis[[ (phenylamino)carbonyl]oxy]-, [R-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 129 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1997:70350 CAPLUS

DOCUMENT NUMBER: 126:199453

ORIGINAL REFERENCE NO.: 126:38559a,38562a

TITLE: Preparation of adamantyl indolylalkylcarbamates and analogs as cholecystokinin antagonists

INVENTOR(S): Horwell, David C.; Roberts, Edward; Holmes, Ann; Padia, Janak K.; Roark, William H.; Roth, Bruce D.; Trivedi, Bharat K.; Kleinschroth, Jurgen; Rees, David C.; Richardson, Reginald S.

PATENT ASSIGNEE(S): Warner-Lambert Company, USA  
 SOURCE: U.S., 77 pp., Cont.-in-part of U.S. Ser. No. 839, 647, abandoned.  
 CODEN: USXXAM  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5593967	A	19970114	US 1993-41647	19930401
ZA 9106922	A	19930301	ZA 1991-6922	19910830
US 5846942	A	19981208	US 1996-709316	19960909
PRIORITY APPLN. INFO.:			US 1990-576628	B2 19900831
			US 1991-726655	B2 19910712
			US 1992-839647	B2 19920221
			US 1993-41647	A3 19930401

OTHER SOURCE(S): MARPAT 126:199453


IT 142627-77-8P 142697-57-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of adamantyl indolylalkylcarbamates and analogs as cholecystokinin antagonists)

RN 142627-77-8 CAPLUS

CN 1H-Indole-3-propanamide,  $\alpha$ -[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]amino]-N-[2-hydroxy-1-(hydroxymethyl)-2-phenylethyl]- $\alpha$ -methyl-, [1S-[1R\*(R\*),2R\*]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 142697-57-2 CAPLUS


CN 1H-Indole-3-propanamide,  $\alpha$ -[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]amino]-N-[2-hydroxy-1-(hydroxymethyl)-2-phenylethyl]- $\alpha$ -methyl-, [1S-[1R\*(S\*),2R\*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 142627-75-6P 142627-76-7P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation of adamantyl indolylalkylcarbamates and analogs as  
 cholecystokinin antagonists)  
 RN 142627-75-6 CAPLUS  
 CN 1H-Indole-3-propanamide,  $\alpha$ -[[[2,6-bis(1-  
 methylethyl)phenyl]amino]carbonyl]amino]-N-(2,2-dimethyl-4-phenyl-1,3-  
 dioxan-5-yl)- $\alpha$ -methyl-, [4S-[4 $\alpha$ ,5 $\alpha$ (R\*)]]- (9CI) (CA  
 INDEX NAME)

Absolute stereochemistry.



RN 142627-76-7 CAPLUS  
 CN 1H-Indole-3-propanamide,  $\alpha$ -[[[2,6-bis(1-  
 methylethyl)phenyl]amino]carbonyl]amino]-N-(2,2-dimethyl-4-phenyl-1,3-  
 dioxan-5-yl)- $\alpha$ -methyl-, [4S-[4 $\alpha$ ,5 $\alpha$ (S\*)]]- (9CI) (CA  
 INDEX NAME)


Absolute stereochemistry.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 130 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1997:66426 CAPLUS  
 DOCUMENT NUMBER: 126:116246  
 ORIGINAL REFERENCE NO.: 126:22433a,22436a  
 TITLE: Evolution of the sweetness receptor in primates. II. Gustatory responses of non-human primates to nine compounds known to be sweet in man  
 AUTHOR(S): Nofre, C.; Tinti, J. M.; Glaser, D.  
 CORPORATE SOURCE: Faculte de Medecine Alexis Carrel, Universite Claude Bernard, Lyon, 69008, Fr.  
 SOURCE: Chemical Senses (1996), 21(6), 747-762  
 CODEN: CHSED8; ISSN: 0379-864X  
 PUBLISHER: Oxford University Press  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 IT 135507-50-5, Superaspartame  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (gustatory responses of non-human primates to nine compds. known to be sweet in man)  
 RN 135507-50-5 CAPLUS  
 CN L-Phenylalanine, N-[(4-cyanophenyl)amino]carbonyl]-L- $\alpha$ -aspartyl-, 2-methyl ester (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 131 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1996:741361 CAPLUS

DOCUMENT NUMBER: 126:54301  
ORIGINAL REFERENCE NO.: 126:10551a,10554a  
TITLE: PD 165929 - the first high affinity non-peptide  
neurodyn-B (NMB) receptor selective antagonist  
AUTHOR(S): Eden, J. M.; Hall, M. D.; Higginbottom, M.; Horwell,  
D. C.; Howson, W.; Hughes, J.; Jordon, R. E.;  
Lewthwaite, R. A.; Martin, K.; McKnight, A. T.  
CORPORATE SOURCE: Park-Davis Neurosci. Res. Cent., Cambridge, CB2 2QB,  
UK  
SOURCE: Bioorganic & Medicinal Chemistry Letters (1996),  
6(21), 2617-2622  
CODEN: BMCLE8; ISSN: 0960-894X  
PUBLISHER: Elsevier  
DOCUMENT TYPE: Journal; General Review  
LANGUAGE: English  
IT 185215-75-2, PD 165929  
RL: BAC (Biological activity or effector, except adverse); BPR (Biological  
process); BSU (Biological study, unclassified); BIOL (Biological study);  
PROC (Process)  
(PD 165929 - the first high affinity non-peptide neurodyn-B (NMB)  
receptor selective antagonist)  
RN 185215-75-2 CAPLUS  
CN 1H-Indole-3-propanamide,  $\alpha$ -[[[2,6-bis(1-  
methylethyl)phenyl]amino]carbonyl]amino]- $\alpha$ -methyl-N-[[1-(2-  
pyridinyl)cyclohexyl]methyl]-, ( $\alpha$ S)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 132 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 1996:593835 CAPLUS  
DOCUMENT NUMBER: 125:248489  
ORIGINAL REFERENCE NO.: 125:46473a  
TITLE: Preparation of dipeptide derivatives as cell adhesion  
inhibitors  
INVENTOR(S): Adams, Steven P.; Lin, Ko-Chung; Lee, Wen-Cherng;  
Castro, Alfredo C.; Zimmerman, Craig N.; Hammond,  
Charles E.; Liao, Yu-Sheng; Cuervo, Julio Hernan;  
Singh, Jussinder  
PATENT ASSIGNEE(S): Biogen, Inc., USA  
SOURCE: PCT Int. Appl., 169 pp.  
CODEN: PIXXD2

DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9622966	A1	19960801	WO 1996-US1349	19960118
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE				
US 6306840	B1	20011023	US 1995-376372	19950123
CA 2211181	A1	19960801	CA 1996-2211181	19960118
AU 9649115	A	19960814	AU 1996-49115	19960118
AU 718926	B2	20000504		
EP 805796	A1	19971112	EP 1996-905316	19960118
EP 805796	B1	20021211		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI				
BR 9606778	A	19980106	BR 1996-6778	19960118
CN 1177343	A	19980325	CN 1996-192270	19960118
CN 1192015	C	20050309		
HU 9702461	A2	19980428	HU 1997-2461	19960118
HU 9702461	A3	19990830		
HU 223350	B1	20040628		
JP 10513160	T	19981215	JP 1996-523071	19960118
JP 4129293	B2	20080806		
EP 1142867	A2	20011010	EP 2001-107877	19960118
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI				
AT 229498	T	20021215	AT 1996-905316	19960118
ES 2183937	T3	20030401	ES 1996-905316	19960118
CZ 291556	B6	20030416	CZ 1997-2340	19960118
EE 4111	B1	20030815	EE 1997-172	19960118
SK 283724	B6	20031202	SK 1997-987	19960118
PL 187313	B1	20040630	PL 1996-321848	19960118
RO 119885	B1	20050530	RO 1997-1369	19960118
TW 500714	B	20020901	TW 1996-85100690	19960122
IL 116846	A	20021110	IL 1996-116846	19960122
FI 9703087	A	19970922	FI 1997-3087	19970722
NO 320914	B1	20060213	NO 1997-3384	19970722
BG 63383	B1	20011231	BG 1997-101841	19970821
US 6376538	B1	20020423	US 1997-875321	19970919
HK 1005241	A1	20030822	HK 1998-104006	19980508
AU 766538	B2	20031016	AU 2000-62432	20001002
US 20030083267	A1	20030501	US 2001-935461	20010822
US 6624152	B2	20030923		
US 20030018016	A1	20030123	US 2001-2341	20011023
US 6630512	B2	20031007		
US 7001921	B1	20060221	US 2003-625626	20030724
US 20060166866	A1	20060727	US 2003-679478	20031007
JP 2008013574	A	20080124	JP 2007-217671	20070823
PRIORITY APPLN. INFO.:				
			US 1995-376372	A2 19950123
			AU 1996-49115	A3 19960118
			EP 1996-905316	A3 19960118
			JP 1996-523071	A3 19960118
			WO 1996-US1349	W 19960118
			US 1997-875321	A3 19970919
			US 2001-935461	A1 20010822

OTHER SOURCE(S): MARPAT 125:248489

IT 181521-39-1P 181521-73-3P 181521-74-4P  
 181521-76-6P 181522-77-0P 181522-88-3P  
 181522-89-4P 181522-90-7P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation of  $\beta$ -amino acid dipeptide derivs. as cell adhesion inhibitors)

RN 181521-39-1 CAPLUS

CN Benzenepropanoic acid,  $\beta$ -[[[(2S)-4-methyl-1-oxo-2-  
 [[(phenylamino)carbonyl]amino]pentyl]amino]-, ( $\beta$ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 181521-73-3 CAPLUS

CN Benzenepropanoic acid,  $\beta$ -[[[(2S)-4-methyl-2-[[[(4-nitrophenyl)amino]carbonyl]amino]-1-oxopentyl]amino]-, ( $\beta$ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 181521-74-4 CAPLUS

CN Benzenepropanoic acid,  $\beta$ -[[[(2S)-2-[[[(4-aminophenyl)amino]carbonyl]amino]-4-methyl-1-oxopentyl]amino]-, ( $\beta$ S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 181521-76-6 CAPLUS

CN Benzenepropanoic acid,  $\beta$ -[[[(2S)-4-methyl-1-oxo-2-[[[(4-  
 [[(phenylamino)carbonyl]amino]phenyl]amino]carbonyl]amino]pentyl]amino]-,

(βS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 181522-77-0 CAPLUS

CN Benzenepropanoic acid, 4-methoxy-β-[[[(2S)-4-(methylsulfinyl)-1-oxo-2-[[[(phenylamino)carbonyl]amino]butyl]amino]-, (βS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 181522-88-3 CAPLUS

CN 1,3-Benzodioxole-5-propanoic acid, β-[[[(2S)-4-(dimethylamino)-1,4-dioxo-2-[[[(phenylamino)carbonyl]amino]butyl]amino]-, (βS)- (CA INDEX NAME)

Absolute stereochemistry.




RN 181522-89-4 CAPLUS

CN 1,3-Benzodioxole-5-propanoic acid, β-[[[(2S)-4-(dimethylamino)-1-oxo-2-[[[(phenylamino)carbonyl]amino]butyl]amino]-, (βS)- (CA INDEX NAME)


Absolute stereochemistry.






RN 181522-90-7 CAPLUS  
 CN 1,3-Benzodioxole-5-propanoic acid,  
 β-[[[(2S)-5-(4-morpholinyl)-1,5-dioxo-2-  
 [[[(phenylamino)carbonyl]amino]pentyl]amino]-, (βS)- (CA INDEX NAME)

Absolute stereochemistry.



IT 181518-83-2P 181518-89-8P 181518-97-8P  
 181519-72-2P 181519-73-3P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation of β-amino acid dipeptide derivs. as cell adhesion  
 inhibitors)  
 RN 181518-83-2 CAPLUS  
 CN 1,3-Benzodioxole-5-propanoic acid,  
 β-[[[(2S)-4-(dimethylamino)-1,4-dioxo-2-  
 [[[(phenylamino)carbonyl]amino]butyl]amino]-, methyl ester, (βS)- (CA  
 INDEX NAME)


Absolute stereochemistry.



RN 181518-89-8 CAPLUS  
 CN 1,3-Benzodioxole-5-propanoic acid,  
 β-[[[(2S)-4-(dimethylamino)-1-oxo-2-  
 [[[(phenylamino)carbonyl]amino]butyl]amino]-, methyl ester, (βS)- (CA  
 INDEX NAME)

[[ (phenylamino)carbonyl]amino]butyl]amino]-, methyl ester, ( $\beta$ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 181518-97-8 CAPLUS

CN Benzenepropanoic acid, 4-methoxy- $\beta$ -[[ (2S)-4-(methylthio)-1-oxo-2-[[ (phenylamino)carbonyl]amino]butyl]amino]-, 1,1-dimethylethyl ester, ( $\beta$ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 181519-72-2 CAPLUS

CN Benzenepropanoic acid,  $\beta$ -[[ (2S)-4-methyl-2-[[[(4-nitrophenyl)amino]carbonyl]amino]-1-oxopentyl]amino]-, 1,1-dimethylethyl ester, ( $\beta$ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 181519-73-3 CAPLUS

CN Benzenepropanoic acid,  $\beta$ -[[ (2S)-2-[[[(4-aminophenyl)amino]carbonyl]amino]-4-methyl-1-oxopentyl]amino]-, 1,1-dimethylethyl ester, ( $\beta$ S)- (CA INDEX NAME)


Absolute stereochemistry.



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 133 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1996:545190 CAPLUS  
 DOCUMENT NUMBER: 125:276541  
 ORIGINAL REFERENCE NO.: 125:51749a,51752a  
 TITLE: Rapid synthesis of novel dipeptide inhibitors of human collagenase and gelatinase using solid phase chemistry  
 AUTHOR(S): Foley, Michael A.; Hassman, Angela S.; Drewry, David H.; Greer, David G.; Wagner, Craig D.; Feldman, Paul L.; Berman, Judd; Bickett, D. Mark; McGeehan, Gerry M.; et al.  
 CORPORATE SOURCE: Glaxo Wellcome Res., Research Triangle Park, NC, 27709, USA  
 SOURCE: Bioorganic & Medicinal Chemistry Letters (1996), 6(16), 1905-1910  
 CODEN: BMCLE8; ISSN: 0960-894X  
 PUBLISHER: Elsevier  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 IT 182501-37-7P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
 (synthesis of novel dipeptide inhibitors of human collagenase and gelatinase using solid phase chemical)  
 RN 182501-37-7 CAPLUS  
 CN L-Phenylalaninamide, N-[(phenylamino)carbonyl]-L-cysteiny- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L5 ANSWER 134 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1996:490192 CAPLUS  
 DOCUMENT NUMBER: 125:191787  
 ORIGINAL REFERENCE NO.: 125:35847a,35850a  
 TITLE: Taste in chimpanzee: I. The summated response to sweeteners and the effect of gymnemic acid

AUTHOR(S): Hellekant, G.; Ninomiya, Y.; DuBois, G. E.; Danilova, V.; Roberts, T. W.  
 CORPORATE SOURCE: Wisconsin Regional Primate Cent., Univ. Wisconsin, Madison, WI, 53706, USA  
 SOURCE: Physiology & Behavior (1996), 60(2), 469-479  
 CODEN: PHBHA4; ISSN: 0031-9384  
 PUBLISHER: Elsevier  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 IT 135507-50-5, Super-aspartame  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)  
 (summated response to sweeteners and effect of gymnemic acid on taste in chimpanzee)  
 RN 135507-50-5 CAPLUS  
 CN L-Phenylalanine, N-[(4-cyanophenyl)amino]carbonyl]-L- $\alpha$ -aspartyl-, 2-methyl ester (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 135 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1996:462297 CAPLUS  
 DOCUMENT NUMBER: 125:143312  
 ORIGINAL REFERENCE NO.: 125:26849a,26852a  
 TITLE: Preparation of [(acylamino)(indolyl)ethyl]azolecarboxylates and related compounds as endothelin antagonists.  
 INVENTOR(S): Von Geldern, Thomas; Kester, Jeffrey A.; Tasker, Andrew S.; Sorensen, Brian K.; Rosenberg, Saul H.; Hutchins, Charles W.; Winn, Martin  
 PATENT ASSIGNEE(S): Abbott Laboratories, USA  
 SOURCE: PCT Int. Appl., 113 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9611927	A1	19960425	WO 1995-US13373	19951010
W: CA, JP, MX				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
PRIORITY APPLN. INFO.:			US 1994-322114	A 19941012
			US 1995-442124	A 19950530


OTHER SOURCE(S): MARPAT 125:143312  
 IT 179168-82-2P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of [(acylamino)(indolyl)ethyl]azolecarboxylates and related compds. as endothelin antagonists)

RN 179168-82-2 CAPLUS

CN 4-Oxazolecarboxylic acid, 2-[1-[[2-[[[(2-fluorophenyl)amino]carbonyl]oxy]-4-methyl-1-oxopentyl]amino]-2-(1-methyl-1H-indol-3-yl)ethyl]-5-methyl-, [S-(R\*,S\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 179169-23-4P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of [(acylamino)(indolyl)ethyl]azolecarboxylates and related compds. as endothelin antagonists)

RN 179169-23-4 CAPLUS

CN 4-Oxazolecarboxylic acid, 2-[1-[[2-[[[(2-fluorophenyl)amino]carbonyl]oxy]-4-methyl-1-oxopentyl]amino]-2-(1-methyl-1H-indol-3-yl)ethyl]-5-methyl-, phenylmethyl ester, [S-(R\*,S\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 136 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1996:443908 CAPLUS

DOCUMENT NUMBER: 125:115147

ORIGINAL REFERENCE NO.: 125:21643a

TITLE: Preparation of peptide aldehyde derivatives as cysteine protease inhibitors

INVENTOR(S): Sohda, Takashi; Fujisawa, Yukio; Yasuma, Tsuneo; Mizoguchi, Junji


PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan  
 SOURCE: PCT Int. Appl., 85 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9610014	A1	19960404	WO 1995-JP1933	19950925
W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, KG, KR, KZ, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TT, UA, US, UZ, VN				
RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2196182	A1	19960404	CA 1995-2196182	19950925
AU 9535341	A	19960419	AU 1995-35341	19950925
JP 08151355	A	19960611	JP 1995-245957	19950925
EP 783489	A1	19970716	EP 1995-932228	19950925
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
PRIORITY APPLN. INFO.:			JP 1994-231839	A 19940927
			WO 1995-JP1933	W 19950925

OTHER SOURCE(S): MARPAT 125:115147


IT 178910-66-2P 178910-76-4P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of peptide aldehyde derivs. as cysteine protease inhibitors and bone resorption inhibitors for treating bone diseases)  
 RN 178910-66-2 CAPLUS  
 CN Pentanamide, N-[1-(1H-indol-3-ylmethyl)-4-oxo-2-butenyl]-3-methyl-2-[[1-naphthalenylamino)carbonyl]amino]-, [2S-[1(R\*),2R\*,3R\*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry unknown.




RN 178910-76-4 CAPLUS  
 CN Pentanamide, N-[1-(1H-indol-3-ylmethyl)-4-oxobutyl]-3-methyl-2-[[1-naphthalenylamino)carbonyl]amino]-, [2S-[1(S\*),2R\*,3R\*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 161708-93-6P 161709-82-6P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation of peptide aldehyde derivs. as cysteine protease inhibitors and  
 bone resorption inhibitors for treating bone diseases)  
 RN 161708-93-6 CAPLUS  
 CN Pentanamide, N-[2-hydroxy-1-(1H-indol-3-ylmethyl)ethyl]-3-methyl-2-[[ (1-  
 naphthalenylamino)carbonyl]amino]-, [2S-[1(R\*),2R\*,3R\*]]- (9CI) (CA INDEX  
 NAME)

Absolute stereochemistry.



RN 161709-82-6 CAPLUS  
 CN Pentanamide, N-[(1S)-1-formyl-2-(1H-indol-3-yl)ethyl]-3-methyl-2-[[ (1-  
 naphthalenylamino)carbonyl]amino]-, (2S,3S)- (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 1996:433530 CAPLUS  
 DOCUMENT NUMBER: 125:111183  
 ORIGINAL REFERENCE NO.: 125:20779a,20782a  
 TITLE: Species differences toward sweeteners  
 AUTHOR(S): Hellekant, Goran; Danilova, Vicktoria  
 CORPORATE SOURCE: Wisconsin Regional Primate Cent., Univ. Wisconsin,  
 Madison, WI, 53706, USA  
 SOURCE: Food Chemistry (1996), 56(3), 323-328  
 CODEN: FOCHDJ; ISSN: 0308-8146  
 PUBLISHER: Elsevier  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 IT 135507-50-5, Super-Aspartame  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological  
 study, unclassified); BIOL (Biological study)  
 (mammalian species differences in ability to taste sweeteners)  
 RN 135507-50-5 CAPLUS  
 CN L-Phenylalanine, N-[[[(4-cyanophenyl)amino]carbonyl]-L- $\alpha$ -aspartyl-,  
 2-methyl ester (CA INDEX NAME)


Absolute stereochemistry.



L5 ANSWER 138 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1996:433520 CAPLUS  
 DOCUMENT NUMBER: 125:138947  
 ORIGINAL REFERENCE NO.: 125:25949a,25952a  
 TITLE: Sweetness reception in man: the multipoint attachment  
 theory  
 AUTHOR(S): Nofre, Claude; Tinti, Jean-Marie  
 CORPORATE SOURCE: Fac. Med. Alexis Carrel, Univ. Claude Bernard, Lyon,  
 F-69008, Fr.  
 SOURCE: Food Chemistry (1996), 56(3), 263-274  
 CODEN: FOCHDJ; ISSN: 0308-8146  
 PUBLISHER: Elsevier  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 IT 135507-50-5  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological  
 study, unclassified); PRP (Properties); BIOL (Biological study)  
 (multipoint attachment theory for sweetness reception in human)  
 RN 135507-50-5 CAPLUS  
 CN L-Phenylalanine, N-[[[(4-cyanophenyl)amino]carbonyl]-L- $\alpha$ -aspartyl-,  
 2-methyl ester (CA INDEX NAME)

Absolute stereochemistry.





L5 ANSWER 139 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1996:241976 CAPLUS

DOCUMENT NUMBER: 124:331828

ORIGINAL REFERENCE NO.: 124:61229a,61232a

TITLE: Inhibitors of Human Immunodeficiency Virus Type 1  
Protease Containing 2-Aminobenzyl-Substituted  
4-Amino-3-hydroxy-5-phenylpentanoic acid: Synthesis,  
Activity, and Oral Bioavailability

AUTHOR(S): Lehr, Philipp; Billich, Andreas; Charpiot, Brigitte;  
Ettmayer, Peter; Scholz, Dieter; Rosenwirth, Brigitte;  
Gstach, Hubert

CORPORATE SOURCE: Sandoz Research Institute, Vienna, A-1235, Austria

SOURCE: Journal of Medicinal Chemistry (1996), 39(10), 2060-7  
CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English


IT 176389-02-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological  
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);  
BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation and bioavailability and HIV-1 protease inhibitory activity of  
(aminobenzyl)hydroxyphenylpentanoates)

RN 176389-02-9 CAPLUS


CN L-Lyxonamide, 2,4,5-trideoxy-N-(2,3-dihydro-2-hydroxy-1H-inden-1-yl)-4-[[2-  
[[[(2,3-dimethoxyphenyl)amino]carbonyl]amino]-3,3-dimethyl-1-  
oxobutyl]amino]-2-[[[(4-methoxyphenyl)methyl]amino]-5-phenyl-,  
[1(1S,2R),4(S)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 140 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 1996:73848 CAPLUS  
DOCUMENT NUMBER: 124:193276  
ORIGINAL REFERENCE NO.: 124:35427a,35430a  
TITLE: Azole Endothelin Antagonists. 2. Structure-Activity  
Studies  
AUTHOR(S): von Geldern, Thomas W.; Kester, Jeffrey A.; Bal,  
Radhika; Wu-Wong, Jinshyun R.; Chiou, William; Dixon,  
Douglas B.; Opgenorth, Terry J.  
CORPORATE SOURCE: Pharmaceutical Products Research, Abbott Laboratories,  
Abbott Park, IL, 60064, USA  
SOURCE: Journal of Medicinal Chemistry (1996), 39(4), 968-81  
CODEN: JMCMAR; ISSN: 0022-2623  
PUBLISHER: American Chemical Society  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
OTHER SOURCE(S): CASREACT 124:193276  
IT 168468-82-4P 168470-35-7P 168470-41-5P  
RL: BAC (Biological activity or effector, except adverse); BPR (Biological  
process); BSU (Biological study, unclassified); PRP (Properties); SPN  
(Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC  
(Process)  
(preparation of azole peptide endothelin antagonists in relation to  
structure)  
RN 168468-82-4 CAPLUS  
CN 1H-Imidazole-4-carboxylic acid, 5-methyl-2-[2-(1-methyl-1H-indol-3-yl)-1-  
[[4-methyl-1-oxo-2-[[ (phenylamino)carbonyl]amino]pentyl]amino]ethyl]-,  
[S-(R\*,S\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 168470-35-7 CAPLUS

CN 4-Oxazolecaboxylic acid, 5-methyl-2-[2-(1-methyl-1H-indol-3-yl)-1-[[4-methyl-1-oxo-2-[[ (phenylamino)carbonyl]amino]pentyl]amino]ethyl]-, [S-(R\*,S\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 168470-41-5 CAPLUS

CN 4-Oxazolecaboxylic acid, 2-[1-[[2-[[[(2-fluorophenyl)amino]carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-(1-methyl-1H-indol-3-yl)ethyl]-5-methyl-, [S-(R\*,S\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 168470-17-5P 168470-19-7P 168470-21-1P

168470-37-9P 168470-43-7P

RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP


(Preparation); PROC (Process)

(preparation of azole peptide endothelin antagonists in relation to structure)

RN 168470-17-5 CAPLUS

CN 4-Oxazolecarboxylic acid, 5-methyl-2-[2-(1-methyl-1H-indol-3-yl)-1-[[4-methyl-1-oxo-2-[[ (2-pyridinylamino)carbonyl]amino]pentyl]amino]ethyl]-, [S-(R\*,S\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 168470-19-7 CAPLUS

CN 4-Oxazolecarboxylic acid, 5-methyl-2-[2-(1-methyl-1H-indol-3-yl)-1-[[4-methyl-1-oxo-2-[[ (3-pyridinylamino)carbonyl]amino]pentyl]amino]ethyl]-, [S-(R\*,S\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 168470-21-1 CAPLUS

CN 4-Oxazolecarboxylic acid, 5-methyl-2-[2-(1-methyl-1H-indol-3-yl)-1-[[4-methyl-1-oxo-2-[[ [(pentafluorophenyl)amino]carbonyl]amino]pentyl]amino]ethyl]-, [S-(R\*,S\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 168470-37-9 CAPLUS

CN 4-Oxazolecarboxylic acid, 2-[1-[[2-[[[(3-fluorophenyl)amino]carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-(1-methyl-1H-indol-3-yl)ethyl]-5-methyl-, [S-(R\*,S\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 168470-43-7 CAPLUS

CN 4-Oxazolecarboxylic acid, 2-[1-[[2-[[[(4-fluorophenyl)amino]carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-(1-methyl-1H-indol-3-yl)ethyl]-5-methyl-, [S-(R\*,S\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



ORIGINAL REFERENCE NO.: 123:46063a,46066a  
 TITLE: Preparation of  
 [(aminocarbonylleucylamino)indolylethyl]azolecarboxyla  
 tes and related compounds as endothelin antagonists.  
 INVENTOR(S): Vongeldern, Thomas W.; Kester, Jeffrey A.; Rosenberg,  
 Saul H.; Winn, Martin; Hutchins, Charles W.  
 PATENT ASSIGNEE(S): Abbott Laboratories, USA  
 SOURCE: PCT Int. Appl., 193 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9508550	A1	19950330	WO 1994-US10049	19940907
W: CA, JP				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
PRIORITY APPLN. INFO.:			US 1993-126822	A 19930924
			US 1994-295441	A 19940829

OTHER SOURCE(S): MARPAT 123:257412  
 IT 168468-83-5P 168470-18-6P 168470-20-0P  
 168470-22-2P 168470-24-4P 168470-36-8P  
 168470-38-0P 168470-42-6P 168470-43-7P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological  
 study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);  
 BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of [(aminocarbonylleucylamino)indolylethyl]azolecarboxylates  
 and related compds. as endothelin antagonists)  
 RN 168468-83-5 CAPLUS  
 CN 1H-Imidazole-4-carboxylic acid, 5-methyl-2-[2-(1-methyl-1H-indol-3-yl)-1-  
 [[4-methyl-1-oxo-2-[(phenylamino)carbonyl]amino]pentyl]amino]ethyl]-,  
 [S-(R\*,S\*)]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 168468-82-4  
 CMF C29 H34 N6 O4

Absolute stereochemistry.



CM 2

CRN 76-05-1  
 CMF C2 H F3 O2



RN 168470-18-6 CAPLUS


CN 4-Oxazolecarboxylic acid, 5-methyl-2-[2-(1-methyl-1H-indol-3-yl)-1-[[4-methyl-1-oxo-2-[[ (2-pyridinylamino)carbonyl]amino]pentyl]amino]ethyl]-, [S-(R\*,S\*)]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 168470-17-5

CMF C28 H32 N6 O5


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 168470-20-0 CAPLUS


CN 4-Oxazolecarboxylic acid, 5-methyl-2-[2-(1-methyl-1H-indol-3-yl)-1-[[4-methyl-1-oxo-2-[[ (3-pyridinylamino)carbonyl]amino]pentyl]amino]ethyl]-, [S-(R\*,S\*)]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 168470-19-7

CMF C28 H32 N6 O5


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 168470-22-2 CAPLUS


CN 4-Oxazolecarboxylic acid, 5-methyl-2-[2-(1-methyl-1H-indol-3-yl)-1-[[4-methyl-1-oxo-2-[[[(pentafluorophenyl)amino]carbonyl]amino]pentyl]amino]ethyl]-, [S-(R\*,S\*)]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 168470-21-1

CMF C29 H28 F5 N5 O5

Absolute stereochemistry.




CM 2

CRN 76-05-1

CMF C2 H F3 O2






RN 168470-24-4 CAPLUS  
 CN 4-Oxazolecarboxylic acid, 2-[1-[[2-[[[(2-hydroxyphenyl)amino]carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-(1-methyl-1H-indol-3-yl)ethyl]-5-methyl-, [S-(R\*,S\*)]-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 168470-23-3  
 CMF C29 H33 N5 O6

Absolute stereochemistry.



CM 2

CRN 76-05-1  
 CMF C2 H F3 O2




RN 168470-36-8 CAPLUS  
 CN 4-Oxazolecarboxylic acid, 5-methyl-2-[2-(1-methyl-1H-indol-3-yl)-1-[[4-methyl-1-oxo-2-[[[(phenylamino)carbonyl]amino]pentyl]amino]ethyl]-, [S-(R\*,S\*)]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 168470-35-7  
 CMF C29 H33 N5 O5


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 168470-38-0 CAPLUS


CN 4-Oxazolecarboxylic acid, 2-[1-[[2-[[[(3-fluorophenyl)amino]carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-(1-methyl-1H-indol-3-yl)ethyl]-5-methyl-, [S-(R\*,S\*)]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 168470-37-9

CMF C29 H32 F N5 O5


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 168470-42-6 CAPLUS  
 CN 4-Oxazolecarboxylic acid, 2-[1-[[2-[[[(2-fluorophenyl)amino]carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-(1-methyl-1H-indol-3-yl)ethyl]-5-methyl-, [S-(R\*,S\*)]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 168470-41-5  
 CMF C29 H32 F N5 O5

Absolute stereochemistry.




CM 2

CRN 76-05-1  
 CMF C2 H F3 O2




RN 168470-43-7 CAPLUS  
 CN 4-Oxazolecarboxylic acid, 2-[1-[[2-[[[(4-fluorophenyl)amino]carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-(1-methyl-1H-indol-3-yl)ethyl]-5-methyl-, [S-(R\*,S\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 168471-14-5P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation of [(aminocarbonylleucylamino)indolylethyl]azolecarboxylates  
 and related compds. as endothelin antagonists)  
 RN 168471-14-5 CAPLUS  
 CN 4-Oxazolecarboxylic acid, 5-methyl-2-[2-(1-methyl-1H-indol-3-yl)-1-[[4-  
 methyl-1-oxo-2-[[[(phenylamino)carbonyl]amino]pentyl]amino]ethyl]-,  
 phenylmethyl ester, [S-(R\*,S\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 142 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1995:812991 CAPLUS  
 DOCUMENT NUMBER: 123:228919  
 ORIGINAL REFERENCE NO.: 123:40924a  
 TITLE: Preparation of substituted di- and tripeptide  
 inhibitors of protein:farnesyl transferase  
 INVENTOR(S): Bolton, Gary Louis; Creswell, Mark Wallace; Hodges,  
 John Cooke; Wilson, Michael William  
 PATENT ASSIGNEE(S): Warner Lambert Co., USA  
 SOURCE: PCT Int. Appl., 67 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9512612	A1	19950511	WO 1994-US11553	19941012
W: AM, AU, BG, BY, CA, CZ, EE, FI, GE, HU, JP, KG, KR, NO, NZ, PL, RO, RU, SI, UA				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2170766	A1	19950511	CA 1994-2170766	19941012
AU 9479760	A	19950523	AU 1994-79760	19941012
AU 681454	B2	19970828		
EP 730605	A1	19960911	EP 1994-930725	19941012
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 09504547	T	19970506	JP 1995-513224	19941012
JP 3597863	B2	20041208		
HU 75308	A2	19970528	HU 1996-1193	19941012
FI 9601819	A	19960429	FI 1996-1819	19960429
NO 9601814	A	19960506	NO 1996-1814	19960503
US 5830868	A	19981103	US 1996-671460	19960627
PRIORITY APPLN. INFO.:				
			US 1993-148735	A 19931105
			US 1994-303301	A 19940913
			WO 1994-US11553	W 19941012

OTHER SOURCE(S): MARPAT 123:228919


IT 168174-36-5P 168174-89-8P 168174-92-3P  
168174-93-4P 168174-94-5P 168174-96-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of substituted di- and tripeptide inhibitors of protein:farnesyl transferase)

RN 168174-36-5 CAPLUS

CN L-Tyrosinamide, N-[(phenylamino)carbonyl]-D-histidyl-N-(3-phenoxypropyl)-O-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 168174-89-8 CAPLUS

CN L-Tyrosinamide, N-[(1-naphthalenylamino)carbonyl]-D-histidyl-N-[2-(phenylmethoxy)ethyl]-O-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 168174-92-3 CAPLUS

CN L-Tyrosinamide, N-[(1-naphthalenylamino)carbonyl]-D-histidyl-N-(4-phenylbutyl)-O-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 168174-93-4 CAPLUS

CN L-Tyrosinamide, N-[(1-naphthalenylamino)carbonyl]-D-histidyl-N,O-bis(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 168174-94-5 CAPLUS

CN L-Tyrosinamide, N-[[[(4-ethoxyphenyl)amino]carbonyl]-D-histidyl-N-[2-(phenylmethoxy)ethyl]-O-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 168174-96-7 CAPLUS


CN L-Tyrosinamide, N-[[[(4-ethoxyphenyl)amino]carbonyl]-D-histidyl-N-(3-phenoxypropyl)-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 168175-56-2P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation of substituted di- and tripeptide inhibitors of  
 protein:farnesyl transferase)  
 RN 168175-56-2 CAPLUS  
 CN L-Tyrosinamide, N-[[ (4-ethoxyphenyl) amino] carbonyl]-1-(triphenylmethyl)-D-  
 histidyl-N-[2-(phenylmethoxy)ethyl]-O-(phenylmethyl)- (9CI) (CA INDEX  
 NAME)


Absolute stereochemistry.



IT 168174-34-3P 168174-35-4P 168174-49-0P  
 168174-50-3P 168174-51-4P 168174-52-5P  
 168174-53-6P 168174-77-4P 168174-78-5P  
 168174-79-6P 168174-80-9P 168174-90-1P  
 168174-91-2P 168174-98-9P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of substituted di- and tripeptide inhibitors of  
 protein:farnesyl transferase)  
 RN 168174-34-3 CAPLUS  
 CN L-Tyrosinamide, N-[(phenylamino) carbonyl]-D-histidyl-N-[2-  
 (phenylmethoxy)ethyl]-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 168174-35-4 CAPLUS

CN L-Tyrosinamide, N-[(phenylamino)carbonyl]-D-histidyl-O-(phenylmethyl)-N-[2-[(phenylmethyl)thio]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 168174-49-0 CAPLUS

CN L-Tyrosinamide, N-[(4-chlorophenyl)amino]carbonyl]-D-histidyl-N-[2-(phenylmethoxy)ethyl]-O-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 168174-50-3 CAPLUS

CN L-Tyrosinamide, N-[(1-naphthalenylamino)carbonyl]-D-histidyl-N-(phenylmethoxy)-O-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 168174-51-4 CAPLUS

CN L-Methionine, N-[N-[N-[(1-naphthalenylamino)carbonyl]-D-histidyl]-O-(phenylmethyl)-L-tyrosyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 168174-52-5 CAPLUS

CN L-Tyrosinamide, N-[[[(4-chlorophenyl)amino]carbonyl]-D-histidyl-N-(4-phenylbutyl)-O-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 168174-53-6 CAPLUS

CN L-Tyrosinamide, N-[[[(4-chlorophenyl)amino]carbonyl]-D-histidyl-N,O-bis(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 168174-77-4 CAPLUS

CN L-Tyrosinamide, N-[(phenylamino)carbonyl]-D-histidyl-N-(4-phenylbutyl)-O-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 168174-78-5 CAPLUS

CN 1H-Imidazole-4-propanamide, N-[2-oxo-1-[[4-(phenylmethoxy)phenyl]methyl]-2-[4-(phenylmethyl)-1-piperazinyl]ethyl]- $\alpha$ -[[ (phenylamino)carbonyl]amino]-, [R-(R\*,S\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 168174-79-6 CAPLUS

CN L-Tyrosinamide, N-[[ (4-phenoxyphenyl)amino]carbonyl]-D-histidyl-N-(2-phenylethyl)-O-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 168174-80-9 CAPLUS

CN L-Tyrosinamide, N-[[ (4-phenoxyphenyl)amino]carbonyl]-D-histidyl-O-(phenylmethyl)-N-[2-[(phenylmethyl)thio]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 168174-90-1 CAPLUS

CN L-Tyrosinamide, N-[[ (4-chlorophenyl)amino]carbonyl]-D-histidyl-N-(phenylmethoxy)-O-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 168174-91-2 CAPLUS


CN L-Methionine, N-[N-[N-[[ (4-chlorophenyl)amino]carbonyl]-D-histidyl]-O-(phenylmethyl)-L-tyrosyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 168174-98-9 CAPLUS  
 CN 1H-Imidazole-4-propanamide,  $\alpha$ -[[[(4-ethoxyphenyl)amino]carbonyl]amino]-N-[2-oxo-1-[[4-(phenylmethoxy)phenyl]methyl]-2-[4-(phenylmethyl)-1-piperazinyl]ethyl]-, [R-(R\*,S\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 143 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1995:750523 CAPLUS  
 DOCUMENT NUMBER: 123:144652  
 ORIGINAL REFERENCE NO.: 123:25801a,25804a  
 TITLE: Preparation of peptide derivatives as endothelin antagonists.  
 INVENTOR(S): Hemmi, Keiji; Neya, Masahiro; Fukami, Naoki; Kayakiri, Natsuko; Tanaka, Hirokazu  
 PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan  
 SOURCE: PCT Int. Appl., 81 pp.

CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9500537	A1	19950105	WO 1994-JP1042	19940628
W: CA, CN, JP, KR, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2165790	A1	19950105	CA 1994-2165790	19940628
EP 706532	A1	19960417	EP 1994-918587	19940628
EP 706532	B1	20000202		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
CN 1129000	A	19960814	CN 1994-193046	19940628
JP 08511798	T	19961210	JP 1994-502656	19940628
AT 189459	T	20000215	AT 1994-918587	19940628
ES 2141827	T3	20000401	ES 1994-918587	19940628
US 5888972	A	19990330	US 1997-564271	19970624
PRIORITY APPLN. INFO.:				
			GB 1993-13330	A 19930628
			WO 1994-JP1042	W 19940628

OTHER SOURCE(S): MARPAT 123:144652


IT 166738-68-7P 166738-69-8P 166738-70-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of peptide derivs. as endothelin antagonists)

RN 166738-68-7 CAPLUS

CN D-Valine, N-[N-[N-(2-aminoethyl)-N-[(2-chlorophenyl)amino]carbonyl]-L-leucyl]-3-(1-naphthalenyl)-D-alanyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 166738-69-8 CAPLUS

CN D-Valine, N-[N-[N-[(2-chlorophenyl)amino]carbonyl]-N-[2-[(3-pyridinylmethyl)amino]ethyl]-L-leucyl]-3-(1-naphthalenyl)-D-alanyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 166738-70-1 CAPLUS

CN D-Valine, N-[N-[N-[[ (2-chlorophenyl)amino]carbonyl]-N-[2-[(3-pyridinylmethyl)amino]ethyl]-L-leucyl]-3-(1-naphthalenyl)-D-alanyl]- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.



IT 166738-67-6


RL: RCT (Reactant); RACT (Reactant or reagent)  
(preparation of peptide derivs. as endothelin antagonists)

RN 166738-67-6 CAPLUS

CN D-Valine, N-[N-[N-[[ (2-chlorophenyl)amino]carbonyl]-N-[2-[(1,1-dimethylethoxy)carbonyl]amino]ethyl]-L-leucyl]-3-(1-naphthalenyl)-D-alanyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.






REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 144 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1995:700804 CAPLUS  
 DOCUMENT NUMBER: 123:314501  
 ORIGINAL REFERENCE NO.: 123:56399a,56402a  
 TITLE: Linear peptide ETA antagonists: rational design and practical derivatization of N-terminal amino- and imino-carbonylated tripeptide derivatives  
 AUTHOR(S): Nagase, Toshio; Mase, Toshiaki; Fukami, Takehiro; Hayama, Takashi; Fujita, Kagari; Niyama, Kenji; Takahashi, Hirobumi; Kumagai, Uno; Urakawa, Yuko; et al.  
 CORPORATE SOURCE: New Drug Discovery Research Laboratories, Banyu Pharmaceutical Co. Ltd., Tsukuba, 300-33, Japan  
 SOURCE: Bioorganic & Medicinal Chemistry Letters (1995), 5(13), 1395-400  
 CODEN: BMCLE8; ISSN: 0960-894X  
 PUBLISHER: Elsevier  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 123:314501  
 IT 141594-99-2P 141624-45-5P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
 (preparation of linear peptide endothelin antagonists via amination of phenoxycarbonyl tripeptide esters)  
 RN 141594-99-2 CAPLUS  
 CN  $\beta$ -Alanine, N-[N-[N-[(3-chlorophenyl)amino]carbonyl]-L-leucyl]-D-tryptophyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 141624-45-5 CAPLUS

CN  $\beta$ -Alanine, N-[N-[N-[[ (3-methylphenyl)amino]carbonyl]-L-leucyl]-D-tryptophyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 170119-13-8P 170119-14-9P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of linear peptide endothelin antagonists via amination of phenoxycarbonyltri-peptide esters)

RN 170119-13-8 CAPLUS


CN  $\beta$ -Alanine, N-[N-[N-[[ (3-methylphenyl)amino]carbonyl]-L-leucyl]-D-tryptophyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 170119-14-9 CAPLUS  
 CN  $\beta$ -Alanine, N-[N-[N-[(3-chlorophenyl)amino]carbonyl]-L-leucyl]-D-tryptophyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 145 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1995:662328 CAPLUS  
 DOCUMENT NUMBER: 123:83996  
 ORIGINAL REFERENCE NO.: 123:15057a,15060a  
 TITLE: Preparation of amino acid derivatives as neuropeptide Y antagonists.  
 INVENTOR(S): Rudolf, Klaus; Eberlein, Wolfgang; Engel, Wolfhard; Mihm, Gerhard; Doods, Henri; Wieland, Heike-Andrea; Willim, Klaus-Dieter; Krause, Juergen; Dollinger, Horst; et al.  
 PATENT ASSIGNEE(S): Dr. Karl Thomae GmbH, Germany  
 SOURCE: PCT Int. Appl., 308 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9417035	A1	19940804	WO 1994-EP109	19940118
W: AU, BG, BY, CA, CN, CZ, FI, HU, JP, KR, NO, NZ, PL, RO, RU, SK, UA				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
DE 4301452	A1	19940721	DE 1993-4301452	19930120
DE 4326465	A1	19950209	DE 1993-4326465	19930806
AU 9458841	A	19940815	AU 1994-58841	19940118
AU 683442	B2	19971113		
EP 680469	A1	19951108	EP 1994-905073	19940118
EP 680469	B1	20000426		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 08505862	T	19960625	JP 1994-516636	19940118
AT 192142	T	20000515	AT 1994-905073	19940118
FI 9503467	A	19950718	FI 1995-3467	19950718
NO 9502869	A	19950919	NO 1995-2869	19950719
PRIORITY APPLN. INFO.:			DE 1993-4301452	A 19930120
			DE 1993-4326465	A 19930806
			WO 1994-EP109	W 19940118
OTHER SOURCE(S):		MARPAT 123:83996		
IT 164643-49-6P				

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of amino acid derivs. as neuropeptide Y antagonists)

RN 164643-49-6 CAPLUS

CN Pentanamide, N-[(4-hydroxyphenyl)methyl]-5-(1H-imidazol-2-ylamino)-2-[[2-naphthalenylamino)carbonyl]amino]- (CA INDEX NAME)




IT 164647-99-8P 164648-01-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of amino acid derivs. as neuropeptide Y antagonists)

RN 164647-99-8 CAPLUS

CN Carbamic acid, [5-[[[(4-hydroxyphenyl)methyl]amino]-4-[[2-naphthalenylamino)carbonyl]amino]-5-oxopentyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 164648-01-5 CAPLUS

CN Pentanamide, 5-amino-N-[(4-hydroxyphenyl)methyl]-2-[[2-naphthalenylamino)carbonyl]amino]-, acetate (1:1) (CA INDEX NAME)

CM 1


CRN 164648-00-4

CMF C23 H26 N4 O3



CM 2

CRN 64-19-7  
CMF C2 H4 O2



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 146 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 1995:657540 CAPLUS  
DOCUMENT NUMBER: 123:82953  
ORIGINAL REFERENCE NO.: 123:14840h,14841a  
TITLE: Preparation of 2,4-diamino-3-hydroxycarboxylic acid-derivative HIV proteinase inhibitors.  
INVENTOR(S): Billich, Andreas; Charpiot, Brigitte; Ettmayer, Peter; Gstach, Hubert; Lehr, Philipp; Scholz, Dieter  
PATENT ASSIGNEE(S): Sandoz Ltd., Switz.; Sandoz-Patent-G.m.b.H.; Sandoz-Erfindungen Verwaltungsgesellschaft m.b.H.  
SOURCE: Eur. Pat. Appl., 19 pp.  
CODEN: EPXXDW  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 615969	A1	19940921	EP 1994-810150	19940309
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
US 5538997	A	19960723	US 1994-177687	19940103
NO 9400844	A	19940913	NO 1994-844	19940310
AU 9457737	A	19940915	AU 1994-57737	19940310
AU 672867	B2	19961017		
FI 9401149	A	19941222	FI 1994-1149	19940310
CA 2118876	A1	19940913	CA 1994-2118876	19940311
JP 07089919	A	19950404	JP 1994-41047	19940311
JP 3987586	B2	20071010		
CN 1104209	A	19950628	CN 1994-102292	19940311
ZA 9401734	A	19950911	ZA 1994-1734	19940311
HU 71793	A2	19960228	HU 1994-745	19940311
PRIORITY APPLN. INFO.:			GB 1993-5144	A 19930312
			GB 1993-19667	A 19930923

OTHER SOURCE(S): MARPAT 123:82953  
IT 164514-82-3P 164515-00-8P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of 2,4-diamino-3-hydroxycarboxylic acid-derivative HIV proteinase inhibitors)  
RN 164514-82-3 CAPLUS  
CN Benzenepentanamide, N-(2,3-dihydro-2-hydroxy-1H-inden-1-yl)-γ-[[2-[[[(2,4-dimethoxyphenyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]amino]-β-hydroxy-α-[[[(4-methoxyphenyl)methyl]amino]-, [1S-[1α[αS\*,βS\*,γR\*(R\*)],2α]]- (9CI) (CA

INDEX NAME)


Absolute stereochemistry.



RN 164515-00-8 CAPLUS

CN Benzenepentanamide, N-(2,3-dihydro-2-hydroxy-1H-inden-1-yl)-β-hydroxy-γ-[[2-[[[(2-hydroxy-4-methoxyphenyl)amino]carbonyl]amino]-3-methyl-1-oxobutyl]amino]-α-[[4-methoxyphenyl)methyl]amino]-, [1S-[1α[αS\*,βS\*,γR\*(R\*)],2α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 147 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1995:580487 CAPLUS

DOCUMENT NUMBER: 122:315099

ORIGINAL REFERENCE NO.: 122:57325a,57328a


TITLE: Preparation of peptides as novel endothelin antagonists

INVENTOR(S): Ishikawa, Kiyofumi; Fukami, Takehiro; Ihara, Masaki;  
Nishikibe, Masaru; Yano, Mitsuo  
PATENT ASSIGNEE(S): Japan  
SOURCE: PCT Int. Appl., 123 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9419368	A1	19940901	WO 1994-JP194	19940209
W: AU, CA, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9460103	A	19940914	AU 1994-60103	19940209
JP 07041498	A	19950210	JP 1994-35239	19940209
PRIORITY APPLN. INFO.:			JP 1993-57814	A 19930223
			JP 1993-144216	A 19930524
			WO 1994-JP194	W 19940209


OTHER SOURCE(S): MARPAT 122:315099  
IT 163445-85-0P 163445-86-1P 163445-87-2P  
163445-88-3P 163445-89-4P 163445-90-7P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of peptides as endothelin receptor antagonists)  
RN 163445-85-0 CAPLUS  
CN D-Norleucine, N-[2-bromo-N-[N-[(2-methoxyphenyl)amino]carbonyl]-L-leucyl]-D-tryptophyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN	163445-86-1	CAPLUS
CN	D-Norleucine, N-[2-bromo-N-[N-[(2-methoxyphenyl)amino]carbonyl]-L-leucyl]-D-tryptophyl]- (9CI) (CA INDEX NAME)	

Absolute stereochemistry.




RN 163445-87-2 CAPLUS  
 CN D-Norleucine, N-[2-bromo-N-[N-[(phenylamino)carbonyl]-L-leucyl]-D-tryptophyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 163445-88-3 CAPLUS  
 CN D-Norleucine, N-[2-bromo-N-[N-[(phenylamino)carbonyl]-L-leucyl]-D-tryptophyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 163445-89-4 CAPLUS  
 CN D-Norleucine, N-[2-bromo-N-[N-[(2-chlorophenyl)amino]carbonyl]-L-leucyl]-D-tryptophyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.





RN 163445-90-7 CAPLUS  
 CN D-Norleucine, N-[2-bromo-N-[N-[(2-chlorophenyl)amino]carbonyl]-L-leucyl]-  
 D-tryptophyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 148 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1995:435611 CAPLUS  
 DOCUMENT NUMBER: 122:214520  
 ORIGINAL REFERENCE NO.: 122:39239a,39242a  
 TITLE: Peptide alcohol or aldehyde derivatives as cathepsin L  
 inhibitors and bone resorption inhibitors  
 INVENTOR(S): Sohda, Takashi; Fujisawa, Yukio; Yasuma, Tsuneo;  
 Mizoguchi, Junji; Kori, Masakuni; Takizawa, Masayuki  
 PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan  
 SOURCE: Eur. Pat. Appl., 62 pp.  
 CODEN: EPXXDW  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 611756	A2	19940824	EP 1994-102404	19940217
EP 611756	A3	19941130		
EP 611756	B1	20030507		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
JP 07101924	A	19950418	JP 1994-11081	19940202
JP 2848232	B2	19990120		
JP 09208545	A	19970812	JP 1996-292418	19940202
US 5498728	A	19960312	US 1994-192038	19940204
AU 9454964	A	19940825	AU 1994-54964	19940207
CA 2115913	A1	19940820	CA 1994-2115913	19940217
NO 9400550	A	19940822	NO 1994-550	19940217
AT 239705	T	20030515	AT 1994-102404	19940217
FI 9400788	A	19940820	FI 1994-788	19940218
HU 66219	A2	19941028	HU 1994-473	19940218
CN 1107363	A	19950830	CN 1994-101373	19940218
US 5639781	A	19970617	US 1995-495814	19950627
US 5716980	A	19980210	US 1995-495097	19950627
US 5955491	A	19990921	US 1995-495352	19950627

PRIORITY APPLN. INFO.:

JP 1993-30182	A	19930219
JP 1993-197305	A	19930809
JP 1994-11081	A3	19940202
US 1994-192038	A3	19940204

OTHER SOURCE(S): MARPAT 122:214520

IT 161708-77-6P 161708-81-2P 161708-93-6P  
161709-52-0P 161709-68-8P 161709-82-6P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of peptide alc. and aldehyde derivs. as inhibitors of cathepsin L and bone resorption)

RN 161708-77-6 CAPLUS

CN Pentanamide, N-[(1S)-2-hydroxy-1-(1H-indol-3-ylmethyl)ethyl]-3-methyl-2-[[[(3-methylphenyl)amino]carbonyl]amino]-, (2S,3S)- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 161708-81-2 CAPLUS


CN Pentanamide, N-[(1S)-2-hydroxy-1-(1H-indol-3-ylmethyl)ethyl]-3-methyl-2-[[[2-(trifluoromethyl)phenyl]amino]carbonyl]amino]-, (2S,3S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 161708-93-6 CAPLUS  
 CN Pentanamide, N-[2-hydroxy-1-(1H-indol-3-ylmethyl)ethyl]-3-methyl-2-[[ (1-naphthalenylamino)carbonyl]amino]-, [2S-[1(R\*),2R\*,3R\*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 161709-52-0 CAPLUS  
 CN Pentanamide, N-[(1S)-1-formyl-2-(1H-indol-3-yl)ethyl]-3-methyl-2-[[[(3-methylphenyl)amino]carbonyl]amino]-, (2S,3S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 161709-68-8 CAPLUS  
 CN Pentanamide, N-[(1S)-1-formyl-2-(1H-indol-3-yl)ethyl]-3-methyl-2-[[[2-(trifluoromethyl)phenyl]amino]carbonyl]amino]-, (2S,3S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 161709-82-6 CAPLUS  
 CN Pentanamide, N-[(1S)-1-formyl-2-(1H-indol-3-yl)ethyl]-3-methyl-2-[[ (1-naphthalenylamino)carbonyl]amino]-, (2S,3S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L5 ANSWER 149 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1995:397079 CAPLUS  
 DOCUMENT NUMBER: 122:161379  
 ORIGINAL REFERENCE NO.: 122:29769a,29772a  
 TITLE: Preparation of amidinophenylureidoalkylamide peptide analogs useful as platelet aggregation inhibitors.  
 INVENTOR(S): Tjoeng, Foe S.; Toth, Mihaly V.; McMackins, Dudley E.; Adams, Steven P.  
 PATENT ASSIGNEE(S): Monsanto Co., USA  
 SOURCE: U.S., 21 pp.  
 CODEN: USXXAM  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5314902	A	19940524	US 1993-9526	19930127
WO 9417041	A1	19940804	WO 1994-US511	19940124
W: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, LV, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US, UZ, VN				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9460286	A	19940815	AU 1994-60286	19940124
US 5475025	A	19951212	US 1994-202148	19940223
US 5624956	A	19970429	US 1995-449446	19950524

PRIORITY APPLN. INFO.:

US 1993-9526

A 19930127

WO 1994-US511

W 19940124

US 1994-202148

A3 19940223

OTHER SOURCE(S): MARPAT 122:161379

IT 161354-97-8P 161354-98-9P 161355-00-6P

161355-02-8P 161355-29-9P 161355-30-2P

161355-31-3P 161355-32-4P 161355-33-5P


161355-63-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of, as blood platelet aggregation inhibitor)

RN 161354-97-8 CAPLUS

CN  $\beta$ -Alanine, N-[N-[[[4-(aminoiminomethyl)phenyl]amino]carbonyl]-L-valyl]-3-(3-pyridinyl)-, ethyl ester, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 161354-98-9 CAPLUS

CN  $\beta$ -Alanine, N-[N-[[[4-(aminoiminomethyl)phenyl]amino]carbonyl]-L-valyl]-3-(3-pyridinyl)-, ethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 161355-00-6 CAPLUS


CN  $\beta$ -Alanine, N-[N-[[[4-(aminoiminomethyl)phenyl]amino]carbonyl]-L-valyl]-3-(3-pyridinyl)-, (S)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 161354-99-0

CMF C21 H26 N6 O4


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 161355-02-8 CAPLUS


CN  $\beta$ -Alanine, N-[N-[[[4-(aminoiminomethyl)phenyl]amino]carbonyl]-L-valyl]-3-(3-pyridinyl)-, (R)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 161355-01-7

CMF C21 H26 N6 O4


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 161355-29-9 CAPLUS

CN  $\beta$ -Alanine, N-[N-[[[4-(aminoiminomethyl)phenyl]amino]carbonyl]-L-leucyl]-3-(3-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 161355-30-2 CAPLUS

CN  $\beta$ -Alanine, N-[N-[[[4-(aminoiminomethyl)phenyl]amino]carbonyl]-L-leucyl]-3-(3-pyridinyl)-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 161355-31-3 CAPLUS  
 CN  $\beta$ -Alanine, N-[N-[[[4-(aminoiminomethyl)phenyl]amino]carbonyl]-L-leucyl]-3-(3-pyridinyl)-, (S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 161355-30-2  
 CMF C22 H28 N6 O4

Absolute stereochemistry.



CM 2


CRN 76-05-1  
 CMF C2 H F3 O2



RN 161355-32-4 CAPLUS  
 CN  $\beta$ -Alanine, N-[N-[[[4-(aminoiminomethyl)phenyl]amino]carbonyl]-L-leucyl]-3-(3-pyridinyl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 161355-33-5 CAPLUS  
 CN  $\beta$ -Alanine, N-[N-[[[4-(aminoiminomethyl)phenyl]amino]carbonyl]-L-leucyl]-(R)-3-(3-pyridinyl)-, (R)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 161355-32-4  
 CMF C22 H28 N6 O4

Absolute stereochemistry.




CM 2

CRN 76-05-1  
 CMF C2 H F3 O2




RN 161355-63-1 CAPLUS  
 CN  $\beta$ -Alanine, N-[N-[[[4-(aminoiminomethyl)phenyl]amino]carbonyl]-L-valyl]-3-(3-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 161355-71-1P 161355-72-2P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of, as intermediate for blood platelet aggregation inhibitor)  
 RN 161355-71-1 CAPLUS  
 CN  $\beta$ -Alanine, N-[N-[[4-cyanophenyl]amino]carbonyl]-L-valyl]-3-(3-pyridinyl)-, ethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 161355-72-2 CAPLUS  
 CN  $\beta$ -Alanine, N-[N-[[4-cyanophenyl]amino]carbonyl]-L-valyl]-3-(3-pyridinyl)-, ethyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 161355-82-4P 161355-85-7P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation of, as intermediate for blood platelet aggregation inhibitor)  
 RN 161355-82-4 CAPLUS  
 CN  $\beta$ -Alanine, N-[N-[[[4-(ethoxyiminomethyl)phenyl]amino]carbonyl]-L-  
 valyl]-3-(3-pyridinyl)-, ethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 161355-85-7 CAPLUS  
 CN  $\beta$ -Alanine, N-[N-[[[4-(ethoxyiminomethyl)phenyl]amino]carbonyl]-L-  
 valyl]-3-(3-pyridinyl)-, ethyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 150 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1994:681232 CAPLUS  
 DOCUMENT NUMBER: 121:281232  
 ORIGINAL REFERENCE NO.: 121:51355a,51358a  
 TITLE: Preparation of peptide endothelin antagonists  
 INVENTOR(S): Ishikawa, Kiyofumi; Fukami, Takehiro; Nagase, Toshio;  
 Mase, Toshiaki; Ihara, Masaki; Yano, Mitsuo;  
 Nishikibe, Masaru

PATENT ASSIGNEE(S): Banyu Pharmaceutical Co., Ltd., Japan  
 SOURCE: Can. Pat. Appl., 182 pp.  
 CODEN: CPXXEB  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 3  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CA 2084163	A1	19930605	CA 1992-2084163	19921130
CA 2084163	C	20040629		
EP 555537	A2	19930818	EP 1992-120225	19921126
EP 555537	A3	19941102		
EP 555537	B1	20001102		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
AT 197305	T	20001115	AT 1992-120225	19921126
AU 9229838	A	19930610	AU 1992-29838	19921202
AU 657585	B2	19950316		
JP 06107680	A	19940419	JP 1992-349905	19921202
JP 3398992	B2	20030421		
KR 230630	B1	19991115	KR 1992-23363	19921204
PRIORITY APPLN. INFO.:			JP 1991-347670	A 19911204
			JP 1991-353738	A 19911218
			JP 1992-234207	A 19920810

OTHER SOURCE(S): MARPAT 121:281232


IT 158739-43-6P 158739-44-7P 158739-57-2P  
 158739-58-3P 158739-59-4P 158739-60-7P  
 158739-61-8P 158739-62-9P 158739-63-0P  
 158739-64-1P 158739-65-2P 158739-85-6P  
 158739-91-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
 (preparation of, as endothelin antagonist)

RN 158739-43-6 CAPLUS

CN D-Norleucine, N-[N-[N-[(2-chlorophenyl)amino]carbonyl]-L-leucyl]-1-(methoxycarbonyl)-D-tryptophyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 158739-44-7 CAPLUS

CN D-Norleucine, N-[N-[N-[(2-chlorophenyl)amino]carbonyl]-L-leucyl]-1-(ethoxycarbonyl)-D-tryptophyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 158739-57-2 CAPLUS

CN D-Norleucine, N-[3-benzo[b]thien-3-yl-N-[N-[(2-chlorophenyl)amino]carbonyl]-L-leucyl]-D-alanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 158739-58-3 CAPLUS

CN D-Norleucine, N-[[ (2-chlorophenyl)amino]carbonyl]-L-leucyl-3-(ethoxycarbonyl)phenylalanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 158739-59-4 CAPLUS

CN D-Norleucine, N-[[[(2-chlorophenyl)amino]carbonyl]-L-leucyl-3-(methoxycarbonyl)phenylalanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 158739-60-7 CAPLUS

CN D-Norleucine, N-[N-[N-[[[(2,6-dichlorophenyl)amino]carbonyl]-L-leucyl]-1-(methoxycarbonyl)-D-tryptophyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 158739-61-8 CAPLUS


CN D-Norleucine, N-[N-[N-[[[(2-fluorophenyl)amino]carbonyl]-L-leucyl]-1-(methoxycarbonyl)-D-tryptophyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 158739-62-9 CAPLUS  
 CN D-Norleucine, N-[1-(methoxycarbonyl)-N-[N-[[2-(trifluoromethyl)phenyl]amino]carbonyl]-L-leucyl]-D-tryptophyl]- (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.



RN 158739-63-0 CAPLUS  
 CN D-Norleucine, N-[1-(methoxycarbonyl)-N-[N-[[2-nitrophenyl]amino]carbonyl]-L-leucyl]-D-tryptophyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 158739-64-1 CAPLUS  
 CN D-Norleucine, N-[N-[N-[[2-aminophenyl]amino]carbonyl]-L-leucyl]-1-

(methoxycarbonyl)-D-tryptophyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 158739-65-2 CAPLUS

CN D-Norleucine, N-[N-[N-[[[2-(formylamino)phenyl]amino]carbonyl]-L-leucyl]-1-(methoxycarbonyl)-D-tryptophyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 158739-85-6 CAPLUS

CN D-Norleucine, N-[1-(methoxycarbonyl)-N-[N-[(2-pyridinylamino)carbonyl]-L-leucyl]-D-tryptophyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 158739-91-4 CAPLUS

CN D-Norleucine, N-[N-[2-[[[(2-chlorophenyl)amino]carbonyl]oxy]-4-methyl-1-oxopentyl]-1-(methoxycarbonyl)-D-tryptophyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 158741-09-4P 158741-14-1P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of, as intermediate for endothelin antagonist)

RN 158741-09-4 CAPLUS


CN D-Norleucine, N-[3-benzo[b]thien-3-yl-N-[N-[[[(2-chlorophenyl)amino]carbonyl]-L-leucyl]-D-alanyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 158741-14-1 CAPLUS  
 CN D-Norleucine, N-[N-[N-[(2,6-dichlorophenyl)amino]carbonyl]-L-leucyl]-1-(methoxycarbonyl)-D-tryptophyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 151 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1994:681224 CAPLUS  
 DOCUMENT NUMBER: 121:281224  
 ORIGINAL REFERENCE NO.: 121:51355a,51358a  
 TITLE: Preparation of peptide derivs. as endothelin receptor antagonists  
 INVENTOR(S): Kitaka, Chieko; Ohtaki, Tetsuya; Fujino, Masahiko  
 PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan  
 SOURCE: Can. Pat. Appl., 74 pp.  
 CODEN: CPXXEB  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CA 2086079	A1	19930628	CA 1992-2086079	19921222
US 5614497	A	19970325	US 1992-992131	19921217

EP 552489	A2	19930728	EP 1992-121908	19921223
EP 552489	A3	19940216		
EP 552489	B1	19980304		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
AT 163649	T	19980315	AT 1992-121908	19921223
JP 06172384	A	19940621	JP 1992-344252	19921224
PRIORITY APPLN. INFO.:			JP 1991-346659	A 19911227
			JP 1992-12013	A 19920127
			JP 1992-269932	A 19921008

OTHER SOURCE(S): MARPAT 121:281224

IT 158803-49-7P 158804-00-3P 158804-01-4P  
158804-02-5P 158804-03-6P


RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of, as endothelin receptor antagonist)

RN 158803-49-7 CAPLUS

CN D-Phenylalanine, N-[N-[N-[N-[N-[N-(phenylamino)carbonyl]-L-leucyl]-D-tryptophyl]-D-alanyl]-β-alanyl]-L-tyrosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B


—OH

RN 158804-00-3 CAPLUS

CN D-Tyrosine, N-[N-[N-[N-[N-(phenylamino)carbonyl]-L-leucyl]-D-tryptophyl]-D-alanyl]-β-alanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B


—OH

RN 158804-01-4 CAPLUS

CN L-Tyrosine, N-[N-[N-[N-[N-[(phenylamino)carbonyl]-L-leucyl]-D-tryptophyl]-D-alanyl]-β-alanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—OH

RN 158804-02-5 CAPLUS

CN D-Phenylalanine, N-[N-[N-[N-[N-[(phenylamino)carbonyl]-L-leucyl]-D-tryptophyl]-D-alanyl]-β-alanyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 158804-03-6 CAPLUS

CN L-Phenylalanine, N-[N-[N-[N-[N-[(phenylamino)carbonyl]-L-leucyl]-D-tryptophyl]-D-alanyl]-β-alanyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L5 ANSWER 152 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1994:681219 CAPLUS  
 DOCUMENT NUMBER: 121:281219  
 ORIGINAL REFERENCE NO.: 121:51351a,51354a  
 TITLE: Preparation of N-(heterocyclalkyl)valineamides and  
 analogs as agrochemical fungicides  
 INVENTOR(S): Shibata, Masaru; Ito, Shigekazu; Sakai, Junetsu;  
 Hayashi, Shigeru  
 PATENT ASSIGNEE(S): Kumiai Chemical Industry Co., Ltd., Japan; Ihara  
 Chemical Industry Co., Ltd.  
 SOURCE: Eur. Pat. Appl., 63 pp.  
 CODEN: EPXXDW  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 587110	A2	19940316	EP 1993-114325	19930907
EP 587110	A3	19940525		
EP 587110	B1	19971217		
R: DE, FR, IT				
JP 06279405	A	19941004	JP 1993-208258	19930730
JP 3283114	B2	20020520		
RU 2098408	C1	19971210	RU 1993-51174	19930906
CN 1086810	A	19940518	CN 1993-119072	19930907
CN 1036195	C	19971022		
US 5348976	A	19940920	US 1993-117284	19930907
KR 139185	B1	19980515	KR 1993-17947	19930907
CN 1149054	A	19970507	CN 1996-111474	19960730
CN 1062270	C	20010221		
CN 1154964	A	19970723	CN 1996-111473	19960730
CN 1062264	C	20010221		
PRIORITY APPLN. INFO.:			JP 1992-262718	A 19920907
			JP 1993-31117	A 19930128
			JP 1993-208258	A 19930730

OTHER SOURCE(S): MARPAT 121:281219  
 IT 159007-68-8P  
 RL: AGR (Agricultural use); BAC (Biological activity or effector, except  
 adverse); BSU (Biological study, unclassified); SPN (Synthetic  
 preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of, as agrochem. fungicide)  
 RN 159007-68-8 CAPLUS  
 CN Butanamide, N-[1-(5-chloro-2-benzofuranyl)ethyl]-2-[[[(4-  
 chlorophenyl)amino]carbonyl]amino]-3-methyl- (CA INDEX NAME)



L5 ANSWER 153 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1994:645108 CAPLUS  
 DOCUMENT NUMBER: 121:245108  
 ORIGINAL REFERENCE NO.: 121:44443a,44446a  
 TITLE: Genetically Evolved Receptor Models: A Computational Approach to Construction of Receptor Models  
 AUTHOR(S): Walters, D. Eric; Hinds, R. Michael  
 CORPORATE SOURCE: Chicago Medical School, Finch University of Health Sciences, North Chicago, IL, 60064-3095, USA  
 SOURCE: Journal of Medicinal Chemistry (1994), 37(16), 2527-36  
 CODEN: JMCMAR; ISSN: 0022-2623  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 IT 135507-50-5, Superaspartame  
 RL: PRP (Properties)  
 (receptor interaction of, structure in relation to)  
 RN 135507-50-5 CAPLUS  
 CN L-Phenylalanine, N-[[[(4-cyanophenyl)amino]carbonyl]-L- $\alpha$ -aspartyl-, 2-methyl ester (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 154 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1994:474659 CAPLUS  
 DOCUMENT NUMBER: 121:74659  
 ORIGINAL REFERENCE NO.: 121:13211a,13214a  
 TITLE: Basic derivatives of glutamic acid and aspartic acid as gastrin or cholecystokinin antagonists  
 INVENTOR(S): Makovec, Francesco; Rovati, Claudio; Rovati, Angelo  
 PATENT ASSIGNEE(S): Rotta Research Laboratorium S.p.A., Italy  
 SOURCE: PCT Int. Appl., 40 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

WO 9321172	A1	19931028	WO 1993-EP842	19930406
W: CA, JP, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, PT, SE				
CA 2132537	C	19931028	CA 1993-2132537	19930406
EP 636125	A1	19950201	EP 1993-908910	19930406
EP 636125	B1	19980311		
R: AT, BE, CH, DE, DK, ES, FR, GB, IE, IT, LI, NL, PT, SE				
JP 07505641	T	19950622	JP 1993-517948	19930406
JP 3614851	B2	20050126		
AT 163928	T	19980315	AT 1993-908910	19930406
ES 2115058	T3	19980616	ES 1993-908910	19930406
US 5587479	A	19961224	US 1994-318651	19941011
US 5744607	A	19980428	US 1996-733568	19961018
PRIORITY APPLN. INFO.:				
			IT 1992-TO325	A 19920409
			IT 1992-325	A 19920409
			WO 1993-EP842	W 19930406
			US 1994-318651	A3 19941011

OTHER SOURCE(S): MARPAT 121:74659

IT 152463-12-2P

RL: PREP (Preparation)


(preparation of, for therapeutic gastrin/cholecystokinin antagonist)

RN 152463-12-2 CAPLUS

CN Pentanediamide, 2-[[[(3-chlorophenyl)amino]carbonyl]amino]-N5-[2-(4-morpholinyl)ethyl]-N1-(2-tricyclo[3.3.1.1<sup>3,7</sup>]dec-1-ylethyl)-, (R)- (9CI)

(CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 155 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1994:410003 CAPLUS

DOCUMENT NUMBER: 121:10003

ORIGINAL REFERENCE NO.: 121:2116h,2117a

TITLE: Preparation of peptides by reaction of olefinic alcohol and enol ether for treatment of tachypnea and myocardial reperfusion injury.

INVENTOR(S): Itsumi, Keiji; Kei, Seihaku; Fukami, Jikiki; Hashihon, Sanashi

PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 131 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

JP 05208914	A	19930820	JP 1992-233604	19920901
US 5430022	A	19950704	US 1993-86094	19930706
US 5656604	A	19970812	US 1995-422944	19950417

PRIORITY APPLN. INFO.:

US 1991-753997	A	19910903
GB 1990-10740	A	19900514
GB 1990-26254	A	19901203
GB 1991-4064	A	19910227
US 1991-696701	A2	19910507
US 1992-845056	B1	19920303
US 1993-86094	A3	19930706

OTHER SOURCE(S): MARPAT 121:10003


IT 142375-44-8P 142375-45-9P 142375-80-2P  
 142376-24-7P 142376-25-8P 142376-26-9P  
 142376-27-0P 142376-28-1P 142376-29-2P  
 142376-50-9P 142376-93-0P 142376-94-1P  
 142376-95-2P 142376-96-3P 142376-97-4P  
 142377-16-0P 142378-22-1P 142378-58-3P  
 142379-00-8P 142409-01-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of, for treatment of tachypnea and myocardial reperfusion injury)

RN 142375-44-8 CAPLUS

CN D-Phenylalanine, N-[1-methyl-N-[N-[(phenylamino)carbonyl]-L-leucyl]-D-tryptophyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 142375-45-9 CAPLUS

CN D-Phenylalanine, N-[1-methyl-N-[N-[(phenylamino)carbonyl]-L-leucyl]-D-tryptophyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 142375-80-2 CAPLUS

CN D-Alanine, N-[1-methyl-N-[N-[(2-pyridinylamino)carbonyl]-L-leucyl]-D-tryptophyl]-3-(2-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 142376-24-7 CAPLUS

CN D-Alanine, N-[1-methyl-N-[N-[(phenylamino)carbonyl]-L-leucyl]-D-tryptophyl]-3-(2-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 142376-25-8 CAPLUS

CN D-Alanine, N-[N-[N-[(4-methoxyphenyl)amino]carbonyl]-L-leucyl]-1-methyl-D-tryptophyl]-3-(2-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 142376-26-9 CAPLUS

CN D-Alanine, N-[1-methyl-N-[N-[(4-methylphenyl)amino]carbonyl]-L-leucyl]-D-tryptophyl]-3-(2-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 142376-27-0 CAPLUS

CN D-Alanine, N-[N-[N-[(4-chlorophenyl)amino]carbonyl]-L-leucyl]-1-methyl-D-tryptophyl]-3-(2-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 142376-28-1 CAPLUS

CN D-Alanine, N-[N-[N-[(3-chlorophenyl)amino]carbonyl]-L-leucyl]-1-methyl-D-

tryptophyl]-3-(2-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 142376-29-2 CAPLUS

CN D-Alanine, N-[N-[N-[(2-chlorophenyl)amino]carbonyl]-L-leucyl]-1-methyl-D-tryptophyl]-3-(2-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 142376-50-9 CAPLUS

CN D-Alanine, N-[1-methyl-N-[N-[(2-pyridinylamino)carbonyl]-L-leucyl]-D-tryptophyl]-3-(2-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 2 HCl

RN 142376-93-0 CAPLUS  
 CN D-Alanine, N-[1-methyl-N-[N-[(phenylamino)carbonyl]-L-leucyl]-D-tryptophyl]-3-(2-pyridinyl)-, monosodium salt (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● Na

RN 142376-94-1 CAPLUS  
 CN D-Alanine, N-[N-[N-[(4-methoxyphenyl)amino]carbonyl]-L-leucyl]-1-methyl-D-tryptophyl]-3-(2-pyridinyl)-, monosodium salt (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● Na

RN 142376-95-2 CAPLUS  
 CN D-Alanine, N-[1-methyl-N-[N-[(4-methylphenyl)amino]carbonyl]-L-leucyl]-D-tryptophyl]-3-(2-pyridinyl)-, monosodium salt (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● Na

RN 142376-96-3 CAPLUS  
 CN D-Alanine, N-[N-[N-[(3-chlorophenyl)amino]carbonyl]-L-leucyl]-1-methyl-D-tryptophyl]-3-(2-pyridinyl)-, monosodium salt (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● Na

RN 142376-97-4 CAPLUS  
 CN D-Alanine, N-[N-[N-[(2-chlorophenyl)amino]carbonyl]-L-leucyl]-1-methyl-D-tryptophyl]-3-(2-pyridinyl)-, monosodium salt (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● Na

RN 142377-16-0 CAPLUS  
 CN D-Leucine, N-[N-[N-[(2-chlorophenyl)amino]carbonyl]-L-leucyl]-1-methyl-D-tryptophyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 142378-22-1 CAPLUS

CN D-Leucine, N-[N-[N-[(2-chlorophenyl)amino]carbonyl]-L-leucyl]-1-methyl-D-tryptophyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 142378-58-3 CAPLUS

CN  $\beta$ -Alanine, N-[N-[N-[N-[(2-chlorophenyl)amino]carbonyl]-L-leucyl]-1-methyl-D-tryptophyl]-3-(2-pyridinyl)-D-alanyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 142379-00-8 CAPLUS

CN  $\beta$ -Alanine, N-[N-[N-[N-[(2-chlorophenyl)amino]carbonyl]-L-leucyl]-1-methyl-D-tryptophyl]-3-(2-pyridinyl)-D-alanyl]-, phenylmethyl ester (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 142409-01-6 CAPLUS

CN D-Alanine, N-[N-[N-[(4-chlorophenyl)amino]carbonyl]-L-leucyl]-1-methyl-D-tryptophyl]-3-(2-pyridinyl)-, monosodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Na

L5 ANSWER 156 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1994:271187 CAPLUS

DOCUMENT NUMBER: 120:271187

ORIGINAL REFERENCE NO.: 120:48075a, 48078a

TITLE: Preparation of antiherpes peptide derivatives having a ureido N-terminus

INVENTOR(S): Deziel, Robert; Moss, Neil; Plante, Raymond

PATENT ASSIGNEE(S): Bio-Mega/Boehringer Ingelheim Research Inc., Can.

SOURCE: Eur. Pat. Appl., 27 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 560274	A1	19930915	EP 1993-103734	19930309
EP 560274	B1	19980624		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
AT 167682	T	19980715	AT 1993-103734	19930309
ZA 9301746	A	19931006	ZA 1993-1746	19930311
HU 63853	A2	19931028	HU 1993-697	19930311
JP 06041189	A	19940215	JP 1993-49767	19930311
CA 2092652	A1	19930913	CA 1993-2092652	19930312
CA 2092652	C	20010724		
AU 9335162	A	19930916	AU 1993-35162	19930312
AU 665059	B2	19951214		
CN 1096299	A	19941214	CN 1993-106796	19930608
US 5830864	A	19981103	US 1995-502981	19950717
PRIORITY APPLN. INFO.:			US 1992-849922	A 19920312
			US 1993-25682	B1 19930303


OTHER SOURCE(S): MARPAT 120:271187

IT 154092-87-2P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of, as virucide for treating herpes infections)

RN 154092-87-2 CAPLUS

CN Glycinamide, 3-methyl-N-[(phenylamino)carbonyl]-L-valyl-4-oxo-4-(1-pyrrolidinyl)-L-2-aminobutanoyl-L-2-(1-carboxycyclopentyl)-N-[1-(hydroxymethyl)-3,3-dimethylbutyl]-, (S)- (9CI) (CA INDEX NAME)



L5 ANSWER 157 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1994:105457 CAPLUS

DOCUMENT NUMBER: 120:105457

ORIGINAL REFERENCE NO.: 120:18599a,18602a

TITLE: Taste modifying compounds and compositions for foods and eatables

INVENTOR(S): Kurtz, Robert J. M. D.; Fuller, William D.

PATENT ASSIGNEE(S): Bioreseach, Inc., USA

SOURCE: PCT Int. Appl., 246 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9310677	A1	19930610	WO 1992-US10179	19921124

W: AU, BB, BG, BR, CA, CS, FI, HU, JP, KP, KR, LK, MG, MW, NO, PL,			
RO, RU, SD, US			
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE			
US 5232735	A	19930803	US 1990-531388 19900601
ZA 9103666	A	19920527	ZA 1991-3666 19910515
CA 2064707	A1	19911202	CA 1991-2064707 19910517
WO 9118523	A1	19911212	WO 1991-US3441 19910517
W: AU, BG, BR, CA, FI, HU, JP, KP, KR, NO, PL, RO, SU			
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE			
AU 9179610	A	19911231	AU 1991-79610 19910517
AU 648804	B2	19940505	
EP 485587	A1	19920520	EP 1991-911565 19910517
EP 485587	B1	19961002	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE			
BR 9105778	A	19920804	BR 1991-5778 19910517
JP 05500756	T	19930218	JP 1991-510227 19910517
HU 64452	A2	19940128	HU 1992-673 19910517
RO 109690	B1	19950530	RO 1991-910022 19910517
RU 2050795	C1	19951227	RU 1991-5011414 19910517
EP 727149	A2	19960821	EP 1996-200731 19910517
EP 727149	A3	20000503	
R: BE, DE, ES, FR, GB, IT, NL			
EP 727150	A2	19960821	EP 1996-200732 19910517
EP 727150	A3	20000503	
R: BE, DE, ES, FR, GB, IT, NL			
EP 727151	A2	19960821	EP 1996-200733 19910517
EP 727151	A3	20000503	
R: BE, DE, ES, FR, GB, IT, NL			
EP 727152	A2	19960821	EP 1996-200735 19910517
EP 727152	A3	20000503	
R: BE, DE, ES, FR, GB, IT, NL			
EP 728419	A2	19960828	EP 1996-200734 19910517
EP 728419	A3	20000503	
R: BE, DE, ES, FR, GB, IT, NL			
RO 111240	B1	19960830	RO 1995-571 19910517
AT 143569	T	19961015	AT 1991-911565 19910517
ES 2093105	T3	19961216	ES 1991-911565 19910517
IL 98241	A	19950731	IL 1991-98241 19910523
CN 1060770	A	19920506	CN 1991-103647 19910601
CN 1029932	C	19951011	
NO 9200419	A	19920311	NO 1992-419 19920131
AU 9332250	A	19930628	AU 1993-32250 19921124
AU 675778	B2	19970220	
JP 07504810	T	19950601	JP 1992-510237 19921124
EP 661932	A1	19950712	EP 1993-900657 19921124
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE			
HU 68764	A2	19950728	HU 1994-1598 19921124
NO 9401972	A	19940714	NO 1994-1972 19940526
FI 9402463	A	19940726	FI 1994-2463 19940526
US 5631038	A	19970520	US 1994-244306 19941121
US 5637618	A	19970610	US 1995-451063 19950525
US 5631294	A	19970520	US 1995-454712 19950531
US 5631231	A	19970520	US 1995-455989 19950531
US 5643955	A	19970701	US 1995-454713 19950531
US 5631232	A	19970520	US 1995-457783 19950601
US 5646122	A	19970708	US 1995-456796 19950601
US 5631292	A	19970520	US 1995-460581 19950602
US 5641811	A	19970624	US 1995-459702 19950602
US 5643894	A	19970701	US 1995-459703 19950602
US 5643956	A	19970701	US 1995-459706 19950602
US 5643941	A	19970701	US 1995-460260 19950602
US 5631295	A	19970520	US 1995-461563 19950605






RN 150463-84-6 CAPLUS

CN L-Phenylalanine, N-[N-[(4-nitrophenyl)amino]carbonyl]-L-α-aspartyl-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 150463-99-3 CAPLUS

CN L-Phenylalanine, N-[N-[(4-cyanophenyl)amino]carbonyl]-L-α-aspartyl-  
, potassium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● x K

IT 135507-50-5


RL: BIOL (Biological study)

(taste modifying compound or composition for removal of undesirable taste from)

RN 135507-50-5 CAPLUS


CN L-Phenylalanine, N-[(4-cyanophenyl)amino]carbonyl]-L-α-aspartyl-,  
2-methyl ester (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 158 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1993:617620 CAPLUS  
 DOCUMENT NUMBER: 119:217620  
 ORIGINAL REFERENCE NO.: 119:38537a,38540a  
 TITLE: Cholecystokinin peptidomimetics as selective CCK-B antagonists: Design, synthesis, and in vitro and in vivo biochemical properties  
 AUTHOR(S): Blommaert, Armand G. S.; Weng, Jian Hui; Dorville, Agnes; McCort, Isabelle; Ducos, Bertrand; Durieux, Christine; Roques, Bernard P.  
 CORPORATE SOURCE: Fac. Pharm., Univ. Rene Descartes, Paris, 75270, Fr.  
 SOURCE: Journal of Medicinal Chemistry (1993), 36(20), 2868-77  
 CODEN: JMCMAR; ISSN: 0022-2623  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 IT 150871-20-8P 150871-29-7P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation and cholecystokinin B receptor binding inhibition by)  
 RN 150871-20-8 CAPLUS  
 CN 1H-Indole-3-propanamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]- $\alpha$ -methyl-N-(2-phenylethyl)- (CA INDEX NAME)




RN 150871-29-7 CAPLUS  
 CN 1H-Indole-3-propanamide,  $\alpha$ -methyl- $\alpha$ -[[[(2-naphthalenylamino)carbonyl]amino]-N-(2-phenylethyl)- (CA INDEX NAME)




L5 ANSWER 159 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1993:539759 CAPLUS  
 DOCUMENT NUMBER: 119:139759  
 ORIGINAL REFERENCE NO.: 119:25099a,25102a  
 TITLE: Bioactive and model peptides characterized by the  
 helicogenic ( $\alpha$ Me)Phe residue  
 AUTHOR(S): Toniolo, Claudio; Formaggio, Fernando; Crisma, Marco;  
 Valle, Giovanni; Boesten, Wilhelmus H. J.; Schoemaker,  
 Hans E.; Kamphuis, Johan; Temussi, Piero A.; Becker,  
 Elmer L.; Precigoux, Gilles  
 CORPORATE SOURCE: Biopolym. Res. Cent., CNR, Padua, 35131, Italy  
 SOURCE: Tetrahedron (1993), 49(17), 3641-53  
 CODEN: TETRAB; ISSN: 0040-4020  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 IT 149673-32-5P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation and acidic deblocking of)  
 RN 149673-32-5 CAPLUS  
 CN L-Phenylalanine, N-[N-[(4-cyanophenyl)amino]carbonyl]-L- $\alpha$ -aspartyl]-  
 $\alpha$ -methyl-, 4-(1,1-dimethylethyl) 1-methyl ester (9CI) (CA INDEX  
 NAME)

Absolute stereochemistry.



IT 149673-29-0P  
 RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)  
 (preparation and crystal structure of, helical methylphenylalanine  
 conformation in)  
 RN 149673-29-0 CAPLUS  
 CN L-Phenylalanine, N-[N-[(4-cyanophenyl)amino]carbonyl]-L- $\alpha$ -aspartyl]-  
 $\alpha$ -methyl-, 1-methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 149673-33-6P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of)

RN 149673-33-6 CAPLUS  
 CN L-Phenylalanine,  $\alpha$ -methyl-N-[N-[[4-nitrophenyl]amino]carbonyl]-L-aspartyl]-, 1-methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 160 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1993:517105 CAPLUS  
 DOCUMENT NUMBER: 119:117105  
 ORIGINAL REFERENCE NO.: 119:21055a,21058a  
 TITLE: Aromatic compounds, pharmaceutical compositions containing them and their use in therapy  
 INVENTOR(S): Baker, Raymond; MacLeod, Angus Murray; Merchant, Kevin John; Swain, Christopher John  
 PATENT ASSIGNEE(S): Merck Sharp and Dohme Ltd., UK  
 SOURCE: PCT Int. Appl., 83 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 4  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9301169	A2	19930121	WO 1992-GB1214	19920703
WO 9301169	A3	19931111		
W: CA, JP, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE				
CA 2110514	A1	19930121	CA 1992-2110514	19920703
AU 9222440	A	19930211	AU 1992-22440	19920703
AU 664188	B2	19951109		
EP 593557	A1	19940427	EP 1992-914055	19920703
EP 593557	B1	19960131		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
EP 593559	A1	19940427	EP 1992-914089	19920703
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
JP 06509332	T	19941020	JP 1992-502085	19920703
US 5472978	A	19951205	US 1993-162096	19931210
US 5629347	A	19970513	US 1993-170190	19931222
PRIORITY APPLN. INFO.:				
			GB 1991-14550	A 19910705
			GB 1991-14886	A 19910710
			GB 1991-14888	A 19910710
			GB 1992-1881	A 19920129
			GB 1991-14554	A 19910705
			GB 1992-5294	A 19920311
			WO 1992-GB1213	A 19920703
			WO 1992-GB1214	W 19920703


OTHER SOURCE(S): MARPAT 119:117105  
 IT 148452-11-3P  
 RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of, as analgesic and inflammation inhibitor (substance P antagonist))

RN 148452-11-3 CAPLUS

CN 1H-Indole-3-propanamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-  
 $\alpha$ -[[[(phenylamino)carbonyl]amino]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 161 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1993:425335 CAPLUS

DOCUMENT NUMBER: 119:25335

ORIGINAL REFERENCE NO.: 119:4653a,4656a

TITLE: SAR of sweet molecules: conformational analysis of two hypersweet and two conformationally restricted aspartame analogs

AUTHOR(S): Kamphuis, Johan; Lelj, Francesco; Tancredi, Teodorico; Toniolo, Claudio; Temussi, Piero A.

CORPORATE SOURCE: Bio-org. Chem. Sect., DSM Res., Geleen, 6160 MD, Neth.

SOURCE: Quantitative Structure-Activity Relationships (1992), 11(4), 486-91

CODEN: QSARDI; ISSN: 0931-8771

DOCUMENT TYPE: Journal

LANGUAGE: English

IT 135507-50-5


RL: PRP (Properties)

(conformation of, sweet taste in relation to)

RN 135507-50-5 CAPLUS

CN L-Phenylalanine, N-[[[(4-cyanophenyl)amino]carbonyl]-L- $\alpha$ -aspartyl-, 2-methyl ester (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 162 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1993:408669 CAPLUS

DOCUMENT NUMBER: 119:8669

ORIGINAL REFERENCE NO.: 119:1777a,1780a



TITLE: Aldehyde derivatives and their use as calpain inhibitors  
 INVENTOR(S): Hosoda, Akihiko; Nakayama, Yukihide; Shibata, Masahiro; Sekine, Yasuo; Inaba, Niro; Ikawa, Hiroshi; Yamaura, Tetsuaki; Tanabe, Naoko  
 PATENT ASSIGNEE(S): Fujirebio Inc., Japan  
 SOURCE: Eur. Pat. Appl., 134 pp.  
 CODEN: EPXXDW  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 520336	A2	19921230	EP 1992-110388	19920619
EP 520336	A3	19930407		
R: CH, DE, FR, GB, IT, LI, NL				
JP 05163221	A	19930629	JP 1991-352877	19911217
CA 2071621	A1	19921220	CA 1992-2071621	19920618
CA 2071621	C	19960806		
JP 06287167	A	19941011	JP 1992-184745	19920619
JP 05345753	A	19931227	JP 1992-358750	19921228
JP 3391038	B2	20030331		
PRIORITY APPLN. INFO.:			JP 1991-173377	A 19910619
			JP 1991-352877	A 19911217
			JP 1991-357647	A 19911226

OTHER SOURCE(S): MARPAT 119:8669


IT 147324-91-2P

RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation and calpain and blood platelet aggregation inhibition by)

RN 147324-91-2 CAPLUS

CN Pentanamide, N-(1-formyl-2-phenylethyl)-4-methyl-2-  
 [[(phenylamino)carbonyloxy]-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 147324-85-4P 147324-92-3P

RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation and calpain inhibition by)

RN 147324-85-4 CAPLUS


CN Carbamic acid, 1-naphthalenyl-, 1-[[[(1-formyl-3-phenylpropyl)amino]carbonyl]-3-methylbutyl ester, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 147324-92-3 CAPLUS  
 CN Carbamic acid, 1-naphthalenyl-, 1-[[[(1-formyl-2-phenylethyl)amino]carbonyl]-3-methylbutyl ester, [S-(R\*,R\*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 147324-97-8P 147325-00-6P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of)  
 RN 147324-97-8 CAPLUS  
 CN Butanamide, N-(1-formyl-2-phenylethyl)-3-methyl-2-[[[(phenylamino)carbonyl]oxy]-, [S-(R\*,R\*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 147325-00-6 CAPLUS  
 CN Pentanamide, N-[1-formyl-2-(1H-indol-3-yl)ethyl]-4-methyl-2-[[[(phenylamino)carbonyl]oxy]-, [S-(R\*,R\*)]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L5 ANSWER 163 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1993:255359 CAPLUS  
 DOCUMENT NUMBER: 118:255359  
 ORIGINAL REFERENCE NO.: 118:44401a,44404a  
 TITLE: Cyclopropenone peptide derivatives  
 INVENTOR(S): Ando, Ryoichi; Morinaka, Yasuhiro; Takahashi, Chizuko;  
 Tamao, Yoshikuni; Tobe, Akirhiro  
 PATENT ASSIGNEE(S): Mitsubishi Kasei Corp., Japan  
 SOURCE: Eur. Pat. Appl., 151 pp.  
 CODEN: EPXXDW  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 520427	A1	19921230	EP 1992-110674	19920625
EP 520427	B1	19941214		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, PT, SE				
JP 05230004	A	19930907	JP 1992-146024	19920605
JP 3228347	B2	20011112		
CA 2072416	A1	19921226	CA 1992-2072416	19920625
CA 2072416	C	20060321		
US 5328909	A	19940712	US 1992-905544	19920625
ES 2068646	T3	19950416	ES 1992-110674	19920625
US 5416117	A	19950516	US 1994-202555	19940228
PRIORITY APPLN. INFO.:			JP 1991-153500	A 19910625
			JP 1991-277904	A 19911024
			JP 1991-341497	A 19911224
			JP 1992-146024	A 19920605
			US 1992-905544	A3 19920625

OTHER SOURCE(S): MARPAT 118:255359  
 IT 147660-52-4P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation and thiol protease inhibitory activity of)  
 RN 147660-52-4 CAPLUS  
 CN Pentanamide, N-[1-[hydroxy(3-oxo-2-phenyl-1-cyclopropen-1-yl)methyl]-2-methylpropyl]-4-methyl-2-[[ (phenylamino)carbonyl]amino]-, [2S-[1[R\*(R\*)],2R\*]]- (9CI) (CA INDEX NAME)




L5 ANSWER 164 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1992:484251 CAPLUS  
 DOCUMENT NUMBER: 117:84251  
 ORIGINAL REFERENCE NO.: 117:14559a,14562a  
 TITLE: Cholecystokinin antagonists, their preparation and therapeutic use  
 INVENTOR(S): Horwell, David Christopher; Kleinschroth, Juergen; Rees, David Charles; Richardson, Reginald Stewart; Roark, William Howard; Roberts, Edward; Roth, Bruce David; Trivedi, Bharat Kalidas; Holmes, Ann; Padia, Janak Khimchand  
 PATENT ASSIGNEE(S): Warner-Lambert Co., USA  
 SOURCE: PCT Int. Appl., 211 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9204045	A1	19920319	WO 1991-US6180	19910829
W: AU, CA, FI, JP, KR, NO				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
AU 9187492	A	19920330	AU 1991-87492	19910829
AU 651390	B2	19940721		
EP 547178	A1	19930623	EP 1991-918880	19910829
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
JP 06502627	T	19940324	JP 1991-517185	19910829
ZA 9106922	A	19930301	ZA 1991-6922	19910830
NO 9300709	A	19930415	NO 1993-709	19930226
NO 312298	B1	20020422		
PRIORITY APPLN. INFO.:			US 1990-576628	A 19900831
			US 1991-726655	A 19910712
			WO 1991-US6180	A 19910829


OTHER SOURCE(S): MARPAT 117:84251  
 IT 142627-75-6P 142627-76-7P  
 RL: RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation and reaction of, for cholecystokinin antagonist)  
 RN 142627-75-6 CAPLUS  
 CN 1H-Indole-3-propanamide,  $\alpha$ -[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]amino]-N-(2,2-dimethyl-4-phenyl-1,3-dioxan-5-yl)- $\alpha$ -methyl-, [4S-[4 $\alpha$ ,5 $\alpha$ (R\*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 142627-76-7 CAPLUS  
 CN 1H-Indole-3-propanamide,  $\alpha$ -[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]amino]-N-(2,2-dimethyl-4-phenyl-1,3-dioxan-5-yl)- $\alpha$ -methyl-, [4S-[4 $\alpha$ ,5 $\alpha$ (S\*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 142627-77-8P 142697-57-2P 142697-58-3P  
 RL: PREP (Preparation)  
 (preparation of, for cholecystokinin antagonist)  
 RN 142627-77-8 CAPLUS  
 CN 1H-Indole-3-propanamide,  $\alpha$ -[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]amino]-N-[2-hydroxy-1-(hydroxymethyl)-2-phenylethyl]- $\alpha$ -methyl-, [1S-[1R\*(R\*),2R\*]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 142697-57-2 CAPLUS


CN 1H-Indole-3-propanamide,  $\alpha$ -[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]amino]-N-[2-hydroxy-1-(hydroxymethyl)-2-phenylethyl]- $\alpha$ -methyl-, [1S-[1R\*(S\*),2R\*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142697-58-3 CAPLUS

CN 1H-Indole-3-propanamide,  $\alpha$ -[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]amino]-N-[2-hydroxy-1-(hydroxymethyl)-2-phenylethyl]- $\alpha$ -methyl- (CA INDEX NAME)



REFERENCE COUNT:

2


THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 165 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1992:449261 CAPLUS  
 DOCUMENT NUMBER: 117:49261  
 ORIGINAL REFERENCE NO.: 117:8815a,8818a  
 TITLE: Preparation of peptides having endothelin antagonist activity and pharmaceutical compositions comprising them.  
 INVENTOR(S): Hemmi, Keiji; Neya, Masahiro; Fukami, Naoki; Hashimoto, Masashi; Tanaka, Hirokazu; Kayakiri, Natsuko  
 PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan  
 SOURCE: Eur. Pat. Appl., 179 pp.  
 CODEN: EPXXDW  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 3  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 457195	A2	19911121	EP 1991-107554	19910509
EP 457195	A3	19921119		
EP 457195	B1	19980415		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
ZA 9103417	A	19920226	ZA 1991-3417	19910506
US 5284828	A	19940208	US 1991-696701	19910507
AU 9176446	A	19911114	AU 1991-76446	19910509
AU 644648	B2	19931216		
AT 165100	T	19980515	AT 1991-107554	19910509
CA 2042442	A1	19911115	CA 1991-2042442	19910513
FI 9102328	A	19911115	FI 1991-2328	19910513
NO 9101854	A	19911115	NO 1991-1854	19910513
CN 1057269	A	19911225	CN 1991-103919	19910513
RU 2092491	C1	19971010	RU 1991-4895608	19910513
HU 57233	A2	19911128	HU 1991-1619	19910514
JP 04244097	A	19920901	JP 1991-206614	19910514
US 5430022	A	19950704	US 1993-86094	19930706
US 5656604	A	19970812	US 1995-422944	19950417
PRIORITY APPLN. INFO.:			GB 1990-10740	A 19900514
			GB 1990-26254	A 19901203
			GB 1991-4064	A 19910227
			US 1991-696701	A2 19910507
			US 1991-753997	B2 19910903
			US 1992-845056	B1 19920303
			US 1993-86094	A3 19930706

OTHER SOURCE(S): MARPAT 117:49261  
 IT 142375-44-8P 142375-45-9P 142375-80-2P  
 142376-24-7P 142376-25-8P 142376-26-9P  
 142376-27-0P 142376-28-1P 142376-29-2P  
 142376-50-9P 142376-93-0P 142376-94-1P  
 142376-95-2P 142376-96-3P 142376-97-4P  
 142377-16-0P 142378-22-1P 142378-58-3P  
 142379-00-8P 142409-01-6P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
 (preparation of, as endothelin antagonist)  
 RN 142375-44-8 CAPLUS  
 CN D-Phenylalanine, N-[1-methyl-N-[N-[(phenylamino)carbonyl]-L-leucyl]-D-tryptophyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 142375-45-9 CAPLUS

CN D-Phenylalanine, N-[1-methyl-N-[N-[(phenylamino)carbonyl]-L-leucyl]-D-tryptophyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 142375-80-2 CAPLUS

CN D-Alanine, N-[1-methyl-N-[N-[(2-pyridinylamino)carbonyl]-L-leucyl]-D-tryptophyl]-3-(2-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 142376-24-7 CAPLUS

CN D-Alanine, N-[1-methyl-N-[N-[(phenylamino)carbonyl]-L-leucyl]-D-tryptophyl]-3-(2-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 142376-25-8 CAPLUS

CN D-Alanine, N-[N-[N-[[ (4-methoxyphenyl)amino]carbonyl]-L-leucyl]-1-methyl-D-tryptophyl]-3-(2-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 142376-26-9 CAPLUS

CN D-Alanine, N-[1-methyl-N-[N-[[ (4-methylphenyl)amino]carbonyl]-L-leucyl]-D-tryptophyl]-3-(2-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 142376-27-0 CAPLUS

CN D-Alanine, N-[N-[N-[[4-chlorophenyl]amino]carbonyl]-L-leucyl]-1-methyl-D-tryptophyl]-3-(2-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 142376-28-1 CAPLUS

CN D-Alanine, N-[N-[N-[[3-chlorophenyl]amino]carbonyl]-L-leucyl]-1-methyl-D-tryptophyl]-3-(2-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 142376-29-2 CAPLUS

CN D-Alanine, N-[N-[N-[[2-chlorophenyl]amino]carbonyl]-L-leucyl]-1-methyl-D-tryptophyl]-3-(2-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 142376-50-9 CAPLUS

CN D-Alanine, N-[1-methyl-N-[N-[(2-pyridinylamino)carbonyl]-L-leucyl]-D-tryptophyl]-3-(2-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 142376-93-0 CAPLUS

CN D-Alanine, N-[1-methyl-N-[N-[(phenylamino)carbonyl]-L-leucyl]-D-tryptophyl]-3-(2-pyridinyl)-, monosodium salt (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● Na

RN 142376-94-1 CAPLUS  
 CN D-Alanine, N-[N-[N-[(4-methoxyphenyl)amino]carbonyl]-L-leucyl]-1-methyl-D-tryptophyl]-3-(2-pyridinyl)-, monosodium salt (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● Na

RN 142376-95-2 CAPLUS  
 CN D-Alanine, N-[1-methyl-N-[N-[(4-methylphenyl)amino]carbonyl]-L-leucyl]-D-tryptophyl]-3-(2-pyridinyl)-, monosodium salt (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● Na

RN 142376-96-3 CAPLUS  
 CN D-Alanine, N-[N-[N-[(3-chlorophenyl)amino]carbonyl]-L-leucyl]-1-methyl-D-tryptophyl]-3-(2-pyridinyl)-, monosodium salt (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● Na

RN 142376-97-4 CAPLUS  
 CN D-Alanine, N-[N-[N-[(2-chlorophenyl)amino]carbonyl]-L-leucyl]-1-methyl-D-tryptophyl]-3-(2-pyridinyl)-, monosodium salt (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● Na


RN 142377-16-0 CAPLUS  
 CN D-Leucine, N-[N-[N-[(2-chlorophenyl)amino]carbonyl]-L-leucyl]-1-methyl-D-tryptophyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142378-22-1 CAPLUS  
 CN D-Leucine, N-[N-[N-[(2-chlorophenyl)amino]carbonyl]-L-leucyl]-1-methyl-D-tryptophyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 142378-58-3 CAPLUS

CN  $\beta$ -Alanine, N-[N-[N-[N-[(2-chlorophenyl)amino]carbonyl]-L-leucyl]-1-methyl-D-tryptophyl]-3-(2-pyridinyl)-D-alanyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 142379-00-8 CAPLUS

CN  $\beta$ -Alanine, N-[N-[N-[N-[(2-chlorophenyl)amino]carbonyl]-L-leucyl]-1-methyl-D-tryptophyl]-3-(2-pyridinyl)-D-alanyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 142409-01-6 CAPLUS

CN D-Alanine, N-[N-[N-[(4-chlorophenyl)amino]carbonyl]-L-leucyl]-1-methyl-D-tryptophyl]-3-(2-pyridinyl)-, monosodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Na

L5 ANSWER 166 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1992:256059 CAPLUS

DOCUMENT NUMBER: 116:256059

ORIGINAL REFERENCE NO.: 116:43443a, 43446a

TITLE: Preparation of phosphonopyrrolidine- and -piperidine-containing pseudopeptides as HIV protease inhibitors.

INVENTOR(S): Haebich, Dieter; Hansen, Jutta; Paessens, Arnold

PATENT ASSIGNEE(S): Bayer A.-G., Germany

SOURCE: Eur. Pat. Appl., 41 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.

KIND

DATE


APPLICATION NO.

DATE




EP 472078	A2	19920226	EP 1991-113483	19910812
EP 472078	A3	19930331		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
DE 4026614	A1	19920227	DE 1990-4026614	19900823
US 5147865	A	19920915	US 1991-746272	19910815
JP 04244091	A	19920901	JP 1991-229749	19910816
CA 2049497	A1	19920224	CA 1991-2049497	19910820
AU 9182684	A	19920227	AU 1991-82684	19910821
AU 634417	B2	19930218		
ZA 9106638	A	19920527	ZA 1991-6638	19910822
HU 59160	A2	19920428	HU 1991-2777	19910823
PRIORITY APPLN. INFO.:			DE 1990-4026614	A 19900823
OTHER SOURCE(S): CASREACT 116:256059; MARPAT 116:256059				
IT 141459-97-4P 141459-98-5P 141507-46-2P				
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)				
(preparation of, as HIV protease inhibitor)				
RN	141459-97-4 CAPLUS			
CN	Phosphonic acid, [1-[5-cyclohexyl-2,4,5-trideoxy-4-[[2-[[1-(naphthalenylamino)carbonyl]amino]-1-oxo-3-phenylpropyl]amino]-L-threo-pentonoyl]-2-pyrrolidinyl]-, diethyl ester, [1(R),4(S)]- (9CI) (CA INDEX NAME)			

PAGE 1-A




PAGE 2-A




RN 141459-98-5 CAPLUS  
 CN Phosphonic acid, [1-[4-[[2-[[[(4-chlorophenyl)amino]carbonyl]amino]-1-oxo-3-phenylpropyl]amino]-5-cyclohexyl-2,4,5-trideoxy-L-threo-pentono-yl]-2-pyrrolidinyl]-, diethyl ester (9CI) (CA INDEX NAME)



PAGE 1-A



PAGE 2-A



RN 141507-46-2 CAPLUS  
 CN Phosphonic acid, [1-[5-cyclohexyl-2,4,5-trideoxy-4-[[2-[[[(1-naphthalenylamino)carbonyl]amino]-1-oxo-3-phenylpropyl]amino]-L-threo-pentano-yl]-2-pyrrolidinyl]-, diethyl ester, [1(S),4(S)]- (9CI) (CA INDEX NAME)



L5 ANSWER 167 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1992:256053 CAPLUS  
 DOCUMENT NUMBER: 116:256053  
 ORIGINAL REFERENCE NO.: 116:43439a,43442a  
 TITLE: Preparation of endothelin antagonistic peptide derivatives  
 INVENTOR(S): Ishikawa, Kiyofumi; Fukami, Takehiro; Hayama, Takashi; Niiyama, Kenji; Nagase, Toshio; Mase, Toshiaki; Fujita, Kagari; Ihara, Masaki; Ikemoto, Fumihiko; Yano, Mitsuo  
 PATENT ASSIGNEE(S): Banyu Pharmaceutical Co., Ltd., Japan  
 SOURCE: Eur. Pat. Appl., 121 pp.  
 CODEN: EPXXDW  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 3  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
EP 460679	A2	19911211	EP 1991-109313	19910606
EP 460679	A3	19921119		
EP 460679	B1	19981028		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE

CA 2043741	A1	19911208	CA 1991-2043741	19910603
CA 2043741	C	20030401		
JP 05178891	A	19930720	JP 1991-160023	19910603
JP 3127488	B2	20010122		
AU 9178182	A	19911212	AU 1991-78182	19910605
AU 632695	B2	19930107		
AT 172741	T	19981115	AT 1991-109313	19910606
US 5470833	A	19951128	US 1994-213829	19940314
US 5691315	A	19971125	US 1995-494818	19950626
PRIORITY APPLN. INFO.:			JP 1990-149105	A 19900607
			US 1991-712095	B3 19910607
			US 1992-884189	B1 19920518
			US 1994-213829	A3 19940314

OTHER SOURCE(S): MARPAT 116:256053


IT 141594-60-7P 141594-63-0P 141594-64-1P  
 141594-66-3P 141594-98-1P 141594-99-2P  
 141595-00-8P 141595-01-9P 141595-02-0P  
 141595-21-3P 141595-22-4P 141624-45-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
 (preparation of, as endothelin antagonist)

RN 141594-60-7 CAPLUS

CN  $\beta$ -Alanine, N-[N-[N-[(phenylamino)carbonyl]-L-leucyl]-D-tryptophyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 141594-63-0 CAPLUS


CN  $\beta$ -Alanine, N-[N-[N-[(2-chlorophenyl)amino]carbonyl]-L-leucyl]-D-tryptophyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 141594-64-1 CAPLUS  
CN  $\beta$ -Alanine, N-[N-[N-[(4-chlorophenyl)amino]carbonyl]-L-leucyl]-D-tryptophyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 141594-66-3 CAPLUS  
CN Glycine, N-[N-[N-[(phenylamino)carbonyl]-L-leucyl]-D-tryptophyl]- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.



RN 141594-98-1 CAPLUS  
CN  $\beta$ -Alanine, N-[N-[N-[(3-methoxyphenyl)amino]carbonyl]-L-leucyl]-D-tryptophyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 141594-99-2 CAPLUS

CN  $\beta$ -Alanine, N-[N-[N-[[ (3-chlorophenyl)amino]carbonyl]-L-leucyl]-D-tryptophyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 141595-00-8 CAPLUS

CN  $\beta$ -Alanine, N-[N-[N-[[ (4-methylphenyl)amino]carbonyl]-L-leucyl]-D-tryptophyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 141595-01-9 CAPLUS

CN  $\beta$ -Alanine, N-[N-[N-[[ (2-methoxyphenyl)amino]carbonyl]-L-leucyl]-D-tryptophyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 141595-02-0 CAPLUS

CN  $\beta$ -Alanine, N-[N-[N-[[ (2-methylphenyl)amino]carbonyl]-L-leucyl]-D-tryptophyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 141595-21-3 CAPLUS

CN  $\beta$ -Alanine, N-[N-[N-[[ (2,6-dimethylphenyl)amino]carbonyl]-L-leucyl]-D-tryptophyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 141595-22-4 CAPLUS

CN  $\beta$ -Alanine, N-[N-[N-[[ [2,6-bis(1-methylethyl)phenyl]amino]carbonyl]-L-leucyl]-D-tryptophyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 141624-45-5 CAPLUS

CN  $\beta$ -Alanine, N-[N-[N-[(3-methylphenyl)amino]carbonyl]-L-leucyl]-D-tryptophyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 141595-85-9P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of, as intermediate for endothelin antagonist)

RN 141595-85-9 CAPLUS

CN  $\beta$ -Alanine, N-[N-[N-[(phenylamino)carbonyl]-L-leucyl]-D-tryptophyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.







DOCUMENT NUMBER: 115:89822  
 ORIGINAL REFERENCE NO.: 115:15395a,15398a  
 TITLE: On the taste of umami in chimpanzee  
 AUTHOR(S): Hellekant, Goran; Ninomiya, Yuzo  
 CORPORATE SOURCE: Dep. Vet. Sci., Univ. Wisconsin, Madison, WI, 53706, USA  
 SOURCE: Physiology & Behavior (1991), 49(5), 927-34  
 CODEN: PHBHA4; ISSN: 0031-9384  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 IT 135507-50-5, Super-aspartame  
 RL: BIOL (Biological study)  
 (chorda tympani nerve stimulation response to, in chimpanzee, taste specificity of nerve fibers and umami taste in relation to)  
 RN 135507-50-5 CAPLUS  
 CN L-Phenylalanine, N-[[ (4-cyanophenyl)amino]carbonyl]-L- $\alpha$ -aspartyl-, 2-methyl ester (CA INDEX NAME)

Absolute stereochemistry.




L5 ANSWER 169 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1991:43535 CAPLUS  
 DOCUMENT NUMBER: 114:43535  
 ORIGINAL REFERENCE NO.: 114:7597a,7600a  
 TITLE: Synthesis, structure and properties of hybrid oligopeptide-based polymers  
 AUTHOR(S): Sogah, D. Y.  
 CORPORATE SOURCE: Cent. Res. Dev. Dep., E. I. du Pont de Nemours and Co., Inc., Wilmington, DE, 19880-0328, USA  
 SOURCE: Polymer Preprints (American Chemical Society, Division of Polymer Chemistry) (1990), 31(1), 185-6  
 CODEN: ACPPAY; ISSN: 0032-3934  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 IT 131328-95-5P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation and copolymn. of, with hexanediamine)  
 RN 131328-95-5 CAPLUS  
 CN Poly[1,2-pyrrolidinediylcarbonylimino-1,2-ethanediyliminocarbonyl-2,1-pyrrolidinediyl[2-(3-amino-3-oxopropyl)-1-oxo-1,2-ethanediyl]imino[2-(2-methylpropyl)-1-oxo-1,2-ethanediyl]iminocarbonylimino-1,4-phenylenemethylene-1,4-phenyleneiminocarbonylimino[1-(2-methylpropyl)-2-oxo-1,2-ethanediyl]imino[1-(3-amino-3-oxopropyl)-2-oxo-1,2-ethanediyl]], stereoisomer (9CI) (CA INDEX NAME)




L5 ANSWER 170 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1991:43487 CAPLUS  
 DOCUMENT NUMBER: 114:43487  
 ORIGINAL REFERENCE NO.: 114:7585a,7588a  
 TITLE: Preparation of nikkomycin derivatives as antimycotics  
 INVENTOR(S): Schaller, Klaus; Moeschler, Heinrich Ferdinand;  
 Plempel, Manfred; Hector, Richard  
 PATENT ASSIGNEE(S): Bayer A.-G., Germany  
 SOURCE: Eur. Pat. Appl., 42 pp.

CODEN: EPXXDW  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 367954	A1	19900516	EP 1989-117435	19890921
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, NL, SE				
US 5019560	A	19910528	US 1988-252613	19881003
JP 02174791	A	19900706	JP 1989-257169	19891003
US 5149795	A	19920922	US 1991-674255	19910325
PRIORITY APPLN. INFO.:			US 1988-252613	A 19881003
OTHER SOURCE(S):	MARPAT 114:43487			
IT 131396-40-2P 131396-41-3P 131396-42-4P 131396-43-5P				
RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of, as antimycotic)				
RN 131396-40-2 CAPLUS				
CN $\beta$ -D-Allofuranuronic acid, 1,5-dideoxy-1-(4-formyl-2,3-dihydro-2-oxo-1H-imidazol-1-yl)-5-[[4-hydroxy-4-(5-hydroxy-2-pyridinyl)-3-methyl-1-oxo-2-[[ (phenylamino)carbonyl]amino]butyl]amino]-, [2S-(2R*,3R*,4R*)]- (9CI) (CA INDEX NAME)				




RN 131396-41-3 CAPLUS  
 CN  $\beta$ -D-Allofuranuronic acid, 5-[[2-[[[(3-chlorophenyl)amino]carbonyl]amino]-4-hydroxy-4-(5-hydroxy-2-pyridinyl)-3-methyl-1-oxobutyl]amino]-1,5-dideoxy-1-(4-formyl-2,3-dihydro-2-oxo-1H-imidazol-1-yl)-, [2S-(2R\*,3R\*,4R\*)]- (9CI) (CA INDEX NAME)




RN 131396-42-4 CAPLUS  
 CN  $\beta$ -D-Allofuranuronic acid, 1,5-dideoxy-1-(4-formyl-2,3-dihydro-2-oxo-

1H-imidazol-1-yl)-5-[[4-hydroxy-4-(5-hydroxy-2-pyridinyl)-3-methyl-1-oxo-2-  
 [[[3-(trifluoromethyl)phenyl]amino]carbonyl]amino]butyl]amino]-,  
 [2S-(2R\*,3R\*,4R\*)]- (9CI) (CA INDEX NAME)



RN 131396-43-5 CAPLUS

CN  $\beta$ -D-Allofuranuronic acid, 5-[[2-[[[3-chloro-4-methylphenyl]amino]carbonyl]amino]-4-hydroxy-4-(5-hydroxy-2-pyridinyl)-3-methyl-1-oxobutyl]amino]-1,5-dideoxy-1-(4-formyl-2,3-dihydro-2-oxo-1H-imidazol-1-yl)-, [2S-(2R\*,3R\*,4R\*)]- (9CI) (CA INDEX NAME)



L5 ANSWER 171 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1990:610346 CAPLUS

DOCUMENT NUMBER: 113:210346

ORIGINAL REFERENCE NO.: 113:35541a,35544a

TITLE: Structure-activity relations of di- and tripeptide sweeteners

AUTHOR(S): Zeng, Guangzhi

CORPORATE SOURCE: Shanghai Inst. Org. Chem., Acad. Sin., Shanghai, 200032, Peop. Rep. China

SOURCE: Yingyong Huaxue (1990), 7(1), 1-9

CODEN: YIHUED; ISSN: 1000-0518

DOCUMENT TYPE: Journal

LANGUAGE: Chinese

IT 92236-16-3 92236-18-5 92236-21-0


92236-22-1 92236-25-4 92236-26-5  
92236-27-6 92236-28-7 92236-33-4  
92236-34-5 129864-36-4 129864-40-0  
129864-45-5 135507-50-5

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study) (sweetness of, structure in relation to)

RN 92236-16-3 CAPLUS

CN L-Phenylalanine, N-[N-[[ (4-nitrophenyl)amino]carbonyl]-L- $\alpha$ -aspartyl]-, 1-methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 92236-18-5 CAPLUS

CN Glycine, N-[N-[[ (4-nitrophenyl)amino]carbonyl]-L- $\alpha$ -aspartyl]-L-2-phenyl-, 1-methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 92236-21-0 CAPLUS

CN Glycine, L-2-cyclohexyl-N-[N-[[ (4-nitrophenyl)amino]carbonyl]-L- $\alpha$ -aspartyl]-, 1-methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 92236-22-1 CAPLUS

CN L-Alanine, 3-cyclohexyl-N-[N-[[ (4-nitrophenyl)amino]carbonyl]-L- $\alpha$ -

aspartyl]-, 1-methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 92236-25-4 CAPLUS

CN L-Phenylalanine, N-[N-[[[4-(ethoxycarbonyl)phenyl]amino]carbonyl]-L- $\alpha$ -aspartyl]-, 1-methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 92236-26-5 CAPLUS

CN L-Phenylalanine, N-[N-[[[4-(acetylphenyl)amino]carbonyl]-L- $\alpha$ -aspartyl]-, 1-methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 92236-27-6 CAPLUS

CN L-Phenylalanine, N-[N-[[[4-(methylsulfonyl)phenyl]amino]carbonyl]-L- $\alpha$ -aspartyl]-, 1-methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 92236-28-7 CAPLUS

CN L-Phenylalanine, N-[N-[[[4-(methoxycarbonyl)phenyl]amino]carbonyl]-L-α-aspartyl]-, 1-methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 92236-33-4 CAPLUS

CN L-Phenylalanine, N-[N-[(4-chlorophenyl)amino]carbonyl]-L-α-aspartyl]-, 1-methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 92236-34-5 CAPLUS

CN L-Phenylalanine, N-[N-[(phenylamino)carbonyl]-L-α-aspartyl]-, 1-methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 129864-36-4 CAPLUS

CN L-Phenylalanine, N-[N-[(4-fluorophenyl)amino]carbonyl]-L-α-aspartyl]-, 1-methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 129864-40-0 CAPLUS

CN Glycine, N-[N-[(4-cyanophenyl)amino]carbonyl]-L-α-aspartyl]-L-2-phenyl-, 1-methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 129864-45-5 CAPLUS

CN Butanoic acid, 3-[[[(4-cyanophenyl)amino]carbonyl]amino]-4-oxo-4-[(1R)-1-phenylethyl]amino]-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.






RN 135507-50-5 CAPLUS  
 CN L-Phenylalanine, N-[[ (4-cyanophenyl)amino]carbonyl]-L- $\alpha$ -aspartyl-,  
 2-methyl ester (CA INDEX NAME)

Absolute stereochemistry.




L5 ANSWER 172 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1990:525778 CAPLUS  
 DOCUMENT NUMBER: 113:125778  
 ORIGINAL REFERENCE NO.: 113:21150h,21151a  
 TITLE: Separation of carboxylic acid enantiomers by gas chromatography after rapid derivatization with (R)- or (S)-1-phenylethylamine after activation by ethyl chloroformate  
 AUTHOR(S): Carlson, Aasa; Gyllenhaal, Olle  
 CORPORATE SOURCE: AB Haessle, Moelndal, S-431 83, Swed.  
 SOURCE: Journal of Chromatography (1990), 508(2), 333-9  
 CODEN: JOCRAM; ISSN: 0021-9673  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 113:125778  
 IT 129248-09-5 129248-10-8  
 RL: ANT (Analyte); PRP (Properties); ANST (Analytical study)  
 (mass spectrum of)  
 RN 129248-09-5 CAPLUS  
 CN Propanamide, 2-[[ (phenylamino)carbonyl]oxy]-N-(1-phenylethyl)-,  
 [S-(R\*,S\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 129248-10-8 CAPLUS  
 CN Propanamide, 2-[[ (phenylamino)carbonyl]oxy]-N-(1-phenylethyl)-,  
 [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 173 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1990:478951 CAPLUS  
 DOCUMENT NUMBER: 113:78951  
 ORIGINAL REFERENCE NO.: 113:13375a,13378a  
 TITLE: Angiotensin-converting enzyme inhibitors: synthesis and biological activity of N-substituted tripeptide inhibitors  
 AUTHOR(S): Sawayama, Tadahiro; Tsukamoto, Masatoshi; Sasagawa, Takashi; Nishimura, Kazuya; Deguchi, Takashi; Takeyama, Kunihiro; Hosoki, Kanoo  
 CORPORATE SOURCE: Res. Lab., Dainippon Pharm. Co., Ltd., Suita, 564, Japan  
 SOURCE: Chemical & Pharmaceutical Bulletin (1990), 38(1), 110-15  
 CODEN: CPBTAL; ISSN: 0009-2363  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 113:78951  
 IT 116587-19-0P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation and inhibition by, of angiotensin-converting enzyme)  
 RN 116587-19-0 CAPLUS  
 CN D-Norvaline, 5-(2-carboxyoctahydro-1H-indol-1-yl)-5-oxo-N-[N2-[(phenylamino)carbonyl]-L-lysyl]-, [2S-(2 $\alpha$ ,3 $\alpha\beta$ ,7 $\alpha\beta$ )]-(9CI) (CA INDEX NAME)



L5 ANSWER 174 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1990:234015 CAPLUS  
 DOCUMENT NUMBER: 112:234015  
 ORIGINAL REFERENCE NO.: 112:39459a,39462a  
 TITLE: Safamycins from myxococcus: antibiotic and tumoricidal derivatives  
 INVENTOR(S): Reichenbach, Hans; Trowitzsch-Kienast, Wolfram; Gerth,

Klaus; Irschik, Herbert; Kunze, Brigitte; Augustiniak, Hermann; Bedorf, Norbert; Jansen, Rolf; Hoefle, Gerhard; Steinmetz, Heinrich  
PATENT ASSIGNEE(S): Ciba-Geigy A.-G., Switz.; Gesellschaft fuer Biotechnologische Forschung m.b.H.  
SOURCE: Eur. Pat. Appl., 31 pp.  
CODEN: EPXXDW  
DOCUMENT TYPE: Patent  
LANGUAGE: German  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 329606	A2	19890823	EP 1989-810094	19890203
EP 329606	A3	19910403		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
AU 8929750	A	19890817	AU 1989-29750	19890208
AU 621857	B2	19920326		
DK 8900622	A	19890813	DK 1989-622	19890210
JP 01273598	A	19891101	JP 1989-30041	19890210
PRIORITY APPLN. INFO.:			CH 1988-514	A 19880212
			CH 1988-515	A 19880212

OTHER SOURCE(S): MARPAT 112:234015

IT 127173-97-1P


RL: PREP (Preparation)

(preparation of, cytotoxicity of, neoplasm inhibitors in relation to)

RN 127173-97-1 CAPLUS

CN Propanamide, N-[(7-cyano-6,7,9,10,13,14,14a,15-octahydro-1,4-dihydroxy-2,5,11-trimethoxy-3,12,16-trimethyl-10,13-dioxo-6,15-imino-5H-isoquino[3,2-b][3]benzazocin-9-yl)methyl]-2-[[ (phenylamino) carbonyl] amino]-, [5S-[5 $\alpha$ ,6 $\alpha$ ,7 $\alpha$ ,9 $\beta$ (R\*),14 $\alpha$ ,15 $\alpha$ ]]- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



DOCUMENT NUMBER: 112:77962  
ORIGINAL REFERENCE NO.: 112:13351a,13354a  
TITLE: Preparation of N-(heterocyclylcarbamoyl)dipeptide  
analogs as sweeteners  
INVENTOR(S): Nofre, Claude; Tinti, Jean Marie  
PATENT ASSIGNEE(S): Universite Claude Bernard Lyon, Fr.  
SOURCE: Eur. Pat. Appl., 22 pp.  
CODEN: EPXXDW  
DOCUMENT TYPE: Patent  
LANGUAGE: French  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 321368	A1	19890621	EP 1988-420420	19881215
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
FR 2624698	A1	19890623	FR 1987-18113	19871218
AU 8826863	A	19890706	AU 1988-26863	19881214
JP 02002326	A	19900108	JP 1988-318351	19881216
PRIORITY APPLN. INFO.:			FR 1987-18113	A 19871218
OTHER SOURCE(S): MARPAT 112:77962				
IT 125118-04-9P 125118-06-1P 125118-07-2P 125118-08-3P 125118-14-1P				
RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of, as sweetener)				
RN 125118-04-9 CAPLUS				
CN L-Phenylalanine, N-[N-[(3-pyridinylamino)carbonyl]-L- $\alpha$ -aspartyl]-, 1-methyl ester (9CI) (CA INDEX NAME)				

Absolute stereochemistry.



RN 125118-06-1 CAPLUS  
CN L-Phenylalanine, N-[N-[(6-chloro-3-pyridinyl)amino]carbonyl]-L- $\alpha$ -  
aspartyl]-, 1-methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 125118-07-2 CAPLUS  
CN L-Phenylalanine, N-[N-[(6-cyano-3-pyridinyl)amino]carbonyl]-L- $\alpha$ -


aspartyl]-, 1-methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 125118-08-3 CAPLUS


CN Butanoic acid, 3-[[[(6-cyano-3-pyridinyl)amino]carbonyl]amino]-4-[(2-furanylphenylmethyl)amino]-4-oxo- (CA INDEX NAME)



RN 125118-14-1 CAPLUS

CN L-Phenylalanine, N-[N-[(1,3-benzodioxol-5-ylamino)carbonyl]-L-alpha-aspartyl]-, 1-methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 176 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1989:173762 CAPLUS

DOCUMENT NUMBER: 110:173762

ORIGINAL REFERENCE NO.: 110:28849a,28852a

TITLE: Preparation, testing, and formulation of indol(in)ecarboxylate-containing tripeptides as antihypertensives.

INVENTOR(S): Sawayama, Tadahiro; Tsukamoto, Masatoshi; Sasagawa, Takashi; Nishimura, Kazuya; Hosoki, Kanoo; Takeyama, Kunihiro

PATENT ASSIGNEE(S): Dainippon Pharmaceutical Co., Ltd., Japan

SOURCE: Eur. Pat. Appl., 91 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 244836	A2	19871111	EP 1987-106526	19870506
EP 244836	A3	19891123		
EP 244836	B1	19930818		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
AU 8772416	A	19871112	AU 1987-72416	19870501
AU 595309	B2	19900329		
US 4826814	A	19890502	US 1987-46189	19870505
CA 1318461	C	19930525	CA 1987-536368	19870505
ZA 8703226	A	19880427	ZA 1987-3226	19870506
AT 93237	T	19930915	AT 1987-106526	19870506
ES 2058074	T3	19941101	ES 1987-106526	19870506
DK 8702357	A	19871110	DK 1987-2357	19870508
DK 171402	B1	19961014		
FI 8702041	A	19871110	FI 1987-2041	19870508
FI 87794	B	19921113		
FI 87794	C	19930225		
DD 256329	A5	19880504	DD 1987-302570	19870508
HU 45268	A2	19880628	HU 1987-2089	19870508
HU 202884	B	19910429		
JP 63295597	A	19881201	JP 1987-112831	19870508
JP 05037998	B	19930607		
SU 1743356	A3	19920623	SU 1987-4202607	19870508
SK 278137	B6	19960207	SK 1987-3323	19870508
CZ 280776	B6	19960417	CZ 1987-3323	19870508

PRIORITY APPLN. INFO.:

JP 1986-107394	A	19860509
JP 1986-156693	A	19860703
JP 1987-16361		19870126
EP 1987-106526	A	19870506

OTHER SOURCE(S):


CASREACT 110:173762; MARPAT 110:173762

IT 116587-19-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
(preparation of, as antihypertensive)

RN 116587-19-0 CAPLUS

CN D-Norvaline, 5-(2-carboxyoctahydro-1H-indol-1-yl)-5-oxo-N-[N2-[(phenylamino)carbonyl]-L-lysyl]-, [2S-(2α,3αβ,7αβ)]-(9CI) (CA INDEX NAME)




L5 ANSWER 177 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1988:37516 CAPLUS  
 DOCUMENT NUMBER: 108:37516  
 ORIGINAL REFERENCE NO.: 108:6267a,6270a

TITLE: Preparation of new saframycins as antibiotics and antitumor agents  
 INVENTOR(S): Arai, Tadashi  
 PATENT ASSIGNEE(S): Ciba-Geigy A.-G. , Switz.  
 SOURCE: Eur. Pat. Appl., 18 pp.  
 CODEN: EPXXDW  
 DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 233841	A1	19870826	EP 1987-810083	19870212
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
DK 8700796	A	19870819	DK 1987-796	19870217
AU 8768877	A	19870820	AU 1987-68877	19870217
ZA 8701134	A	19870930	ZA 1987-1134	19870217
JP 62223182	A	19871001	JP 1987-32623	19870217
PRIORITY APPLN. INFO.:			GB 1986-3957	A 19860218
			GB 1986-3958	A 19860218


OTHER SOURCE(S): MARPAT 108:37516  
 IT 106101-13-7P 106101-14-8P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of, as antibiotic and antitumor agent)  
 RN 106101-13-7 CAPLUS  
 CN Propanamide, N-[(7-cyano-1,5,6,7,9,10,13,14,14a,15-decahydro-2,11-dimethoxy-3,12,16-trimethyl-1,4,10,13-tetraoxo-6,15-imino-4H-isoquino[3,2-b][3]benzazocin-9-yl)methyl]-2-[[ (phenylamino)carbonyl]amino]-, [6R-[6 $\alpha$ , 7 $\beta$ , 9 $\alpha$ (S\*), 14a $\beta$ , 15 $\alpha$ ]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 106101-14-8 CAPLUS  
 CN Propanamide, N-[(7-cyano-1,5,6,7,9,10,13,14,14a,15-decahydro-2,11-dimethoxy-3,12,16-trimethyl-1,4,10,13-tetraoxo-6,15-imino-4H-isoquino[3,2-b][3]benzazocin-9-yl)methyl]-2-[[ (1-naphthalenylamino)carbonyl]amino]-, [6R-[6 $\alpha$ , 7 $\beta$ , 9 $\alpha$ (S\*), 14a $\beta$ , 15 $\alpha$ ]]- (9CI) (CA INDEX


Absolute stereochemistry.



L5 ANSWER 178 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 1987:27369 CAPLUS  
DOCUMENT NUMBER: 106:27369  
ORIGINAL REFERENCE NO.: 106:4471a,4474a  
TITLE: Antitumor activity of new semisynthetic saframycin  
derivatives  
AUTHOR(S): Kaneda, Satoru; Chen, Hour-Young; Yazawa, Katsukiyo;  
Takahashi, Katsuhiko; Mikami, Yuzuru; Arai, Tadashi  
CORPORATE SOURCE: Res. Inst. Chemobiodyn., Chiba Univ., Chiba, 280,  
Japan  
SOURCE: Japanese Journal of Cancer Research (1986), 77(10),  
1043-9  
CODEN: JJCREP; ISSN: 0910-5050  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
IT 106101-13-7, Phenylcarbamoylsaframycin Y3 106101-14-8,  
Naphthylcarbamoylsaframycin Y3  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological  
study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES  
(Uses)  
(neoplasm inhibition by, structure in)  
RN 106101-13-7 CAPLUS  
CN Propanamide, N-[(7-cyano-1,5,6,7,9,10,13,14,14a,15-decahydro-2,11-  
dimethoxy-3,12,16-trimethyl-1,4,10,13-tetraoxo-6,15-imino-4H-isoquino[3,2-  
b][3]benzazocin-9-yl)methyl]-2-[[ (phenylamino) carbonyl] amino]-,  
[6R-[6 $\alpha$ ,7 $\beta$ ,9 $\alpha$ (S\*),14a $\beta$ ,15 $\alpha$ ]]- (9CI) (CA INDEX  
NAME)


Absolute stereochemistry.





RN 106101-14-8 CAPLUS  
 CN Propanamide, N-[(7-cyano-1,5,6,7,9,10,13,14,14a,15-decahydro-2,11-dimethoxy-3,12,16-trimethyl-1,4,10,13-tetraoxo-6,15-imino-4H-isoquino[3,2-b][3]benzazocin-9-yl)methyl]-2-[[[(1-naphthalenylamino)carbonyl]amino]-, [6R-[6 $\alpha$ ,7 $\beta$ ,9 $\alpha$ (S\*),14 $\alpha\beta$ ,15 $\alpha$ ]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L5 ANSWER 179 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1986:404220 CAPLUS  
 DOCUMENT NUMBER: 105:4220  
 ORIGINAL REFERENCE NO.: 105:819a,822a  
 TITLE: Molecular correlations of taste including a new class of amino acid based sweeteners  
 AUTHOR(S): Goodman, M.; Bland, J.; Tsang, J.; Coddington, J.; Temussi, P. A.; Tancredi, T.; Lelj, F.; Fuller, W. D.;


Verlander, M. S.  
 CORPORATE SOURCE: Dep. Chem., Univ. California, San Diego, La Jolla, CA, 92093, USA  
 SOURCE: Pept.: Struct. Funct., Proc. Am. Pept. Symp., 9th (1985), 725-8  
 CODEN: 54ZNAJ  
 DOCUMENT TYPE: Conference  
 LANGUAGE: English  
 IT 102643-51-6 102643-52-7 102643-53-8  
 102643-54-9 102643-55-0 102643-56-1  
 102643-57-2  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study) (taste of, structure in relation to)  
 RN 102643-51-6 CAPLUS  
 CN L-Phenylalanine, N-[N-[[4-methylphenyl]amino]carbonyl]-L- $\alpha$ -aspartyl]-, 1-methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 102643-52-7 CAPLUS  
 CN L-Phenylalanine, N-[N-[[3-methylphenyl]amino]carbonyl]-L- $\alpha$ -aspartyl]-, 1-methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 102643-53-8 CAPLUS  
 CN L-Phenylalanine, N-[N-[[2-methylphenyl]amino]carbonyl]-L- $\alpha$ -aspartyl]-, 1-methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 102643-54-9 CAPLUS

CN L-Phenylalanine, N-[N-[(3-nitrophenyl)amino]carbonyl]-L-α-aspartyl]-  
, 1-methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 102643-55-0 CAPLUS

CN L-Phenylalanine, N-[N-[(2-nitrophenyl)amino]carbonyl]-L-α-aspartyl]-  
, 1-methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 102643-56-1 CAPLUS


CN L-Phenylalanine, N-[N-[(3-cyanophenyl)amino]carbonyl]-L-α-aspartyl]-  
, 1-methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 102643-57-2 CAPLUS  
 CN L-Phenylalanine, N-[N-[(2-cyanophenyl)amino]carbonyl]-L-α-aspartyl]-  
 , 1-methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L5 ANSWER 180 OF 188 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1985:471122 CAPLUS  
 DOCUMENT NUMBER: 103:71122  
 ORIGINAL REFERENCE NO.: 103:11441a,11444a  
 TITLE: Safracine derivatives  
 INVENTOR(S): Naka, Yoichi; Uemori, Satoru; Ikeda, Yoshifumi;  
 Okumoto, Takeki  
 PATENT ASSIGNEE(S): Yoshitomi Pharmaceutical Industries, Ltd. , Japan  
 SOURCE: PCT Int. Appl., 22 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 8501049	A1	19850314	WO 1984-JP411	19840827
W: US				
RW: DE, FR, GB, NL, SE				
JP 60054386	A	19850328	JP 1983-162465	19830902
PRIORITY APPLN. INFO.:			JP 1983-162465	A 19830902
IT 97576-15-3P				
RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)				
RN 97576-15-3	CAPLUS			
CN Propanamide, N-[(6,7,9,10,13,14,14a,15-octahydro-1,7-dihydroxy-2,11-				

dimethoxy-3,12,16-trimethyl-10,13-dioxo-6,15-imino-5H-isoquino[3,2-b][3]benzazocin-9-yl)methyl]-2-[[ (phenylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>